Gene,Gene synonym,Ensembl,Gene description,Uniprot,Chromosome,Position,Protein class,Biological process,Molecular function,Disease involvement,Evidence,HPA evidence,UniProt evidence,NeXtProt evidence,RNA tissue specificity,RNA tissue distribution,RNA tissue specificity score,RNA tissue specific nTPM,RNA single cell type specificity,RNA single cell type distribution,RNA single cell type specificity score,RNA single cell type specific nTPM,RNA cancer specificity,RNA cancer distribution,RNA cancer specificity score,RNA cancer specific FPKM,RNA brain regional specificity,RNA brain regional distribution,RNA brain regional specificity score,RNA brain regional specific nTPM,RNA blood cell specificity,RNA blood cell distribution,RNA blood cell specificity score,RNA blood cell specific nTPM,RNA blood lineage specificity,RNA blood lineage distribution,RNA blood lineage specificity score,RNA blood lineage specific nTPM,RNA cell line specificity,RNA cell line distribution,RNA cell line specificity score,RNA cell line specific nTPM,RNA tissue cell type enrichment,RNA mouse brain regional specificity,RNA mouse brain regional distribution,RNA mouse brain regional specificity score,RNA mouse brain regional specific nTPM,RNA pig brain regional specificity,RNA pig brain regional distribution,RNA pig brain regional specificity score,RNA pig brain regional specific nTPM,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Secretome location,Secretome function,CCD Protein,CCD Transcript,Blood concentration - Conc. blood IM [pg/L],Blood concentration - Conc. blood MS [pg/L],Blood expression cluster,Tissue expression cluster,Brain expression cluster,Cell line expression cluster,Single cell expression cluster,Interactions,Subcellular main location,Subcellular additional location,Antibody RRID,Pathology prognostics - Breast cancer,Pathology prognostics - Cervical cancer,Pathology prognostics - Colorectal cancer,Pathology prognostics - Endometrial cancer,Pathology prognostics - Glioma,Pathology prognostics - Head and neck cancer,Pathology prognostics - Liver cancer,Pathology prognostics - Lung cancer,Pathology prognostics - Melanoma,Pathology prognostics - Ovarian cancer,Pathology prognostics - Pancreatic cancer,Pathology prognostics - Prostate cancer,Pathology prognostics - Renal cancer,Pathology prognostics - Stomach cancer,Pathology prognostics - Testis cancer,Pathology prognostics - Thyroid cancer,Pathology prognostics - Urothelial cancer
CFH,"ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS",ENSG00000000971,Complement factor H,P08603,1,196651754-196752476,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Host-virus interaction, Immunity, Innate immunity",,"Age-related macular degeneration, Cancer-related genes, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,6.0,liver: 1645.3,Cell type enhanced,Detected in many,,Fibroblasts: 355.9;Hepatocytes: 834.8;Leydig cells: 285.2;Mesothelial cells: 388.2;Ovarian stromal cells: 208.2,Cancer enriched,Detected in all,9.0,liver cancer: 151.1,Region enhanced,Detected in all,,choroid plexus: 43.6,Immune cell enhanced,Detected in some,,MAIT T-cell: 17.6,Lineage enriched,Detected in single,56.0,T-cells: 17.6,Cancer enhanced,Detected in many,,Gallbladder cancer: 59.2,"Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2",,,,,,,,,"CAB016385, CAB016769, HPA038922, HPA049176, HPA053326",Supported,,Approved,Vesicles,Secreted to blood,Immunity,,,396000000000.0,100000000000.0,Cluster 1: T-cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 42: Choroid plexus - Mitochondria,Cluster 71: Lymphoma - Inflammatory response,Cluster 53: Fibroblasts - ECM organization,6.0,Vesicles,,"CAB016385: AB_627572, CAB016769: , HPA038922: AB_2676271, HPA049176: AB_2680663, HPA053326: AB_2682113",unprognostic (2.40e-1),unprognostic (9.86e-2),unprognostic (1.22e-1),unprognostic (8.39e-2),unprognostic (5.40e-3),unprognostic (1.80e-1),unprognostic (3.75e-3),unprognostic (7.40e-2),unprognostic (1.06e-1),unprognostic (1.04e-1),unprognostic (9.08e-2),unprognostic (2.08e-1),prognostic unfavorable (1.92e-6),unprognostic (6.50e-3),unprognostic (4.49e-3),unprognostic (1.73e-1),unprognostic (1.37e-1)
PON1,"ESA, PON",ENSG00000005421,Paraoxonase 1,P27169,7,95297676-95324532,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",,Hydrolase,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,103.0,liver: 516.3,Cell type enriched,Detected in some,13.0,Hepatocytes: 428.5,Cancer enriched,Detected in some,78.0,liver cancer: 97.8,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 1.0;prostate cancer: 2.4,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA001610,Approved,,,,Secreted to blood,Enzyme,,,96000000000.0,17000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 10: Cerebellum - Nucleic acid binding,Cluster 59: Leukemia - T-cell receptor,Cluster 43: Hepatocytes - Metabolism,,,,HPA001610: AB_1079656,unprognostic (2.02e-2),unprognostic (2.41e-2),unprognostic (3.04e-1),unprognostic (3.54e-2),unprognostic (2.70e-1),,prognostic favorable (7.24e-7),unprognostic (2.24e-1),unprognostic (1.95e-1),unprognostic (9.02e-3),unprognostic (1.76e-3),unprognostic (3.97e-2),unprognostic (6.74e-9),unprognostic (1.09e-3),unprognostic (2.29e-2),unprognostic (2.07e-1),unprognostic (5.54e-3)
ITGA2B,"CD41, CD41B, GP2B, PPP1R93",ENSG00000005961,Integrin subunit alpha 2b,P08514,17,44372180-44389649,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Cell adhesion,"Integrin, Receptor","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,bone marrow: 16.4;epididymis: 10.4;lymphoid tissue: 10.9,Cell type enhanced,Detected in many,,Erythroid cells: 38.7;Late spermatids: 26.7;Lymphatic endothelial cells: 8.9;Oligodendrocyte precursor cells: 9.0,Cancer enhanced,Detected in some,,testis cancer: 2.1,Low region specificity,Detected in all,,,Immune cell enriched,Detected in some,14.0,basophil: 65.1,Lineage enriched,Detected in single,75.0,granulocytes: 65.1,Cancer enriched,Detected in some,59.0,Leukemia: 83.1,Testis - Late spermatids,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171",Enhanced,,Approved,Plasma membrane,,,,,,90000000.0,Cluster 41: Basophils - Unknown function,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 48: Non-specific - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 57: Platelets - Hemostasis,1.0,Plasma membrane,,"CAB018611: AB_2265153, HPA031168: AB_10664706, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773",unprognostic (6.11e-2),unprognostic (3.23e-2),unprognostic (1.23e-1),unprognostic (4.85e-2),unprognostic (1.59e-2),unprognostic (3.98e-3),unprognostic (4.23e-5),unprognostic (1.25e-1),unprognostic (1.33e-2),unprognostic (7.22e-2),unprognostic (2.97e-3),unprognostic (1.30e-1),unprognostic (8.83e-9),unprognostic (7.82e-2),unprognostic (1.85e-1),unprognostic (1.95e-1),unprognostic (2.25e-1)
LTF,HLF2,ENSG00000012223,Lactotransferrin,P02788,3,46435645-46485234,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Immunity, Ion transport, Iron transport, Osteogenesis, Transcription, Transcription regulation, Transport","Antibiotic, Antimicrobial, DNA-binding, Heparin-binding, Hydrolase, Protease, Serine protease",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,bone marrow: 4212.2;salivary gland: 1128.6,Group enriched,Detected in many,5.0,Breast glandular cells: 1470.5;Club cells: 393.9;Mucus glandular cells: 1389.1;Serous glandular cells: 1532.1,Group enriched,Detected in all,5.0,breast cancer: 239.0;endometrial cancer: 170.3;glioma: 152.6;prostate cancer: 195.2,Low region specificity,Detected in all,,,Group enriched,Detected in some,23.0,neutrophil: 5.4;non-classical monocyte: 17.0,Group enriched,Detected in many,23.0,granulocytes: 5.4;monocytes: 17.0,Cancer enhanced,Detected in some,,Myeloma: 2.9,Lung - Neutrophil_1,Not detected,Not detected,,,Low region specificity,Detected in many,,,"CAB008646, CAB016201, HPA057177, HPA059976",Enhanced,,,,Secreted to blood,Transport,,,,350000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 6: Bone marrow - Innate immune response,Cluster 46: Brainstem - Mixed function,Cluster 51: Myeloma - Immunoglobulins,Cluster 17: Breast glandular cells - Lactation,,,,"CAB008646: AB_1618695, CAB016201: AB_629860, HPA057177: AB_2683361, HPA059976: AB_2684185",unprognostic (7.24e-3),unprognostic (2.43e-1),unprognostic (5.94e-2),unprognostic (3.41e-2),unprognostic (7.14e-3),unprognostic (3.45e-2),unprognostic (6.43e-3),unprognostic (2.52e-1),unprognostic (1.92e-1),unprognostic (4.21e-2),unprognostic (3.43e-1),unprognostic (1.04e-1),prognostic favorable (6.30e-5),unprognostic (1.66e-2),unprognostic (3.53e-1),unprognostic (2.05e-1),unprognostic (9.09e-3)
C8B,,ENSG00000021852,Complement C8 beta chain,P07358,1,56929207-56974383,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,127.0,liver: 630.0,Cell type enriched,Detected in some,11.0,Hepatocytes: 247.1,Cancer enriched,Detected in some,181.0,liver cancer: 107.0,Not detected,Not detected,,,Immune cell enriched,Detected in single,23.0,basophil: 2.3,Lineage enriched,Detected in single,23.0,granulocytes: 2.3,Cancer enriched,Detected in single,11.0,liver cancer: 1.1,"Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA023694,Supported,,,,Secreted to blood,Complement pathway,,,,6700000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA023694: AB_1847128,,,,unprognostic (6.65e-2),,,prognostic favorable (9.31e-5),unprognostic (2.37e-1),,,unprognostic (2.37e-1),,,unprognostic (1.29e-2),unprognostic (6.57e-2),unprognostic (5.12e-3),
VCL,,ENSG00000035403,Vinculin,P18206,10,73995193-74121363,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",Cell adhesion,Actin-binding,"Cardiomyopathy, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Alveolar cells type 1: 232.0;Cardiomyocytes: 345.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Smooth muscle cells, Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Thyroid - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002131, CAB002453, HPA063777",Enhanced,,Enhanced,Focal adhesion sites,,,,,,750000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 42: Choroid plexus - Mitochondria,Cluster 52: Non-specific - Mitochondria,Cluster 32: Smooth muscle cells - Muscle contraction,4.0,Focal adhesion sites,,"CAB002453: AB_564057, HPA002131: AB_1080570, HPA063777: AB_2685121",unprognostic (8.49e-2),unprognostic (1.61e-2),unprognostic (3.14e-1),unprognostic (6.31e-2),unprognostic (3.34e-1),unprognostic (9.62e-3),unprognostic (2.72e-3),unprognostic (2.67e-3),unprognostic (3.42e-2),unprognostic (1.46e-1),prognostic unfavorable (2.75e-4),unprognostic (1.29e-1),unprognostic (3.68e-2),unprognostic (4.03e-2),unprognostic (4.02e-2),unprognostic (1.89e-1),unprognostic (1.37e-3)
C6,,ENSG00000039537,Complement C6,P13671,5,41142116-41261438,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Complement pathway, Cytolysis, Immunity, Innate immunity",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,11.0,liver: 610.3,Cell type enhanced,Detected in some,,Cholangiocytes: 125.9;Ciliated cells: 63.9;Hepatocytes: 323.6;Late spermatids: 53.2;Leydig cells: 118.1,Group enriched,Detected in many,7.0,liver cancer: 49.0;pancreatic cancer: 12.5,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,Bone cancer: 1.1,"Breast - Adipocytes (Breast), Liver - Hepatocytes, Lung - Respiratory ciliated cells",Not detected,Not detected,,,Low region specificity,Detected in single,,,"HPA043823, CAB069427",Enhanced,,,,Secreted to blood,Complement pathway,,,45000000000.0,9200000000.0,,Cluster 83: Liver - Metabolism,Cluster 3: Choroid plexus - Cilium,Cluster 44: Connective tissue cells - ECM organization,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB069427: AB_1614336, HPA043823: AB_10960262",unprognostic (9.79e-2),unprognostic (1.96e-2),unprognostic (5.94e-3),unprognostic (3.02e-2),unprognostic (1.67e-1),unprognostic (1.18e-1),unprognostic (1.12e-3),unprognostic (4.66e-2),unprognostic (3.72e-2),unprognostic (1.53e-1),unprognostic (2.34e-1),unprognostic (3.04e-3),prognostic favorable (4.31e-4),unprognostic (2.69e-4),unprognostic (1.61e-1),unprognostic (1.40e-2),unprognostic (3.51e-2)
ITIH4,"H4P, IHRP, ITIHL1",ENSG00000055955,Inter-alpha-trypsin inhibitor heavy chain 4,Q14624,3,52812962-52830688,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,38.0,liver: 1807.4,Group enriched,Detected in many,4.0,Early spermatids: 68.4;Hepatocytes: 91.9;Late spermatids: 159.0,Cancer enriched,Detected in single,27.0,liver cancer: 7.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 1.4,"Adipose subcutaneous - Smooth muscle cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA001835, HPA003948, CAB072872",Enhanced,,Approved,Vesicles,Secreted to blood,Acute phase,,,3060000.0,58000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 32: Cerebral cortex - Mixed function,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"CAB072872: AB_2665724, HPA001835: AB_1079432, HPA003948: AB_1079433",unprognostic (6.08e-2),unprognostic (4.45e-2),unprognostic (1.67e-1),unprognostic (2.69e-1),unprognostic (2.64e-1),unprognostic (1.96e-1),unprognostic (5.86e-2),unprognostic (1.98e-2),unprognostic (5.64e-2),unprognostic (1.02e-1),unprognostic (2.47e-2),unprognostic (1.52e-1),unprognostic (1.10e-14),unprognostic (1.71e-3),unprognostic (2.96e-2),unprognostic (1.52e-1),unprognostic (4.21e-5)
ITIH1,"H1P, IATIH, ITIH",ENSG00000055957,Inter-alpha-trypsin inhibitor heavy chain 1,P19827,3,52777595-52792068,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,777.0,liver: 1459.7,Cell type enriched,Detected in some,23.0,Hepatocytes: 793.7,Cancer enriched,Detected in some,598.0,liver cancer: 329.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Adipose subcutaneous - Smooth muscle cells, Adipose visceral - Smooth muscle cells, Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"HPA041639, HPA042049",Approved,,Approved,Vesicles,Secreted to blood,Enzyme inhibitor,,,4490000.0,59000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"HPA041639: AB_10796349, HPA042049: AB_10797379",unprognostic (1.87e-4),unprognostic (1.31e-3),unprognostic (2.38e-1),unprognostic (8.55e-2),unprognostic (1.03e-1),unprognostic (2.64e-3),prognostic favorable (1.89e-5),unprognostic (2.27e-2),unprognostic (1.70e-1),unprognostic (1.30e-1),unprognostic (2.91e-2),unprognostic (8.45e-2),unprognostic (4.53e-4),unprognostic (4.02e-3),unprognostic (5.70e-3),unprognostic (2.08e-1),unprognostic (2.24e-2)
F7,,ENSG00000057593,Coagulation factor VII,P08709,13,113105788-113120685,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,102.0,liver: 156.3,Cell type enriched,Detected in some,7.0,Hepatocytes: 119.3,Cancer enriched,Detected in some,17.0,liver cancer: 41.4,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,breast cancer: 3.0;liver cancer: 8.7,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,HPA004826,,,Approved,Mitochondria,Secreted to blood,Blood coagulation,,,351000000.0,1300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 1: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,Mitochondria,,HPA004826: AB_10602805,unprognostic (2.06e-1),unprognostic (2.55e-1),unprognostic (1.03e-1),unprognostic (1.34e-1),unprognostic (3.27e-1),unprognostic (1.91e-1),unprognostic (1.50e-3),unprognostic (3.81e-1),unprognostic (4.36e-3),unprognostic (1.16e-1),unprognostic (4.19e-3),unprognostic (1.15e-1),unprognostic (1.35e-3),unprognostic (3.36e-3),unprognostic (1.09e-1),unprognostic (2.86e-1),unprognostic (1.47e-1)
PKM,"OIP3, PK3, PKM2, THBP1",ENSG00000067225,Pyruvate kinase M1/2,P14618,15,72199029-72231819,"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Glycolysis, Translation regulation","Allosteric enzyme, Kinase, Transferase",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,skeletal muscle: 3889.6;tongue: 2564.9,Cell type enhanced,Detected in all,,Basal respiratory cells: 1894.9;Cone photoreceptor cells: 1779.0;Extravillous trophoblasts: 1559.9;Late spermatids: 1768.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Adipose progenitor cells, Skeletal muscle - Skeletal myocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB019421, HPA029501",Uncertain,,Enhanced,Cytosol,,,No,No,,310000000.0,Cluster 26: Monocytes - Plasma membrane proteins,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 45: Non-specific - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 45: Non-specific - Mixed function,11.0,Cytosol,,"CAB019421: AB_2252325, HPA029501: AB_10602118",unprognostic (8.73e-3),unprognostic (4.63e-3),unprognostic (1.68e-2),unprognostic (3.09e-1),unprognostic (6.51e-2),prognostic unfavorable (1.30e-4),prognostic unfavorable (2.74e-6),prognostic unfavorable (2.85e-4),unprognostic (9.51e-2),unprognostic (1.17e-2),prognostic unfavorable (5.17e-5),unprognostic (3.16e-1),unprognostic (3.22e-1),unprognostic (7.85e-2),unprognostic (3.17e-2),unprognostic (1.44e-1),unprognostic (1.25e-2)
SPP2,SPP24,ENSG00000072080,Secreted phosphoprotein 2,Q13103,2,234050679-234077134,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,4403.0,liver: 502.9,Cell type enriched,Detected in some,28.0,Hepatocytes: 246.6,Cancer enriched,Detected in some,112.0,liver cancer: 65.3,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Low region specificity,Detected in some,,,Low region specificity,Detected in all,,,,,,,,Secreted to blood,No annotated function,,,,480000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 5: Rhabdoid - Unknown function,Cluster 43: Hepatocytes - Metabolism,,,,,,,,,,,prognostic favorable (2.33e-6),unprognostic (7.02e-3),,unprognostic (9.62e-3),,,,,,,
ACTN1,,ENSG00000072110,Actinin alpha 1,P12814,14,68874128-68979440,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Actin-binding,"Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,smooth muscle: 515.0,Cell type enhanced,Detected in many,,Extravillous trophoblasts: 369.9;Pancreatic endocrine cells: 336.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 346.0,Low lineage specificity,Detected in many,,,Cancer enhanced,Detected in all,,Adrenocortical cancer: 1086.0,"Colon - Smooth muscle cells, Lung - Smooth muscle cells, Prostate - Smooth muscle cells, Skin - Outer root sheath cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB004303, HPA006035",Approved,,Approved,"Plasma membrane,Actin filaments,Focal adhesion sites,Cytosol",,,,,,210000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 23: Choroid plexus - Mixed function,Cluster 30: Non-specific - Gene expression regulation,Cluster 32: Smooth muscle cells - Muscle contraction,26.0,"Actin filaments, Focal adhesion sites","Plasma membrane, Cytosol","CAB004303: AB_626633, HPA006035: AB_1078095",unprognostic (4.40e-2),unprognostic (1.03e-3),unprognostic (2.49e-2),unprognostic (1.96e-1),unprognostic (1.19e-1),prognostic unfavorable (2.49e-4),unprognostic (6.19e-3),prognostic unfavorable (7.63e-5),unprognostic (3.62e-1),unprognostic (3.23e-2),unprognostic (3.16e-2),unprognostic (1.71e-1),prognostic unfavorable (9.08e-10),unprognostic (2.87e-2),unprognostic (2.00e-1),unprognostic (6.05e-3),prognostic unfavorable (8.00e-4)
CD5L,"API6, Spalpha",ENSG00000073754,CD5 molecule like,O43866,1,157830911-157898256,"Plasma proteins, Predicted secreted proteins","Apoptosis, Immunity, Inflammatory response",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,lymphoid tissue: 558.4,Group enriched,Detected in some,29.0,Hofbauer cells: 226.6;Kupffer cells: 624.6,Cancer enriched,Detected in some,5.0,liver cancer: 4.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Kupffer cells,Not detected,Not detected,,,Not detected,Not detected,,,"HPA065686, HPA068384",Enhanced,,,,Secreted to blood,Immunity,,,4030000000.0,4300000000.0,,Cluster 47: Spleen - Immune response,,Cluster 51: Myeloma - Immunoglobulins,Cluster 58: Macrophages - Innate immune response,,,,"HPA065686: AB_2685532, HPA068384: AB_2685979",,unprognostic (2.96e-1),,unprognostic (2.90e-1),unprognostic (1.08e-1),unprognostic (1.94e-1),prognostic favorable (8.88e-5),unprognostic (1.73e-2),unprognostic (4.51e-2),unprognostic (1.89e-1),unprognostic (1.56e-1),,unprognostic (5.95e-3),unprognostic (2.26e-1),unprognostic (1.06e-1),unprognostic (3.63e-1),
ENO1,"ENO1L1, MBP-1, MPB1, PPH",ENSG00000074800,Enolase 1,P06733,1,8861000-8879190,"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Glycolysis, Plasminogen activation, Transcription, Transcription regulation","DNA-binding, Lyase, Repressor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Ductal cells: 2000.6;Extravillous trophoblasts: 2170.5;Muller glia cells: 2541.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB018614, HPA068284, HPA068721, CAB069394, CAB080034",Supported,,Enhanced,"Plasma membrane,Cytosol",,,,,,310000000.0,Cluster 33: Non-specific - ATP binding,Cluster 17: Neuronal - Synaptic function,Cluster 21: Non-specific - Metabolism,Cluster 15: Kidney cancer - Membrane components,Cluster 39: Non-specific - Basic cellular processes,4.0,"Plasma membrane, Cytosol",,"CAB018614: AB_2099061, CAB069394: , CAB080034: , HPA068284: , HPA068721: AB_2732119",unprognostic (6.51e-3),unprognostic (9.50e-3),unprognostic (3.56e-2),unprognostic (1.86e-1),prognostic unfavorable (2.71e-4),unprognostic (1.82e-2),prognostic unfavorable (1.30e-8),unprognostic (2.37e-2),unprognostic (5.58e-2),unprognostic (9.72e-2),unprognostic (1.67e-2),unprognostic (1.46e-1),unprognostic (7.53e-2),unprognostic (6.20e-2),unprognostic (1.97e-1),unprognostic (2.22e-1),unprognostic (1.36e-3)
ACTB,,ENSG00000075624,Actin beta,P60709,7,5526409-5563902,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Hydrolase,"Deafness, Disease variant, Dystonia, Intellectual disability",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 13764.8;Hofbauer cells: 15165.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Smooth muscle cells, Colon - Smooth muscle cells, Prostate - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002621, HPA041264, HPA041271",Supported,,,,,,,,,5800000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 29: Squamous epithelium - Innate immune response,Cluster 27: Non-specific - Mixed function,Cluster 67: Non-specific - Unknown function,Cluster 14: Langerhans cells - Innate immune response,25.0,,,"CAB002621: , HPA041264: AB_2677383, HPA041271: AB_2677386",unprognostic (1.66e-1),unprognostic (1.15e-1),unprognostic (4.20e-2),unprognostic (1.15e-2),unprognostic (1.01e-2),prognostic unfavorable (4.51e-4),unprognostic (9.80e-3),unprognostic (1.57e-3),unprognostic (1.73e-1),unprognostic (5.99e-2),unprognostic (3.33e-2),unprognostic (3.77e-1),prognostic unfavorable (3.78e-5),unprognostic (2.68e-2),unprognostic (3.20e-1),unprognostic (1.50e-1),unprognostic (4.88e-3)
FBLN1,FBLN,ENSG00000077942,Fibulin 1,P23142,22,45502238-45601135,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Host-virus interaction,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,choroid plexus: 1826.9,Cell type enhanced,Detected in many,,Cytotrophoblasts: 636.6;Endometrial stromal cells: 611.2;Extravillous trophoblasts: 720.8;Fibroblasts: 1354.1;Syncytiotrophoblasts: 1303.4,Cancer enhanced,Detected in all,,endometrial cancer: 199.6,Region enriched,Detected in all,13.0,choroid plexus: 1731.1,Immune cell enhanced,Detected in some,,non-classical monocyte: 2.5,Low lineage specificity,Detected in many,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Adipose progenitor cells, Breast - Fibroblasts, Colon - Fibroblasts, Heart muscle - Fibroblasts, Kidney - Fibroblasts, Liver - Hepatic stellate cells, Lung - Fibroblast_2, Pancreas - Fibroblasts, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2, Stomach - Fibroblasts, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001612, HPA001613, CAB004393, CAB068187",Enhanced,,Approved,Endoplasmic reticulum,Secreted to extracellular matrix,Other,,,,21000000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,Endoplasmic reticulum,,"CAB004393: AB_671972, CAB068187: AB_2665634, HPA001612: AB_1078825, HPA001613: AB_1078824",unprognostic (6.62e-2),unprognostic (2.47e-2),unprognostic (1.64e-1),prognostic favorable (9.28e-4),unprognostic (1.26e-3),unprognostic (4.82e-2),unprognostic (9.79e-3),unprognostic (2.49e-1),unprognostic (6.30e-2),unprognostic (3.86e-2),unprognostic (2.84e-2),unprognostic (3.30e-2),prognostic unfavorable (3.02e-10),unprognostic (1.08e-3),unprognostic (1.46e-1),unprognostic (1.29e-2),unprognostic (3.64e-2)
AFM,"ALB2, ALBA",ENSG00000079557,Afamin,P43652,4,73481745-73504001,"Plasma proteins, Predicted secreted proteins","Protein transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,liver: 932.0,Cell type enriched,Detected in some,8.0,Hepatocytes: 294.0,Cancer enriched,Detected in single,167.0,liver cancer: 62.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA017006, HPA052437",Enhanced,,Uncertain,Plasma membrane,Secreted to blood,Transport,,,54900000000.0,8700000000.0,,Cluster 1: Liver & Kidney - Metabolism,,Cluster 55: Lymphoma - Immune response,Cluster 43: Hepatocytes - Metabolism,1.0,Plasma membrane,,"HPA017006: AB_1844635, HPA052437: AB_2732575",,,,,,,prognostic favorable (1.80e-4),,,,unprognostic (5.73e-2),,unprognostic (4.24e-2),,,,
CPB2,"CPU, PCPB, TAFI",ENSG00000080618,Carboxypeptidase B2,Q96IY4,13,46053186-46105033,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis","Carboxypeptidase, Hydrolase, Metalloprotease, Protease",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,84.0,liver: 1439.0,Cell type enriched,Detected in some,5.0,Hepatocytes: 1226.7,Cancer enriched,Detected in some,112.0,liver cancer: 268.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,liver cancer: 11.2,"Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Low region specificity,Detected in some,,,HPA004146,Approved,,,,Secreted to blood,Blood coagulation,,,,8500000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 28: Oligodendrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,,,HPA004146: AB_1078397,unprognostic (3.44e-2),unprognostic (1.25e-1),unprognostic (2.94e-2),unprognostic (1.89e-2),unprognostic (7.69e-2),unprognostic (1.17e-2),prognostic favorable (2.06e-4),unprognostic (1.89e-1),unprognostic (2.74e-1),unprognostic (2.48e-1),unprognostic (3.17e-2),unprognostic (4.83e-2),unprognostic (3.20e-3),unprognostic (1.34e-1),unprognostic (7.10e-2),unprognostic (3.34e-2),unprognostic (9.61e-2)
APOB,,ENSG00000084674,Apolipoprotein B,P04114,2,21001429-21044073,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",Heparin-binding,"Atherosclerosis, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in some,143.0,intestine: 296.0;liver: 1155.6,Group enriched,Detected in some,7.0,Hepatocytes: 2290.4;Proximal enterocytes: 1342.2,Cancer enriched,Detected in some,99.0,liver cancer: 295.0,Low region specificity,Detected in some,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,13.0,liver cancer: 178.6,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast), Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"CAB016070, HPA049793, CAB080297, CAB080298, CAB080299",Supported,,Supported,"Vesicles,Cytosol",Secreted to blood,Apolipoprotein,,,1490000000000.0,100000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,"Vesicles, Cytosol",,"CAB016070: AB_626690, CAB080297: , CAB080298: , CAB080299: , HPA049793: AB_2680885",unprognostic (1.63e-2),unprognostic (2.71e-2),unprognostic (1.75e-1),unprognostic (1.06e-1),unprognostic (1.04e-2),unprognostic (7.31e-2),unprognostic (1.46e-2),unprognostic (6.53e-3),unprognostic (4.43e-2),unprognostic (8.89e-3),unprognostic (3.01e-1),unprognostic (4.59e-3),unprognostic (3.60e-3),unprognostic (2.89e-2),unprognostic (2.38e-1),unprognostic (2.99e-1),unprognostic (6.23e-2)
F11,FXI,ENSG00000088926,Coagulation factor XI,P03951,4,186266189-186289681,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,4.0,liver: 235.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 69.2,Cancer enriched,Detected in some,13.0,liver cancer: 16.8,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 1.8,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA039808,,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,,4400000000.0,,Cluster 83: Liver - Metabolism,Cluster 38: Sub-cortical - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,HPA039808: AB_2676693,,,unprognostic (1.28e-1),,unprognostic (3.15e-1),,prognostic favorable (3.29e-5),unprognostic (1.88e-1),,,unprognostic (2.08e-1),unprognostic (2.11e-1),unprognostic (1.85e-3),unprognostic (2.91e-2),unprognostic (7.65e-2),,
FETUB,,ENSG00000090512,Fetuin B,Q9UGM5,3,186635969-186653141,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Fertilization,"Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,27.0,liver: 227.3,Cell type enriched,Detected in some,6.0,Hepatocytes: 46.2,Cancer enriched,Detected in some,12.0,liver cancer: 44.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,"HPA035132, HPA035133",Supported,,Approved,Vesicles,Secreted to blood,Enzyme inhibitor,,,47500000000.0,3600000000.0,,Cluster 83: Liver - Metabolism,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 43: Hepatocytes - Metabolism,6.0,Vesicles,,"HPA035132: AB_10601650, HPA035133: ",,unprognostic (9.01e-2),,unprognostic (1.95e-1),unprognostic (4.62e-1),unprognostic (8.74e-2),unprognostic (6.28e-3),unprognostic (1.24e-2),unprognostic (7.55e-2),unprognostic (9.78e-2),unprognostic (1.73e-2),,,unprognostic (9.18e-2),unprognostic (1.79e-1),unprognostic (8.39e-2),
TF,"PRO1557, PRO2086",ENSG00000091513,Transferrin,P02787,3,133746040-133796641,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Ion transport, Iron transport, Transport",,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,brain: 1466.9;liver: 7278.6;retina: 2358.0,Group enriched,Detected in many,8.0,Hepatocytes: 5785.8;Muller glia cells: 10733.8,Cancer enriched,Detected in many,42.0,liver cancer: 783.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,liver cancer: 221.9,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Colon - Enteric glia cells, Liver - Hepatocytes, Skin - Sebaceous gland cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001527, HPA005692, CAB009538",Enhanced,,,,Secreted to blood,Transport,,,19800000000000.0,98000000000.0,,Cluster 83: Liver - Metabolism,Cluster 30: White matter - Myelination,Cluster 18: Liver cancer - Metabolism,Cluster 10: Muller glia cells - Visual perception,20.0,,,"CAB009538: AB_793365, HPA001527: AB_1080357, HPA005692: AB_1080354",prognostic favorable (4.05e-4),unprognostic (2.45e-2),unprognostic (1.78e-1),unprognostic (1.50e-1),unprognostic (8.99e-2),unprognostic (5.18e-2),unprognostic (6.63e-2),unprognostic (8.46e-2),unprognostic (2.82e-1),unprognostic (3.08e-1),unprognostic (1.37e-1),unprognostic (7.60e-2),prognostic unfavorable (2.35e-13),unprognostic (2.17e-3),unprognostic (5.49e-2),unprognostic (3.47e-3),unprognostic (9.70e-2)
APOH,"B2G1, BG",ENSG00000091583,Apolipoprotein H,P02749,17,66212033-66256525,"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,Heparin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,567.0,liver: 17409.3,Cell type enriched,Detected in some,29.0,Hepatocytes: 7848.6,Cancer enriched,Detected in many,232.0,liver cancer: 2878.9,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,46.0,liver cancer: 154.3,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Alveolar cells type 2, Pancreas - Alpha cells",Low region specificity,Detected in many,,,Not detected,Not detected,,,"HPA001654, HPA003732, CAB022214",Enhanced,,Supported,Golgi apparatus,Secreted to blood,Apolipoprotein,,,247000000000.0,41000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,5.0,Golgi apparatus,,"CAB022214: , HPA001654: AB_1078181, HPA003732: AB_1078183",,,unprognostic (2.11e-2),unprognostic (1.87e-1),unprognostic (1.28e-1),,prognostic favorable (2.39e-7),unprognostic (1.26e-1),,unprognostic (5.99e-2),unprognostic (2.88e-3),,prognostic unfavorable (1.10e-6),unprognostic (1.26e-2),unprognostic (5.76e-2),,
IGFALS,ALS,ENSG00000099769,Insulin like growth factor binding protein acid labile subunit,P35858,16,1790413-1794971,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Cell adhesion,,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,11.0,liver: 113.8,Cell type enriched,Detected in some,6.0,Hepatocytes: 65.5,Cancer enhanced,Detected in many,,liver cancer: 11.1,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in single,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA040692, HPA040948",Supported,,,,Secreted to blood,Cell adhesion,,,14700000000.0,26000000000.0,,Cluster 83: Liver - Metabolism,Cluster 6: Non-specific - Immune response,Cluster 15: Kidney cancer - Membrane components,Cluster 43: Hepatocytes - Metabolism,,,,"HPA040692: AB_10794067, HPA040948: AB_10794999",unprognostic (2.74e-3),unprognostic (1.95e-1),unprognostic (9.13e-2),prognostic unfavorable (6.06e-4),unprognostic (2.54e-1),unprognostic (1.37e-2),prognostic favorable (5.97e-4),unprognostic (5.54e-4),unprognostic (3.00e-1),unprognostic (1.17e-1),unprognostic (9.06e-2),unprognostic (1.05e-2),unprognostic (1.10e-1),unprognostic (1.49e-1),unprognostic (1.23e-1),unprognostic (4.39e-1),unprognostic (5.51e-2)
SERPIND1,"D22S673, HC-II, HC2, HCF2, HLS2",ENSG00000099937,Serpin family D member 1,P05546,22,20774113-20787720,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Chemotaxis, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor","Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,liver: 1214.6,Cell type enriched,Detected in some,13.0,Hepatocytes: 238.0,Cancer enriched,Detected in many,80.0,liver cancer: 334.4,Region enriched,Detected in all,21.0,choroid plexus: 191.0,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in many,15.0,liver cancer: 30.6;ovarian cancer: 66.9,"Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,"CAB008639, HPA055767",Supported,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,,50000000000.0,Cluster 30: Non-specific - DNA binding,Cluster 31: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 66: Non-specific - Mitochondria,Cluster 62: Hepatocytes - Metabolism,,Vesicles,,"CAB008639: AB_1618010, HPA055767: AB_2682912",unprognostic (1.68e-1),unprognostic (8.27e-2),unprognostic (4.40e-2),prognostic favorable (4.09e-4),unprognostic (5.42e-2),unprognostic (1.23e-1),unprognostic (1.12e-3),unprognostic (1.56e-1),unprognostic (1.13e-1),unprognostic (1.74e-1),unprognostic (1.21e-2),unprognostic (2.88e-1),unprognostic (3.94e-9),unprognostic (2.01e-1),unprognostic (4.66e-2),unprognostic (8.36e-3),unprognostic (1.46e-1)
APOL1,APOL,ENSG00000100342,Apolipoprotein L1,O14791,22,36253071-36267530,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 174.5,Cell type enhanced,Detected in many,,Basal prostatic cells: 107.3;Glandular and luminal cells: 219.4;Hepatocytes: 97.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in many,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in many,,Kidney cancer: 244.0,"Heart muscle - Endothelial cells, Kidney - Endothelial cells",,,,,,,,,"HPA018885, CAB056156",Supported,,,,Secreted to blood,Apolipoprotein,,,1640000000.0,9200000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 11: Liver - Plasma proteins,Cluster 42: Choroid plexus - Mitochondria,Cluster 15: Kidney cancer - Membrane components,Cluster 37: Glandular & Luminal cells - Unknown function,1.0,,,"CAB056156: AB_2665576, HPA018885: AB_1844953",unprognostic (1.05e-2),unprognostic (1.53e-1),unprognostic (1.57e-1),unprognostic (8.98e-3),unprognostic (1.67e-1),unprognostic (8.28e-2),unprognostic (1.41e-2),prognostic unfavorable (5.35e-4),unprognostic (4.41e-2),unprognostic (1.58e-1),unprognostic (4.07e-3),unprognostic (5.15e-2),prognostic unfavorable (7.43e-6),unprognostic (1.93e-1),unprognostic (3.15e-2),unprognostic (5.05e-3),prognostic favorable (2.01e-5)
MYH9,"DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA",ENSG00000100345,Myosin heavy chain 9,P35579,22,36281280-36388010,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins","Cell adhesion, Cell shape","Actin-binding, Calmodulin-binding, Motor protein, Myosin","Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease variant, Non-syndromic deafness",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in many,,Alveolar cells type 1: 471.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Adipose subcutaneous - Endothelial cells, Testis - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001644, CAB015386, HPA064783",Enhanced,,Supported,"Nuclear bodies,Plasma membrane,Actin filaments,Cytosol",,,No,No,,410000000.0,Cluster 36: Eosinophils - Protein ubiquitination,Cluster 7: Adipose tissue - Mixed function,Cluster 47: Endothelial cells - Vasculature,Cluster 15: Kidney cancer - Membrane components,Cluster 32: Smooth muscle cells - Muscle contraction,11.0,"Plasma membrane, Actin filaments","Nuclear bodies, Cytosol","CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721",unprognostic (1.38e-1),unprognostic (9.12e-2),unprognostic (4.21e-2),unprognostic (6.34e-2),unprognostic (1.49e-1),unprognostic (3.90e-2),unprognostic (9.56e-2),unprognostic (8.28e-2),unprognostic (5.50e-2),unprognostic (6.38e-2),unprognostic (1.93e-2),unprognostic (1.61e-1),unprognostic (7.98e-2),unprognostic (9.48e-2),unprognostic (1.64e-1),unprognostic (1.62e-1),unprognostic (2.59e-2)
CST3,,ENSG00000101439,Cystatin C,P01034,20,23626706-23638473,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Thiol protease inhibitor","Age-related macular degeneration, Amyloidosis, Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,brain: 4419.8;choroid plexus: 4010.9,Cell type enhanced,Detected in all,,Langerhans cells: 22281.6;Schwann cells: 10946.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in all,7.0,classical monocyte: 4979.2;intermediate monocyte: 6434.2;myeloid DC: 7977.6;non-classical monocyte: 4321.2;plasmacytoid DC: 4438.0,Group enriched,Detected in all,9.0,dendritic cells: 7977.6;monocytes: 6434.2,Low cancer specificity,Detected in all,,,"Kidney - Fibroblasts, Skin - Fibroblast_2, Stomach - Fibroblasts, Testis - Sertoli cells, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000118, HPA013143",Enhanced,,Supported,"Golgi apparatus,Vesicles",Secreted to blood,Enzyme inhibitor,,,1040000000.0,2800000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 39: Astrocytes - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 28: Dendritic cells - Antigen presentation,1.0,"Golgi apparatus, Vesicles",,"CAB000118: , HPA013143: AB_1847417",unprognostic (3.89e-2),unprognostic (1.63e-1),unprognostic (1.45e-1),prognostic favorable (1.83e-4),unprognostic (8.53e-2),unprognostic (4.06e-2),unprognostic (2.10e-2),unprognostic (2.18e-2),unprognostic (3.46e-2),unprognostic (3.72e-1),unprognostic (2.29e-3),unprognostic (3.51e-2),unprognostic (1.85e-1),unprognostic (1.16e-1),unprognostic (2.97e-1),unprognostic (5.01e-2),prognostic favorable (8.77e-4)
F9,FIX,ENSG00000101981,Coagulation factor IX,P00740,X,139530739-139563459,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets, Hemophilia, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,2448.0,liver: 683.7,Group enriched,Detected in some,12.0,Hepatocytes: 519.8;Kupffer cells: 161.1,Cancer enriched,Detected in single,1354.0,liver cancer: 67.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Blood coagulation,,,,8200000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 10: Ciliated cells - Ion channel activity,Cluster 62: Hepatocytes - Metabolism,,,,,,,,,,,prognostic favorable (6.69e-4),,,,,,,,,,
COMP,"EDM1, EPD1, MED, PSACH, THBS5",ENSG00000105664,Cartilage oligomeric matrix protein,P49747,19,18782773-18791305,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Cell adhesion",Heparin-binding,"Disease variant, Dwarfism",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 75.1;heart muscle: 63.2;skin 1: 78.0,Cell type enhanced,Detected in some,,Basal respiratory cells: 15.9;Early spermatids: 35.1;Fibroblasts: 46.5;Glandular and luminal cells: 38.2;Late spermatids: 73.6;Smooth muscle cells: 31.6,Low cancer specificity,Detected in many,,,Region enhanced,Detected in single,,cerebellum: 2.8,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,6.0,Bladder cancer: 6.7;Gastric cancer: 4.2;ovarian cancer: 12.3;Rhabdoid: 5.1,"Testis - Early spermatids, Testis - Late spermatids",Low region specificity,Detected in single,,,Low region specificity,Detected in single,,,HPA077555,,,Approved,Golgi apparatus,Secreted to extracellular matrix,Cell adhesion,,,,1500000000.0,,Cluster 21: Testis - Unknown function,Cluster 35: Non-specific - DNA binding,Cluster 64: Connective tissue cells - ECM organization,Cluster 32: Smooth muscle cells - Muscle contraction,7.0,Golgi apparatus,,HPA077555: ,unprognostic (1.26e-1),unprognostic (7.22e-2),prognostic unfavorable (9.08e-5),prognostic unfavorable (2.04e-4),unprognostic (8.05e-2),unprognostic (8.45e-2),unprognostic (3.62e-2),unprognostic (5.12e-2),unprognostic (1.65e-1),unprognostic (1.55e-2),unprognostic (2.18e-2),unprognostic (3.85e-1),prognostic unfavorable (1.52e-6),unprognostic (5.96e-3),unprognostic (1.44e-1),unprognostic (2.87e-2),prognostic unfavorable (6.95e-4)
C5,"C5a, C5b, CPAMD4",ENSG00000106804,Complement C5,P01031,9,120932987-121075195,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Inflammatory response, Innate immunity",,FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,30.0,liver: 434.4,Cell type enriched,Detected in many,14.0,Hepatocytes: 435.9,Cancer enriched,Detected in many,17.0,liver cancer: 73.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,liver cancer: 21.1,"Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in single,,,Low region specificity,Detected in many,,,HPA029339,Supported,,,,Secreted to blood,Complement pathway,,,113000000000.0,39000000000.0,,Cluster 83: Liver - Metabolism,Cluster 46: Brainstem - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,17.0,,,HPA029339: AB_10601125,unprognostic (2.51e-1),unprognostic (5.88e-3),unprognostic (2.50e-3),unprognostic (1.57e-2),unprognostic (5.05e-2),unprognostic (9.52e-3),prognostic favorable (9.43e-4),unprognostic (1.83e-1),unprognostic (3.19e-2),unprognostic (1.55e-1),unprognostic (2.35e-2),unprognostic (4.41e-2),unprognostic (1.46e-5),unprognostic (5.91e-2),unprognostic (1.20e-1),unprognostic (3.67e-2),unprognostic (2.75e-1)
AMBP,"EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI",ENSG00000106927,Alpha-1-microglobulin/bikunin precursor,P02760,9,114060127-114078328,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Host-virus interaction,"Oxidoreductase, Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,68.0,liver: 10607.0,Group enriched,Detected in many,23.0,Cholangiocytes: 2459.2;Hepatocytes: 9092.4,Cancer enriched,Detected in many,115.0,liver cancer: 2620.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,8.0,liver cancer: 556.5,"Breast - Breast glandular cells, Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001497, CAB069436, HPA075585",Approved,,Approved,"Golgi apparatus,Vesicles,Cytosol",Secreted to blood,Enzyme,,,,47000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,2.0,Vesicles,"Golgi apparatus, Cytosol","CAB069436: AB_1611916, HPA001497: AB_1078144, HPA075585: ",unprognostic (6.92e-2),unprognostic (3.61e-1),unprognostic (4.95e-3),prognostic favorable (1.20e-4),unprognostic (9.79e-2),unprognostic (2.90e-1),unprognostic (1.04e-3),unprognostic (7.59e-2),unprognostic (2.83e-2),unprognostic (2.04e-1),unprognostic (2.14e-1),unprognostic (7.84e-2),unprognostic (4.36e-2),unprognostic (2.89e-3),unprognostic (4.66e-2),unprognostic (2.97e-3),unprognostic (9.45e-3)
PFN1,,ENSG00000108518,Profilin 1,P07737,17,4945652-4949061,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Actin-binding,"Amyotrophic lateral sclerosis, Disease variant, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 5808.0;Hofbauer cells: 4235.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Skeletal muscle - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in single,,,"CAB037134, CAB037140",Enhanced,,Approved,Cytosol,,,,,,660000000.0,Cluster 29: Non-specific - Unknown function,Cluster 70: Lymphoid tissue - Immune response,Cluster 27: Non-specific - Mixed function,Cluster 42: Non-specific - Unknown function,Cluster 14: Langerhans cells - Innate immune response,2.0,Cytosol,,"CAB037134: AB_1079599, CAB037140: AB_1079598",unprognostic (1.07e-1),unprognostic (3.57e-1),unprognostic (1.60e-1),unprognostic (5.45e-3),unprognostic (1.65e-1),unprognostic (7.54e-2),unprognostic (4.01e-3),unprognostic (7.83e-3),unprognostic (3.38e-1),unprognostic (1.09e-3),unprognostic (2.17e-1),unprognostic (3.40e-2),prognostic unfavorable (1.06e-4),unprognostic (3.62e-1),unprognostic (8.17e-2),unprognostic (1.02e-2),unprognostic (1.28e-1)
VTN,VN,ENSG00000109072,Vitronectin,P04004,17,28367284-28373091,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins, Transporters",Cell adhesion,Heparin-binding,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,61.0,liver: 5852.0,Cell type enriched,Detected in many,4.0,Hepatocytes: 4354.3,Cancer enriched,Detected in many,85.0,liver cancer: 2216.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,liver cancer: 132.3,"Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,"CAB016695, CAB016765, HPA060933, HPA068011",Supported,,Supported,"Endoplasmic reticulum,Vesicles",Secreted to blood,Cell adhesion,,,606000000000.0,33000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,7.0,"Endoplasmic reticulum, Vesicles",,"CAB016695: AB_1624536, CAB016765: , HPA060933: AB_2684389, HPA068011: ",unprognostic (1.19e-1),unprognostic (2.12e-1),unprognostic (2.29e-2),unprognostic (6.13e-2),unprognostic (9.74e-2),unprognostic (8.42e-2),prognostic favorable (3.74e-4),unprognostic (6.20e-2),unprognostic (3.97e-1),unprognostic (8.95e-2),unprognostic (3.24e-3),unprognostic (1.01e-2),prognostic unfavorable (4.10e-11),unprognostic (8.82e-3),unprognostic (2.27e-1),unprognostic (4.86e-3),unprognostic (7.09e-2)
PF4V1,"CXCL4L1, CXCL4V1, SCYB4V1",ENSG00000109272,Platelet factor 4 variant 1,P10720,4,73853296-73854483,"Plasma proteins, Predicted secreted proteins",,"Cytokine, Heparin-binding",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,intestine: 1.6;lymphoid tissue: 2.3,Cell type enhanced,Detected in some,,Cholangiocytes: 17.2;Club cells: 10.7;Enteroendocrine cells: 16.0;Hepatocytes: 4.0,Cancer enhanced,Detected in some,,renal cancer: 3.4,Not detected,Not detected,,,Group enriched,Detected in some,42.0,basophil: 12.5;neutrophil: 9.2,Lineage enriched,Detected in single,48.0,granulocytes: 12.5,Cancer enhanced,Detected in single,,thyroid cancer: 1.2,,,,,,,,,,HPA052485,Supported,,,,Secreted to blood,Cytokine,,,,,Cluster 4: Neutrophils - Degranulation,Cluster 25: Small intestine - Absorption,,Cluster 64: Connective tissue cells - ECM organization,Cluster 57: Platelets - Hemostasis,1.0,,,HPA052485: AB_2681847,,unprognostic (4.95e-1),unprognostic (5.68e-2),unprognostic (1.54e-1),unprognostic (1.16e-3),unprognostic (9.88e-2),unprognostic (1.72e-2),unprognostic (1.68e-3),,unprognostic (2.66e-1),unprognostic (6.02e-2),unprognostic (2.65e-1),unprognostic (1.95e-3),unprognostic (1.39e-2),,,unprognostic (2.11e-1)
HGFAC,"HGFA, HGFAP",ENSG00000109758,HGF activator,Q04756,4,3441968-3449486,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",,"Hydrolase, Protease, Serine protease",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,57.0,liver: 211.9,Group enriched,Detected in some,5.0,Early spermatids: 75.5;Hepatocytes: 55.8;Late spermatids: 163.2,Cancer enriched,Detected in some,22.0,liver cancer: 26.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,thyroid cancer: 1.1,,Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA058279, HPA059076",Enhanced,,,,Secreted to blood,Enzyme,,,7590000.0,9300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 48: Non-specific - Mixed function,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 11: Late spermatids - Unknown function,4.0,,,"HPA058279: AB_2683665, HPA059076: AB_2683898",unprognostic (2.70e-2),unprognostic (8.20e-2),unprognostic (1.57e-1),unprognostic (1.86e-1),unprognostic (1.36e-1),unprognostic (1.39e-2),unprognostic (2.85e-3),unprognostic (5.37e-3),unprognostic (5.90e-2),unprognostic (1.81e-1),unprognostic (8.54e-3),unprognostic (5.52e-2),prognostic unfavorable (9.31e-4),unprognostic (2.87e-1),unprognostic (2.24e-1),unprognostic (9.49e-2),unprognostic (3.74e-4)
HSPA8,"HSC70, HSC71, HSP73, HSPA10",ENSG00000109971,Heat shock protein family A (Hsp70) member 8,P11142,11,123057489-123063230,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins","Autophagy, Host-virus interaction, mRNA processing, mRNA splicing, Stress response, Transcription, Transcription regulation","Chaperone, Hydrolase, Repressor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Adipocytes (Breast), Testis - Spermatogonia",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002056, HPA052504",Uncertain,,Approved,"Nucleoplasm,Vesicles",,,,Yes,,140000000.0,Cluster 9: T-regs - Cell cycle regulation,Cluster 23: Non-specific - Cellular respiration,Cluster 21: Non-specific - Metabolism,Cluster 22: Non-specific - mRNA splicing & Cell cycle,Cluster 80: Non-specific - Transcription,35.0,Nucleoplasm,Vesicles,"CAB002056: , HPA052504: AB_2681854",unprognostic (2.28e-3),unprognostic (1.19e-3),prognostic favorable (6.14e-6),unprognostic (1.75e-1),unprognostic (1.84e-2),unprognostic (5.70e-2),prognostic unfavorable (1.93e-4),unprognostic (9.65e-3),unprognostic (3.82e-1),unprognostic (9.64e-2),unprognostic (2.93e-1),unprognostic (3.22e-1),prognostic favorable (3.81e-4),unprognostic (2.53e-1),unprognostic (1.83e-1),unprognostic (2.74e-1),unprognostic (7.16e-2)
HPX,,ENSG00000110169,Hemopexin,P02790,11,6431049-6442617,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Host-virus interaction, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,886.0,liver: 5126.7,Cell type enriched,Detected in some,23.0,Hepatocytes: 4942.9,Cancer enriched,Detected in many,79.0,liver cancer: 571.1,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 9.0,"Breast - Breast glandular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016725, HPA065318, HPA068847",Approved,,,,Secreted to blood,Transport,,,425000000000.0,190000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,"CAB016725: , HPA065318: , HPA068847: ",unprognostic (3.39e-2),unprognostic (9.26e-2),unprognostic (3.88e-1),unprognostic (6.19e-4),unprognostic (2.05e-2),unprognostic (2.41e-1),prognostic favorable (2.26e-4),unprognostic (6.33e-2),unprognostic (5.67e-3),unprognostic (3.88e-1),unprognostic (5.08e-3),unprognostic (2.78e-2),unprognostic (5.82e-12),unprognostic (2.01e-1),unprognostic (4.48e-1),unprognostic (1.84e-2),unprognostic (2.14e-2)
APOA5,"APOA-V, RAP3",ENSG00000110243,Apolipoprotein A5,Q6Q788,11,116789367-116792420,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,218.0,liver: 567.7,Cell type enriched,Detected in some,59.0,Hepatocytes: 1096.0,Cancer enriched,Detected in single,489.0,liver cancer: 112.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,18.0,liver cancer: 2.7,"Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Apolipoprotein,,,114000000.0,21000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,12.0,,,,unprognostic (1.57e-4),,,,,,unprognostic (4.67e-3),unprognostic (5.57e-2),,unprognostic (2.60e-3),,unprognostic (2.40e-1),,unprognostic (2.31e-4),,,
APOA4,,ENSG00000110244,Apolipoprotein A4,P06727,11,116820700-116823304,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,intestine: 3023.3,Cell type enriched,Detected in some,29.0,Proximal enterocytes: 7501.7,Cancer enriched,Detected in some,29.0,liver cancer: 291.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,7.0,liver cancer: 3.8,,Not detected,Not detected,,,Not detected,Not detected,,,"HPA001352, HPA002549, CAB068250, CAB068251, CAB068252",Enhanced,,Approved,Vesicles,Secreted to blood,Apolipoprotein,,,61200000000.0,74000000000.0,,Cluster 25: Small intestine - Absorption,,Cluster 34: Testis cancer - Unknown function,Cluster 22: Proximal enterocytes - Digestion,4.0,Vesicles,,"CAB068250: AB_2665657, CAB068251: AB_2665659, CAB068252: AB_2665658, HPA001352: AB_1078179, HPA002549: AB_1078177",,,,,,,unprognostic (8.81e-2),,,,unprognostic (2.12e-2),,,unprognostic (1.75e-2),unprognostic (7.91e-2),,
APOC3,"Apo-C3, Apo-CIII, ApoC-3, ApoC-III, APOCIII",ENSG00000110245,Apolipoprotein C3,P02656,11,116829706-116833072,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid degradation, Lipid metabolism, Lipid transport, Transport",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,25.0,liver: 26980.2,Cell type enriched,Detected in some,9.0,Hepatocytes: 87587.5,Cancer enriched,Detected in many,643.0,liver cancer: 4021.9,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,4.0,liver cancer: 40.4,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Low region specificity,Detected in some,,,Not detected,Not detected,,,"HPA065365, HPA073918",Supported,,Approved,"Nucleoplasm,Nucleoli,Cell Junctions",Secreted to blood,Apolipoprotein,,,106000000000.0,45000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,Nucleoplasm,"Nucleoli, Cell Junctions","HPA065365: AB_2732733, HPA073918: ",,,,,,,prognostic favorable (3.77e-4),,,,unprognostic (2.33e-1),,prognostic unfavorable (6.87e-5),unprognostic (1.60e-2),unprognostic (5.21e-2),,
GAPDH,GAPD,ENSG00000111640,Glyceraldehyde-3-phosphate dehydrogenase,P04406,12,6534512-6538374,"Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins","Apoptosis, Glycolysis, Immunity, Innate immunity, Translation regulation","Oxidoreductase, Transferase",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,skeletal muscle: 26611.3;tongue: 18150.7,Cell type enhanced,Detected in all,,Extravillous trophoblasts: 11520.0,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Skeletal muscle - Skeletal myocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB005197, CAB016392, HPA040067, HPA061280, CAB079968",Supported,,Enhanced,"Nuclear membrane,Vesicles,Plasma membrane,Cytosol",,,No,No,,1400000000.0,Cluster 26: Monocytes - Plasma membrane proteins,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 27: Non-specific - Mixed function,Cluster 38: Non-specific - Transcription,Cluster 45: Non-specific - Mixed function,28.0,"Plasma membrane, Cytosol","Nuclear membrane, Vesicles","CAB005197: AB_641107, CAB016392: AB_627678, CAB079968: , HPA040067: AB_10965903, HPA061280: AB_2684463",unprognostic (3.03e-1),unprognostic (2.62e-3),unprognostic (3.58e-2),unprognostic (4.20e-1),unprognostic (9.73e-3),unprognostic (1.77e-3),prognostic unfavorable (1.79e-6),unprognostic (2.89e-3),unprognostic (2.86e-1),unprognostic (2.06e-2),unprognostic (9.50e-3),unprognostic (4.52e-1),prognostic unfavorable (6.25e-10),unprognostic (2.33e-1),unprognostic (4.28e-1),unprognostic (1.40e-1),unprognostic (1.26e-2)
C7,,ENSG00000112936,Complement C7,P10643,5,40909492-41020216,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 884.6,Group enriched,Detected in many,4.0,Fibroblasts: 729.1;Leydig cells: 1107.4,Cancer enriched,Detected in all,4.0,pancreatic cancer: 73.8,Region enhanced,Detected in many,,choroid plexus: 33.5,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,12.0,Neuroblastoma: 50.9,"Heart muscle - Fibroblasts, Kidney - Fibroblasts, Liver - Hepatic stellate cells, Lung - Fibroblast_2, Pancreas - Fibroblasts, Prostate - Fibroblasts",Not detected,Not detected,,,Region enhanced,Detected in many,,spinal cord: 18.6,HPA001465,Approved,,,,Secreted to blood,Complement pathway,,,,48000000000.0,,Cluster 7: Adipose tissue - Mixed function,Cluster 8: Immune cells - Immune response,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,1.0,,,HPA001465: AB_1078554,unprognostic (5.01e-2),unprognostic (3.74e-2),unprognostic (7.40e-2),unprognostic (4.68e-3),unprognostic (5.35e-2),unprognostic (1.43e-3),prognostic favorable (5.89e-4),unprognostic (6.67e-2),unprognostic (3.45e-1),unprognostic (2.21e-2),unprognostic (1.33e-1),unprognostic (1.93e-3),unprognostic (2.24e-2),unprognostic (6.10e-3),unprognostic (1.12e-1),unprognostic (2.14e-1),unprognostic (2.06e-3)
THBS4,,ENSG00000113296,Thrombospondin 4,P35443,5,79991311-80083287,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Cell adhesion, Tissue remodeling, Unfolded protein response","Growth factor, Mitogen",Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 209.2;heart muscle: 162.0;smooth muscle: 243.3;tongue: 206.3,Cell type enhanced,Detected in many,,Adipocytes: 40.7;Cone photoreceptor cells: 52.7;Early spermatids: 50.7;Fibroblasts: 71.4;Oligodendrocyte precursor cells: 56.6;Peritubular cells: 42.2;Prostatic glandular cells: 46.7;Sertoli cells: 182.2;Smooth muscle cells: 56.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,46.0,eosinophil: 4.6,Lineage enriched,Detected in single,46.0,granulocytes: 4.6,Low cancer specificity,Detected in many,,,Skeletal muscle - Fibroblasts,Region enriched,Detected in many,8.0,white matter: 85.8,Region enriched,Detected in many,29.0,spinal cord: 117.4,"CAB004597, HPA042426",Approved,,Approved,Vesicles,Secreted to extracellular matrix,Growth factor,,,,510000000.0,Cluster 22: Eosinophils - Transcription,Cluster 7: Adipose tissue - Mixed function,Cluster 41: Monoamines - Neurotransmitter signalling,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,Vesicles,,"CAB004597: AB_628352, HPA042426: AB_2677992",unprognostic (1.41e-1),unprognostic (5.33e-2),unprognostic (4.26e-3),unprognostic (3.64e-2),unprognostic (9.94e-2),unprognostic (8.10e-2),unprognostic (5.64e-2),unprognostic (7.12e-2),unprognostic (1.66e-1),unprognostic (2.25e-1),unprognostic (2.06e-1),unprognostic (2.14e-1),unprognostic (1.96e-3),unprognostic (2.74e-2),unprognostic (3.98e-2),unprognostic (1.76e-3),prognostic unfavorable (3.33e-4)
C9,,ENSG00000113600,Complement C9,P02748,5,39284140-39371324,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,"Age-related macular degeneration, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,264.0,liver: 1268.7,Cell type enriched,Detected in some,10.0,Hepatocytes: 1939.7,Cancer enriched,Detected in single,244.0,liver cancer: 90.4,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in some,,,"CAB002151, HPA029577",Uncertain,,,,Secreted to blood,Complement pathway,,,69600000000.0,64000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB002151: AB_563670, HPA029577: AB_10603779",unprognostic (1.00e-1),unprognostic (1.57e-1),unprognostic (1.50e-1),,unprognostic (2.01e-1),unprognostic (6.58e-2),unprognostic (1.30e-1),unprognostic (2.91e-1),unprognostic (5.49e-3),,unprognostic (1.91e-2),unprognostic (1.29e-2),unprognostic (2.19e-2),unprognostic (9.43e-5),unprognostic (1.36e-1),unprognostic (1.80e-1),unprognostic (2.04e-1)
KNG1,"BDK, BK, HK, HMWK, KNG",ENSG00000113889,Kininogen 1,P01042,3,186717348-186744410,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis, Inflammatory response","Protease inhibitor, Thiol protease inhibitor, Vasoactive, Vasodilator",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,7.0,liver: 3097.3,Cell type enriched,Detected in some,6.0,Hepatocytes: 1654.3,Cancer enriched,Detected in some,126.0,liver cancer: 608.6,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,11.0,Gastric cancer: 4.6;liver cancer: 8.0,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in single,,,"HPA001616, HPA001645, CAB009809",Enhanced,,,,Secreted to blood,Blood coagulation,,,90000000000.0,47000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB009809: AB_2134781, HPA001616: AB_1079216, HPA001645: AB_1079215",unprognostic (3.88e-1),unprognostic (1.63e-1),unprognostic (2.82e-1),unprognostic (3.27e-1),unprognostic (8.30e-3),unprognostic (2.04e-1),prognostic favorable (1.28e-6),unprognostic (1.29e-2),unprognostic (1.10e-1),unprognostic (1.97e-2),unprognostic (9.96e-2),unprognostic (1.65e-1),unprognostic (3.45e-3),unprognostic (5.20e-2),unprognostic (2.46e-1),unprognostic (4.52e-2),
HRG,"HPRG, HRGP",ENSG00000113905,Histidine rich glycoprotein,P04196,3,186660216-186678234,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins","Angiogenesis, Blood coagulation, Chemotaxis, Fibrinolysis, Hemostasis",Heparin-binding,"Disease variant, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,174.0,liver: 5270.7,Cell type enriched,Detected in some,11.0,Hepatocytes: 396.9,Cancer enriched,Detected in some,262.0,liver cancer: 406.7,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Ascending Loop of Henle cells, Liver - Hepatocytes",Not detected,Not detected,,,Not detected,Not detected,,,"HPA050269, HPA054598",Supported,,,,Secreted to blood,Blood coagulation,,,120000000000.0,28000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,,,"HPA050269: AB_2681068, HPA054598: AB_2682539",,unprognostic (2.67e-1),,unprognostic (1.74e-2),,unprognostic (7.58e-5),prognostic favorable (9.64e-5),unprognostic (1.44e-1),,unprognostic (2.98e-3),unprognostic (2.22e-1),,unprognostic (1.55e-2),unprognostic (1.14e-1),unprognostic (5.50e-2),unprognostic (1.05e-1),unprognostic (1.46e-2)
FN1,"CIG, FINC, GFND2, LETS, MSF",ENSG00000115414,Fibronectin 1,P02751,2,215360440-215436073,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Angiogenesis, Cell adhesion, Cell shape",Heparin-binding,"Cancer-related genes, Disease variant, Dwarfism, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 1674.5;placenta: 2828.8,Cell type enhanced,Detected in many,,Extravillous trophoblasts: 3161.0;Fibroblasts: 697.7;Hepatocytes: 800.2;Pancreatic endocrine cells: 517.9;Smooth muscle cells: 482.6,Cancer enhanced,Detected in all,,thyroid cancer: 833.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in all,,testis cancer: 4284.8;thyroid cancer: 4456.7,"Adipose subcutaneous - Adipose progenitor cells, Breast - Fibroblasts, Colon - Smooth muscle cells, Prostate - Smooth muscle cells, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000126, HPA027066",Enhanced,,,,Secreted to blood,Acute phase,,,227000000000.0,47000000000.0,,Cluster 11: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 64: Connective tissue cells - ECM organization,Cluster 32: Smooth muscle cells - Muscle contraction,21.0,,,"CAB000126: , HPA027066: AB_10602500",unprognostic (8.08e-2),unprognostic (1.09e-3),unprognostic (2.20e-2),unprognostic (3.45e-3),unprognostic (1.82e-2),unprognostic (3.47e-3),unprognostic (3.36e-2),unprognostic (5.91e-3),unprognostic (2.96e-2),unprognostic (2.91e-3),unprognostic (1.41e-2),unprognostic (2.84e-1),prognostic unfavorable (3.44e-8),prognostic unfavorable (8.82e-5),unprognostic (7.88e-2),unprognostic (7.74e-2),prognostic unfavorable (3.33e-4)
IGFBP2,IBP2,ENSG00000115457,Insulin like growth factor binding protein 2,P18065,2,216632828-216664436,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Growth regulation,Growth factor binding,Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,pancreas: 926.0,Cell type enhanced,Detected in many,,Breast myoepithelial cells: 656.1;Endometrial stromal cells: 1446.9;Granulosa cells: 948.5;Hepatocytes: 527.2,Low cancer specificity,Detected in all,,,Region enriched,Detected in all,8.0,choroid plexus: 238.7,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in all,,,"Pancreas - Exocrine glandular cells, Stomach - Parietal cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA077723,,,Approved,Endoplasmic reticulum,Secreted to blood,Other,,,303000000.0,810000000.0,,Cluster 68: Non-specific - Protein processing,Cluster 23: Choroid plexus - Mixed function,Cluster 49: HMC-1 - Innate immune response,Cluster 9: Endometrial stromal cells - Transcription,1.0,Endoplasmic reticulum,,HPA077723: AB_2686853,unprognostic (2.58e-1),unprognostic (5.95e-2),unprognostic (1.94e-1),unprognostic (3.32e-3),unprognostic (9.50e-3),unprognostic (2.36e-2),unprognostic (2.06e-1),unprognostic (9.11e-3),prognostic unfavorable (2.43e-4),unprognostic (2.34e-1),unprognostic (1.63e-3),unprognostic (1.82e-1),prognostic unfavorable (2.22e-5),unprognostic (5.04e-2),unprognostic (1.07e-1),unprognostic (5.83e-2),unprognostic (1.22e-1)
PROC,,ENSG00000115718,"Protein C, inactivator of coagulation factors Va and VIIIa",P04070,2,127418427-127429242,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,40.0,liver: 584.1,Cell type enriched,Detected in some,4.0,Hepatocytes: 339.4,Cancer enriched,Detected in many,22.0,liver cancer: 118.3,Low region specificity,Detected in many,,,Immune cell enriched,Detected in some,9.0,plasmacytoid DC: 59.8,Lineage enriched,Detected in many,9.0,dendritic cells: 59.8,Cancer enriched,Detected in many,6.0,liver cancer: 28.4,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Skin - Outer root sheath cells",,,,,Not detected,Not detected,,,"HPA005550, CAB016721, CAB016792",Approved,,,,Secreted to blood,Blood coagulation,,,,5200000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 26: Oligodendrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB016721: , CAB016792: , HPA005550: AB_1079687",unprognostic (2.46e-2),unprognostic (1.08e-1),unprognostic (1.38e-1),unprognostic (1.58e-1),unprognostic (6.64e-2),unprognostic (3.13e-2),unprognostic (4.90e-3),unprognostic (2.63e-1),unprognostic (1.67e-1),unprognostic (3.29e-1),unprognostic (3.74e-3),unprognostic (2.56e-2),unprognostic (8.12e-3),unprognostic (2.01e-2),unprognostic (1.71e-1),unprognostic (4.60e-3),unprognostic (8.06e-2)
QSOX1,QSCN6,ENSG00000116260,Quiescin sulfhydryl oxidase 1,O00391,1,180154869-180204030,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",,Oxidoreductase,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enriched,Detected in many,8.0,Extravillous trophoblasts: 1872.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Prostate - Fibroblasts,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA056243,,,Supported,"Golgi apparatus,Vesicles",Secreted to extracellular matrix,Enzyme,,,,2600000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 20: Macrophages & Microglia - Immune response,Cluster 64: Connective tissue cells - ECM organization,Cluster 4: Extravillous trophoblasts - Unknown function,,Golgi apparatus,Vesicles,HPA056243: AB_2683077,unprognostic (1.13e-1),unprognostic (2.62e-3),unprognostic (2.46e-1),unprognostic (2.49e-2),unprognostic (2.00e-2),unprognostic (2.73e-1),unprognostic (5.47e-2),unprognostic (2.22e-1),unprognostic (3.94e-1),unprognostic (3.12e-2),unprognostic (5.07e-2),unprognostic (2.80e-3),prognostic unfavorable (1.86e-5),unprognostic (3.25e-1),unprognostic (2.14e-1),unprognostic (3.53e-2),unprognostic (1.40e-1)
PRG4,"bG174L6.2, CACP, FLJ32635, HAPO, JCAP, MSF, SZP",ENSG00000116690,Proteoglycan 4,Q92954,1,186296279-186314567,"Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,adipose tissue: 90.2;liver: 180.2,Cell type enriched,Detected in some,11.0,Mesothelial cells: 3614.7,Cancer enriched,Detected in many,10.0,liver cancer: 28.4,Region enriched,Detected in some,8.0,hypothalamus: 66.4,Immune cell enriched,Detected in single,5.0,T-reg: 1.2,Lineage enriched,Detected in single,12.0,T-cells: 1.2,Cancer enriched,Detected in some,18.0,Rhabdoid: 33.0,"Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Low region specificity,Detected in many,,,Low region specificity,Detected in some,,,CAB054258,Supported,,,,Secreted to extracellular matrix,No annotated function,,,,4300000000.0,Cluster 16: Non-specific - Cell proliferation,Cluster 83: Liver - Metabolism,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,,,CAB054258: ,unprognostic (8.67e-2),unprognostic (2.28e-1),unprognostic (1.82e-3),unprognostic (1.98e-1),unprognostic (1.77e-1),unprognostic (7.87e-2),unprognostic (7.33e-2),unprognostic (1.78e-1),unprognostic (1.28e-1),unprognostic (1.53e-1),unprognostic (5.03e-2),unprognostic (4.11e-1),unprognostic (1.91e-13),unprognostic (1.40e-2),unprognostic (2.60e-1),unprognostic (1.60e-3),unprognostic (7.05e-3)
SERPINC1,"AT3, ATIII, MGC22579",ENSG00000117601,Serpin family C member 1,P01008,1,173903800-173917327,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor","Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,1350.0,liver: 4902.3,Cell type enriched,Detected in some,36.0,Hepatocytes: 2537.3,Cancer enriched,Detected in some,871.0,liver cancer: 1504.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,Gastric cancer: 1.6;liver cancer: 5.7,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001816, CAB016790, HPA024007",Supported,,,,Secreted to blood,Blood coagulation,,,,120000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,,,"CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732",unprognostic (1.28e-2),unprognostic (2.22e-1),unprognostic (3.83e-2),unprognostic (5.98e-2),unprognostic (6.91e-2),unprognostic (1.93e-2),prognostic favorable (3.40e-5),unprognostic (1.75e-2),unprognostic (8.67e-2),unprognostic (3.48e-2),unprognostic (4.74e-2),unprognostic (1.91e-1),unprognostic (2.36e-2),unprognostic (5.28e-3),unprognostic (5.80e-2),unprognostic (6.35e-2),unprognostic (8.21e-2)
APOA1,,ENSG00000118137,Apolipoprotein A1,P02647,11,116835751-116837622,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,"Amyloidosis, Atherosclerosis, Cancer-related genes, Disease variant, Neuropathy",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,liver: 18779.1,Group enriched,Detected in many,13.0,Hepatocytes: 24174.5;Proximal enterocytes: 12804.9,Cancer enriched,Detected in many,48.0,liver cancer: 4515.8,Low region specificity,Detected in some,,,Immune cell enhanced,Detected in single,,plasmacytoid DC: 1.2,Low lineage specificity,Detected in single,,,Group enriched,Detected in some,14.0,Gastric cancer: 176.6;liver cancer: 494.9,"Liver - Hepatocytes, Testis - Sertoli cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016778, HPA046715",Supported,,Approved,"Vesicles,Cytosol",Secreted to blood,Apolipoprotein,,,1450000000000.0,110000000000.0,,Cluster 83: Liver - Metabolism,Cluster 34: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,10.0,Vesicles,Cytosol,"CAB016778: , HPA046715: AB_2679768",unprognostic (1.88e-3),unprognostic (4.53e-2),unprognostic (7.46e-2),unprognostic (4.00e-3),unprognostic (3.70e-2),unprognostic (1.41e-1),prognostic favorable (5.05e-4),unprognostic (5.40e-2),unprognostic (1.89e-1),unprognostic (9.60e-3),unprognostic (1.59e-3),unprognostic (7.02e-2),prognostic unfavorable (1.67e-8),unprognostic (3.46e-3),unprognostic (1.15e-1),unprognostic (6.24e-2),unprognostic (9.54e-2)
TTR,"CTS, CTS1, HsT2651, PALB",ENSG00000118271,Transthyretin,P02766,18,31557009-31598833,"Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Transport,"Hormone, Thyroid hormone","Amyloidosis, Cancer-related genes, Disease variant, FDA approved drug targets, Neuropathy",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,34.0,choroid plexus: 692067.5,Cell type enriched,Detected in many,7.0,Hepatocytes: 26585.9,Group enriched,Detected in many,28.0,liver cancer: 928.2;pancreatic cancer: 666.0,Region enriched,Detected in all,82.0,choroid plexus: 302089.2,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in many,7.0,Gastric cancer: 130.8;liver cancer: 177.5,"Liver - Hepatocytes, Pancreas - Alpha cells, Testis - Early spermatids",Group enriched,Detected in all,5.0,basal ganglia: 1538.8;hippocampal formation: 4894.4;pons and medulla: 5760.6;thalamus: 3403.0,Region enhanced,Detected in all,,medulla oblongata: 1291.2,"CAB002517, HPA002550, CAB062567, CAB073406",Supported,,Approved,Golgi apparatus,Secreted to blood,Hormone,,,345000000000.0,99000000000.0,,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,56.0,Golgi apparatus,,"CAB002517: AB_563965, CAB062567: AB_2665620, CAB073406: , HPA002550: AB_1080419",unprognostic (6.79e-3),,unprognostic (3.38e-2),unprognostic (4.10e-1),unprognostic (1.74e-1),,unprognostic (1.84e-2),unprognostic (8.15e-2),unprognostic (3.74e-2),,unprognostic (9.66e-3),unprognostic (8.72e-2),unprognostic (1.23e-2),unprognostic (8.35e-3),unprognostic (5.26e-1),,unprognostic (3.52e-2)
CPN1,,ENSG00000120054,Carboxypeptidase N subunit 1,P15169,10,100042193-100081869,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",,"Carboxypeptidase, Hydrolase, Metalloprotease, Protease",Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,55.0,liver: 79.5,Cell type enriched,Detected in some,4.0,Hepatocytes: 35.4,Group enriched,Detected in some,12.0,liver cancer: 26.6;melanoma: 7.9,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,skin cancer: 35.3,Liver - Hepatocytes,Low region specificity,Detected in some,,,Not detected,Not detected,,,,,,,,Secreted to blood,Enzyme,,,,13000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 69: Skin cancer - ECM organization,Cluster 62: Hepatocytes - Metabolism,4.0,,,,,,unprognostic (2.97e-2),unprognostic (2.23e-2),,,unprognostic (3.93e-2),,unprognostic (1.64e-1),,unprognostic (6.75e-2),,unprognostic (2.93e-2),unprognostic (5.26e-2),unprognostic (2.63e-1),,
CLU,"APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2",ENSG00000120885,Clusterin,P10909,8,27596917-27614700,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Complement pathway, Immunity, Innate immunity",Chaperone,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 9442.3,Cell type enhanced,Detected in all,,Basal prostatic cells: 3199.0;Cholangiocytes: 2558.4;Collecting duct cells: 3117.6;Hepatocytes: 3758.6;Muller glia cells: 6791.7;Secretory cells: 6049.9,Cancer enhanced,Detected in all,,glioma: 1485.6,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,10.0,basophil: 773.3,Lineage enriched,Detected in all,33.0,granulocytes: 773.3,Low cancer specificity,Detected in all,,,"Liver - Hepatocytes, Lung - Fibroblast_2, Prostate - Smooth muscle cells, Testis - Sertoli cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA000572, CAB016253, HPA075983, CAB080180",Enhanced,,Supported,Cytosol,Secreted to blood,Complement pathway,,,169000000000.0,29000000000.0,Cluster 41: Basophils - Unknown function,Cluster 50: Epididymis - Male reproductive secretion,Cluster 39: Astrocytes - Mixed function,Cluster 72: Neuronal - Signal transduction,Cluster 10: Muller glia cells - Visual perception,8.0,Cytosol,,"CAB016253: AB_673562, CAB080180: , HPA000572: AB_1078539, HPA075983: ",unprognostic (1.10e-2),unprognostic (1.81e-2),unprognostic (1.14e-3),unprognostic (2.74e-2),unprognostic (5.59e-2),unprognostic (4.13e-2),unprognostic (1.76e-2),unprognostic (2.37e-1),unprognostic (1.46e-1),unprognostic (1.05e-1),unprognostic (2.87e-2),unprognostic (1.41e-1),unprognostic (1.80e-2),unprognostic (2.33e-2),unprognostic (1.72e-1),prognostic favorable (7.66e-5),unprognostic (5.29e-2)
A1BG,,ENSG00000121410,Alpha-1-B glycoprotein,P04217,19,58345178-58353492,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1513.0,liver: 1194.2,Cell type enhanced,Detected in many,,Hepatocytes: 18.2;Oligodendrocytes: 8.1;Plasma cells: 8.2,Cancer enriched,Detected in single,85.0,liver cancer: 22.3,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,,Not detected,Not detected,,,Low region specificity,Detected in many,,,"CAB016673, HPA044252",Supported,,,,Secreted to blood,No annotated function,,,200000000000.0,51000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 17: Choroid plexus - Cilium,Cluster 18: Liver cancer - Metabolism,Cluster 7: T-cells - T-cell receptor,,,,"CAB016673: AB_1611892, HPA044252: AB_2678876",unprognostic (9.95e-2),unprognostic (5.31e-2),unprognostic (3.67e-2),unprognostic (3.44e-2),unprognostic (1.18e-1),unprognostic (1.66e-2),prognostic favorable (3.97e-4),unprognostic (1.09e-1),unprognostic (2.59e-1),unprognostic (2.10e-1),unprognostic (1.47e-2),unprognostic (1.37e-2),unprognostic (4.19e-5),unprognostic (2.37e-2),unprognostic (1.94e-1),unprognostic (1.72e-1),unprognostic (6.72e-2)
PLG,,ENSG00000122194,Plasminogen,P00747,6,160702194-160754097,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,11.0,liver: 2571.0,Cell type enriched,Detected in some,8.0,Hepatocytes: 1618.7,Cancer enriched,Detected in some,84.0,liver cancer: 180.7,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,liver cancer: 2.6,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Respiratory ciliated cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB000668, CAB016678, HPA021602, HPA048823, HPA053770",Supported,,Approved,Vesicles,Secreted to blood,Blood coagulation,,,140000000000.0,45000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 14: Neurons - Synaptic function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,2.0,Vesicles,,"CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: AB_2680532, HPA053770: AB_2682256",,unprognostic (1.70e-1),,unprognostic (2.16e-3),unprognostic (2.44e-1),,unprognostic (8.54e-3),unprognostic (1.41e-1),,unprognostic (1.76e-3),unprognostic (6.28e-2),unprognostic (7.25e-2),prognostic favorable (4.22e-4),unprognostic (3.97e-3),unprognostic (5.21e-2),,unprognostic (2.33e-2)
C4BPA,C4BP,ENSG00000123838,Complement component 4 binding protein alpha,P04003,1,207104233-207144972,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,11.0,liver: 1860.6,Group enriched,Detected in some,4.0,Alveolar cells type 2: 321.7;Hepatocytes: 852.2,Cancer enriched,Detected in many,7.0,liver cancer: 434.8,Low region specificity,Detected in many,,,Immune cell enriched,Detected in single,137.0,neutrophil: 29.6,Lineage enriched,Detected in single,137.0,granulocytes: 29.6,Cancer enhanced,Detected in some,,liver cancer: 7.4;lung cancer: 3.9,"Liver - Hepatocytes, Lung - Alveolar cells type 2",Not detected,Not detected,,,Region enhanced,Detected in single,,midbrain: 1.6,"HPA000926, HPA001578",Enhanced,,,,Secreted to blood,Complement pathway,,,30800000000.0,28000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 83: Liver - Metabolism,Cluster 26: Oligodendrocytes - Mixed function,Cluster 72: Neuronal - Signal transduction,Cluster 62: Hepatocytes - Metabolism,,,,"HPA000926: AB_1078355, HPA001578: AB_1078354",unprognostic (3.85e-4),unprognostic (9.07e-2),unprognostic (2.06e-1),prognostic favorable (6.37e-5),unprognostic (3.58e-2),unprognostic (2.41e-1),prognostic favorable (2.24e-4),unprognostic (3.64e-2),unprognostic (1.94e-1),unprognostic (5.90e-4),unprognostic (4.47e-2),unprognostic (2.58e-1),unprognostic (5.51e-7),unprognostic (9.74e-2),unprognostic (2.52e-2),unprognostic (6.92e-2),unprognostic (2.66e-1)
C4BPB,C4BP,ENSG00000123843,Complement component 4 binding protein beta,P20851,1,207088860-207099993,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,13.0,liver: 458.6,Cell type enriched,Detected in many,12.0,Hepatocytes: 654.1,Cancer enriched,Detected in many,19.0,liver cancer: 83.7,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,plasmacytoid DC: 1.1,Low lineage specificity,Detected in single,,,Cancer enhanced,Detected in many,,Bile duct cancer: 39.5,"Adipose subcutaneous - Macrophages, Testis - Late spermatids",,,,,Not detected,Not detected,,,"HPA000925, HPA051620",Approved,,Uncertain,Golgi apparatus,Secreted to blood,Complement pathway,,,265000000000.0,1100000000.0,Cluster 30: Non-specific - DNA binding,Cluster 31: Liver - Plasma proteins,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 43: Hepatocytes - Metabolism,,Golgi apparatus,,"HPA000925: , HPA051620: AB_2681554",unprognostic (1.73e-1),unprognostic (2.62e-1),unprognostic (3.26e-1),unprognostic (2.07e-3),unprognostic (1.72e-1),unprognostic (2.54e-2),unprognostic (4.58e-3),unprognostic (9.49e-2),unprognostic (1.37e-1),unprognostic (4.25e-1),unprognostic (6.39e-2),unprognostic (2.64e-2),unprognostic (1.21e-2),unprognostic (1.55e-1),unprognostic (1.03e-1),unprognostic (1.05e-2),unprognostic (8.25e-2)
F13A1,F13A,ENSG00000124491,Coagulation factor XIII A chain,P00488,6,6144084-6321013,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Acyltransferase, Transferase","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,adipose tissue: 224.8;placenta: 473.0,Group enriched,Detected in many,4.0,Hofbauer cells: 791.5;Langerhans cells: 206.4;Macrophages: 321.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,classical monocyte: 141.3;myeloid DC: 179.8,Group enriched,Detected in many,184.0,dendritic cells: 179.8;granulocytes: 50.0;monocytes: 141.3,Cancer enhanced,Detected in some,,cervical cancer: 13.1;Leukemia: 20.7,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,"HPA001804, CAB002155",Enhanced,,,,Secreted to blood,Blood coagulation,,,,1400000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 58: Placenta - Pregnancy,Cluster 8: Immune cells - Immune response,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 58: Macrophages - Innate immune response,12.0,,,"CAB002155: AB_564077, HPA001804: AB_1078792",unprognostic (4.44e-1),unprognostic (5.90e-2),unprognostic (2.65e-2),unprognostic (3.93e-2),unprognostic (5.02e-2),unprognostic (3.75e-2),unprognostic (5.27e-2),unprognostic (1.96e-1),unprognostic (2.68e-2),unprognostic (6.84e-3),unprognostic (4.96e-2),unprognostic (1.97e-1),prognostic unfavorable (6.61e-6),unprognostic (2.79e-2),unprognostic (1.52e-1),unprognostic (1.57e-1),unprognostic (2.54e-3)
C3,"ARMD9, C3a, C3b, CPAMD1",ENSG00000125730,Complement C3,P01024,19,6677704-6730562,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Fatty acid metabolism, Immunity, Inflammatory response, Innate immunity, Lipid metabolism",,"Age-related macular degeneration, Disease variant, FDA approved drug targets, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,9.0,liver: 5250.9,Cell type enhanced,Detected in many,,Ductal cells: 657.6;Exocrine glandular cells: 845.2;Hepatocytes: 3158.4;Mesothelial cells: 2220.5,Cancer enriched,Detected in all,5.0,liver cancer: 1213.6,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,5.0,non-classical monocyte: 14.5,Lineage enriched,Detected in many,5.0,monocytes: 14.5,Cancer enhanced,Detected in many,,liver cancer: 255.0,"Liver - Hepatocytes, Lung - Fibroblast_2, Thyroid - Macrophages",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,"HPA003563, CAB004209, HPA020432",Enhanced,,,,Secreted to blood,Complement pathway,,,1260000000000.0,200000000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 83: Liver - Metabolism,Cluster 20: Macrophages & Microglia - Immune response,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 62: Hepatocytes - Metabolism,9.0,,,"CAB004209: AB_627277, HPA003563: AB_1847117, HPA020432: AB_1847118",unprognostic (3.26e-3),unprognostic (3.91e-1),unprognostic (3.92e-1),unprognostic (5.98e-3),unprognostic (3.31e-1),unprognostic (1.04e-1),prognostic favorable (8.11e-4),unprognostic (1.99e-1),unprognostic (9.26e-2),unprognostic (5.80e-2),unprognostic (8.12e-3),unprognostic (5.48e-2),prognostic unfavorable (1.09e-5),unprognostic (2.63e-2),unprognostic (2.49e-2),unprognostic (6.03e-3),unprognostic (3.88e-1)
F10,,ENSG00000126218,Coagulation factor X,P00742,13,113122799-113149529,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 156.1,Cell type enhanced,Detected in many,,Fibroblasts: 109.1;Hepatocytes: 170.7;Leydig cells: 217.7;Peritubular cells: 232.6;Smooth muscle cells: 57.6,Cancer enriched,Detected in many,11.0,liver cancer: 95.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Adrenocortical cancer: 6.9;liver cancer: 16.8,"Breast - Fibroblasts, Colon - Fibroblasts, Liver - Hepatocytes, Pancreas - Alpha cells, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_1, Skin - Fibroblast_2, Thyroid - Fibroblasts",Not detected,Not detected,,,Low region specificity,Detected in many,,,,,,,,Secreted to blood,Blood coagulation,,,,13000000000.0,,Cluster 83: Liver - Metabolism,Cluster 49: Hindbrain - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 53: Fibroblasts - ECM organization,3.0,,,,unprognostic (4.18e-2),unprognostic (1.07e-1),unprognostic (7.62e-2),unprognostic (9.88e-2),unprognostic (9.44e-2),unprognostic (1.15e-2),unprognostic (4.90e-2),unprognostic (1.02e-2),unprognostic (2.54e-1),unprognostic (1.24e-1),prognostic favorable (1.82e-5),unprognostic (6.39e-2),prognostic unfavorable (5.14e-5),unprognostic (6.60e-2),unprognostic (1.21e-1),unprognostic (3.87e-2),unprognostic (2.23e-3)
PROZ,PZ,ENSG00000126231,"Protein Z, vitamin K dependent plasma glycoprotein",P22891,13,113158648-113172386,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",Serine protease homolog,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,8.0,liver: 106.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 63.9,Cancer enriched,Detected in single,27.0,liver cancer: 12.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in some,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,,,,,HPA052006,Supported,,,,Secreted to blood,Blood coagulation,,,1720000000.0,650000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 5: Non-specific - Mixed function,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA052006: AB_2681691,unprognostic (5.03e-2),unprognostic (4.05e-2),unprognostic (1.11e-1),unprognostic (2.36e-1),unprognostic (6.48e-2),unprognostic (1.39e-1),prognostic favorable (3.46e-4),unprognostic (4.10e-1),unprognostic (2.21e-1),unprognostic (2.50e-1),unprognostic (5.20e-2),unprognostic (2.87e-1),unprognostic (9.83e-2),unprognostic (5.63e-2),unprognostic (1.41e-1),unprognostic (9.99e-2),unprognostic (2.51e-4)
CFP,PFC,ENSG00000126759,Complement factor properdin,P27918,X,47623172-47630305,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity",,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,6.0,bone marrow: 83.0;lymphoid tissue: 57.0,Cell type enhanced,Detected in some,,Kupffer cells: 8.4;Langerhans cells: 21.9;Macrophages: 43.6;monocytes: 11.1,Low cancer specificity,Detected in many,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,8.0,classical monocyte: 1169.0;intermediate monocyte: 1275.0;myeloid DC: 995.2;neutrophil: 733.0;non-classical monocyte: 872.6,Group enriched,Detected in all,46.0,dendritic cells: 995.2;granulocytes: 733.0;monocytes: 1275.0,Cancer enriched,Detected in some,9.0,Leukemia: 12.2,"Adipose subcutaneous - Macrophages, Breast - Macrophages, Colon - Macrophages, Lung - Neutrophil_2, Skeletal muscle - Macrophages, Stomach - Macrophages",Low region specificity,Detected in many,,,Low region specificity,Detected in some,,,HPA072644,,,Approved,Vesicles,Secreted to blood,Immunity,,,,6200000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 15: Non-specific - Transcription,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 29: Monocytes - Innate immune response,22.0,Vesicles,,HPA072644: ,unprognostic (2.77e-3),unprognostic (2.21e-3),unprognostic (1.00e-1),unprognostic (2.15e-2),unprognostic (4.15e-2),unprognostic (9.66e-5),unprognostic (9.90e-3),unprognostic (1.30e-2),unprognostic (5.37e-2),unprognostic (1.20e-1),unprognostic (1.08e-2),unprognostic (2.70e-1),unprognostic (1.97e-2),unprognostic (2.58e-1),unprognostic (1.32e-1),unprognostic (4.62e-2),unprognostic (2.17e-1)
MASP1,"CRARF, MAP-1, Map44, MASP, MASP-3, PRSS5",ENSG00000127241,MBL associated serine protease 1,P48740,3,187217282-187291980,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Complement activation lectin pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,cervix: 116.0;heart muscle: 111.9;liver: 178.0,Cell type enhanced,Detected in some,,Astrocytes: 26.6;Cardiomyocytes: 29.0;Cholangiocytes: 26.7;Endometrial stromal cells: 29.6;Fibroblasts: 16.5;Hepatocytes: 57.4,Group enriched,Detected in some,9.0,glioma: 6.8;liver cancer: 7.7;prostate cancer: 3.0;renal cancer: 3.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 11.8;Rhabdoid: 14.6,"Breast - Fibroblasts, Pancreas - Fibroblasts, Prostate - Smooth muscle cells, Skin - Fibroblast_1, Skin - Fibroblast_2",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001617, HPA009641",Supported,,Enhanced,"Nucleoplasm,Cytosol",Secreted to blood,Immunity,No,,8670000000.0,1900000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,"Nucleoplasm, Cytosol",,"HPA001617: AB_1079314, HPA009641: AB_1079313",unprognostic (1.67e-1),unprognostic (1.02e-2),unprognostic (1.99e-1),unprognostic (5.20e-2),unprognostic (1.02e-2),unprognostic (1.25e-6),prognostic favorable (2.20e-4),unprognostic (9.92e-2),unprognostic (3.22e-1),unprognostic (2.29e-1),unprognostic (4.18e-1),unprognostic (1.29e-1),unprognostic (2.82e-3),unprognostic (3.56e-3),unprognostic (1.97e-1),unprognostic (7.85e-2),unprognostic (4.29e-1)
RAP1B,"DKFZp586H0723, K-REV, RAL1B",ENSG00000127314,"RAP1B, member of RAS oncogene family",P61224,12,68610855-68671901,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",,Hydrolase,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,monocytes: 1030.1;NK-cells: 597.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Endothelial cells, Heart muscle - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,,,,,,,,,,,,Cluster 28: Neutrophils - Unknown function,Cluster 77: Bone marrow - Cell proliferation,Cluster 55: Non-specific - Transcription,Cluster 5: Rhabdoid - Unknown function,Cluster 57: Platelets - Hemostasis,6.0,,,,unprognostic (1.20e-1),unprognostic (1.47e-3),unprognostic (1.11e-1),unprognostic (1.20e-1),unprognostic (4.15e-2),unprognostic (7.23e-2),unprognostic (1.60e-3),unprognostic (1.48e-1),unprognostic (5.83e-2),unprognostic (1.80e-1),unprognostic (2.01e-2),unprognostic (2.86e-1),prognostic unfavorable (8.08e-4),unprognostic (1.08e-1),unprognostic (8.86e-2),unprognostic (7.86e-2),unprognostic (3.22e-1)
TUBA4A,"FLJ30169, H2-ALPHA, TUBA1",ENSG00000127824,Tubulin alpha 4a,P68366,2,219249710-219277902,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,Hydrolase,"Amyotrophic lateral sclerosis, FDA approved drug targets, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,skeletal muscle: 351.6;tongue: 256.2,Cell type enhanced,Detected in many,,Late spermatids: 899.2;Suprabasal keratinocytes: 645.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in many,,,Testis - Late spermatids,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB004621, CAB005887, HPA039247, HPA043684, HPA063394",Approved,,Enhanced,Microtubules,,,,,,130000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 14: Skeletal muscle - Muscle contraction,Cluster 52: Neurons & Synapses - Synaptic function,Cluster 7: Liver cancer - Metabolism,Cluster 57: Platelets - Hemostasis,4.0,Microtubules,,"CAB004621: AB_628411, CAB005887: AB_2288001, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003",unprognostic (8.08e-2),unprognostic (2.31e-1),unprognostic (4.03e-2),unprognostic (2.56e-2),unprognostic (5.18e-3),unprognostic (3.99e-2),prognostic unfavorable (4.54e-6),unprognostic (1.52e-3),unprognostic (4.47e-1),unprognostic (8.85e-2),unprognostic (1.49e-2),unprognostic (5.27e-2),unprognostic (1.94e-1),unprognostic (2.70e-1),unprognostic (2.36e-1),unprognostic (7.38e-3),unprognostic (9.32e-2)
LBP,BPIFD2,ENSG00000129988,Lipopolysaccharide binding protein,P18428,20,38346482-38377013,"Plasma proteins, Predicted secreted proteins, Transporters","Immunity, Innate immunity, Lipid transport, Transport","Antibiotic, Antimicrobial",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,23.0,liver: 1304.6,Cell type enriched,Detected in some,14.0,Hepatocytes: 388.2,Cancer enriched,Detected in many,20.0,liver cancer: 356.7,Region enhanced,Detected in single,,medulla oblongata: 2.2,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,8.0,Brain cancer: 6.7;breast cancer: 2.7;liver cancer: 2.3;lymphoma: 1.8;thyroid cancer: 2.9,"Breast - Adipocytes (Breast), Kidney - Proximal tubular cells, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001508, CAB025905",Approved,,,,Secreted to blood,Transport,,,25000000000.0,1300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 39: Astrocytes - Mixed function,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB025905: , HPA001508: AB_1079241",unprognostic (4.20e-2),prognostic unfavorable (5.56e-4),unprognostic (4.54e-2),unprognostic (2.47e-1),unprognostic (3.80e-2),unprognostic (2.53e-2),unprognostic (5.50e-2),unprognostic (2.48e-3),unprognostic (6.15e-2),unprognostic (2.12e-1),unprognostic (7.93e-2),unprognostic (2.62e-1),prognostic unfavorable (3.62e-12),prognostic unfavorable (5.76e-4),unprognostic (1.69e-1),unprognostic (1.22e-1),unprognostic (1.67e-1)
APOE,AD2,ENSG00000130203,Apolipoprotein E,P02649,19,44905791-44909393,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Host-virus interaction, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",Heparin-binding,"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease variant, Hyperlipidemia, Neurodegeneration",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,adrenal gland: 3346.3;brain: 2687.4;liver: 6430.8,Cell type enhanced,Detected in many,,Hepatocytes: 8279.7;Hofbauer cells: 5560.9;Leydig cells: 2605.0;Melanocytes: 3267.4;Muller glia cells: 8388.3;Peritubular cells: 4712.6;Proximal tubular cells: 6121.1,Cancer enhanced,Detected in all,,liver cancer: 3183.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in all,,liver cancer: 501.2;Rhabdoid: 348.5,"Heart muscle - Fibroblasts, Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Lung - Macrophages, Pancreas - Macrophages, Skeletal muscle - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB008363, HPA065539, HPA068768, CAB069921",Enhanced,,Approved,Vesicles,Secreted to blood,Apolipoprotein,,,51800000000.0,29000000000.0,,Cluster 69: Liver - Oxidoreductase activity,Cluster 19: Astrocytes - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 58: Macrophages - Innate immune response,30.0,Vesicles,,"CAB008363: AB_590560, CAB069921: AB_920623, HPA065539: AB_2685509, HPA068768: AB_2686029",unprognostic (8.98e-2),unprognostic (2.32e-2),unprognostic (2.49e-2),unprognostic (5.28e-2),unprognostic (3.77e-2),unprognostic (7.25e-2),unprognostic (5.22e-3),unprognostic (6.13e-2),unprognostic (5.06e-2),unprognostic (4.13e-1),unprognostic (5.78e-2),unprognostic (1.38e-1),unprognostic (1.74e-1),unprognostic (7.76e-2),unprognostic (1.64e-1),unprognostic (1.12e-3),unprognostic (4.13e-2)
APOC1,,ENSG00000130208,Apolipoprotein C1,P02654,19,44914247-44919349,"Cancer-related genes, Candidate cardiovascular disease genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,9.0,liver: 17322.1,Cell type enriched,Detected in many,8.0,Hepatocytes: 34314.8,Cancer enriched,Detected in all,21.0,liver cancer: 3253.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,8.0,myeloid DC: 5.9,Lineage enriched,Detected in single,14.0,dendritic cells: 5.9,Cancer enhanced,Detected in all,,Leukemia: 273.6;liver cancer: 289.3,"Liver - Hepatocytes, Lung - Macrophages, Skin - Sebaceous gland cells",Low region specificity,Detected in all,,,,,,,HPA051518,Supported,,,,Secreted to blood,Apolipoprotein,,,20300000000.0,15000000000.0,Cluster 2: Dendritic cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 21: Non-specific - Metabolism,Cluster 47: Leukemia - Hemostasis,Cluster 43: Hepatocytes - Metabolism,23.0,,,HPA051518: AB_2681519,unprognostic (3.51e-2),unprognostic (3.31e-3),unprognostic (1.14e-1),unprognostic (2.59e-2),unprognostic (2.06e-1),unprognostic (1.47e-1),prognostic favorable (1.15e-7),unprognostic (9.51e-3),unprognostic (1.30e-1),unprognostic (4.18e-2),unprognostic (1.11e-1),unprognostic (2.52e-1),unprognostic (7.13e-3),unprognostic (3.48e-3),unprognostic (1.65e-1),unprognostic (2.01e-3),unprognostic (1.65e-1)
F12,,ENSG00000131187,Coagulation factor XII,P00748,5,177402133-177416583,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,311.0,liver: 589.9,Cell type enriched,Detected in many,5.0,Hepatocytes: 375.4,Cancer enriched,Detected in many,21.0,liver cancer: 171.0,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,eosinophil: 1.7,Lineage enhanced,Detected in single,,granulocytes: 1.7,Low cancer specificity,Detected in many,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Stomach - Mitotic cells (Stomach)",Low region specificity,Detected in single,,,Not detected,Not detected,,,HPA003825,Approved,,,,Secreted to blood,Blood coagulation,,,1040000.0,7000000000.0,Cluster 19: Eosinophils - Unknown function,Cluster 31: Liver - Plasma proteins,,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA003825: AB_1078790,unprognostic (9.75e-2),unprognostic (1.71e-1),unprognostic (2.93e-1),unprognostic (4.47e-2),unprognostic (1.01e-1),unprognostic (2.32e-1),prognostic favorable (4.63e-5),unprognostic (6.97e-2),unprognostic (1.26e-2),unprognostic (3.96e-2),unprognostic (4.41e-1),unprognostic (6.54e-2),prognostic unfavorable (7.09e-4),unprognostic (4.11e-2),unprognostic (3.69e-1),unprognostic (3.40e-6),unprognostic (6.48e-2)
SERPINF1,"EPC-1, PEDF, PIG35",ENSG00000132386,Serpin family F member 1,P36955,17,1762029-1777565,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Dwarfism, Osteogenesis imperfecta",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,choroid plexus: 4719.0,Cell type enhanced,Detected in many,,Basal respiratory cells: 665.9;Cytotrophoblasts: 799.4;Fibroblasts: 881.9;Hepatocytes: 714.4;Leydig cells: 1843.9;Peritubular cells: 1051.8,Cancer enhanced,Detected in all,,liver cancer: 245.2,Region enriched,Detected in all,20.0,choroid plexus: 3985.5,Immune cell enriched,Detected in many,18.0,plasmacytoid DC: 1458.3,Lineage enriched,Detected in all,121.0,dendritic cells: 1458.3,Cancer enhanced,Detected in many,,Rhabdoid: 156.0,"Adipose visceral - Macrophages, Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA005825,Uncertain,,,,Secreted to blood,No annotated function,,,9290000000.0,44000000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 36: Choroid plexus - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,3.0,,,HPA005825: AB_1079921,unprognostic (3.85e-1),prognostic favorable (5.49e-4),unprognostic (9.44e-2),unprognostic (2.32e-2),unprognostic (2.96e-2),unprognostic (2.09e-1),unprognostic (3.32e-3),unprognostic (2.33e-1),unprognostic (7.88e-2),unprognostic (5.92e-2),unprognostic (1.69e-1),unprognostic (4.18e-2),prognostic unfavorable (1.40e-8),unprognostic (2.11e-3),unprognostic (2.82e-1),unprognostic (4.53e-3),unprognostic (1.25e-3)
JCHAIN,"IGCJ, IGJ, JCH",ENSG00000132465,Joining chain of multimeric IgA and IgM,P01591,4,70655541-70681817,"Plasma proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,breast: 2922.1;intestine: 7701.3;stomach 1: 5747.7,Cell type enriched,Detected in many,13.0,Plasma cells: 78745.1,Low cancer specificity,Detected in all,,,Region enhanced,Detected in many,,spinal cord: 13.1,Group enriched,Detected in all,122.0,memory B-cell: 4194.2;naive B-cell: 2578.5;plasmacytoid DC: 3595.4,Group enriched,Detected in all,137.0,B-cells: 4194.2;dendritic cells: 3595.4,Cancer enriched,Detected in many,10.0,Myeloma: 12971.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB034436, HPA044132",Enhanced,,,,Secreted to blood,No annotated function,,,,2200000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 45: Intestine - Digestion,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"CAB034436: AB_2233368, HPA044132: AB_2678826",prognostic favorable (1.81e-6),unprognostic (1.45e-3),unprognostic (7.44e-3),unprognostic (1.82e-2),unprognostic (4.23e-2),prognostic favorable (7.56e-7),unprognostic (2.37e-2),unprognostic (2.70e-2),unprognostic (6.30e-2),unprognostic (2.64e-3),unprognostic (3.36e-1),unprognostic (7.34e-2),prognostic unfavorable (1.40e-4),unprognostic (3.43e-1),unprognostic (3.03e-2),unprognostic (2.22e-1),unprognostic (1.96e-1)
CRP,PTX1,ENSG00000132693,C-reactive protein,P02741,1,159712289-159714589,"Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,80.0,liver: 9151.6,Group enriched,Detected in some,7.0,Ductal cells: 1316.9;Hepatocytes: 3016.1,Cancer enriched,Detected in some,13.0,liver cancer: 1010.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,Gastric cancer: 1.1,,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB005036, HPA027367, HPA027396",Supported,,Approved,"Nucleoplasm,Vesicles,Intermediate filaments",Secreted to blood,Acute phase,,,2920000000.0,5200000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 51: Myeloma - Immunoglobulins,Cluster 62: Hepatocytes - Metabolism,7.0,"Nucleoplasm, Vesicles",Intermediate filaments,"CAB005036: AB_562362, HPA027367: AB_1847216, HPA027396: AB_1847217",unprognostic (3.74e-1),unprognostic (5.31e-2),,,,unprognostic (2.97e-2),unprognostic (1.27e-1),unprognostic (3.57e-2),,,unprognostic (1.33e-2),unprognostic (3.13e-1),prognostic unfavorable (4.17e-10),unprognostic (3.39e-2),unprognostic (3.48e-1),unprognostic (5.60e-2),unprognostic (6.61e-2)
APCS,"MGC88159, PTX2, SAP",ENSG00000132703,"Amyloid P component, serum",P02743,1,159587826-159588865,"Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,76.0,liver: 3515.6,Cell type enriched,Detected in some,10.0,Hepatocytes: 4133.8,Cancer enriched,Detected in some,25.0,liver cancer: 826.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,10.0,liver cancer: 14.2,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB007817, HPA053294",Supported,,,,Secreted to blood,No annotated function,,,27700000000.0,39000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 7: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,,,"CAB007817: AB_598185, HPA053294: AB_2682104",,,,,,,unprognostic (3.19e-3),,,,unprognostic (2.30e-2),,,,,,
CFHR5,"CFHL5, FHR-5, FHR5",ENSG00000134389,Complement factor H related 5,Q9BXR6,1,196975010-197009678,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1620.0,liver: 162.0,Cell type enriched,Detected in some,21.0,Hepatocytes: 95.1,Cancer enriched,Detected in single,396.0,liver cancer: 57.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,,,,,,,,,"HPA038915, HPA040726",Supported,,,,Secreted to blood,Complement pathway,,,,1900000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,15.0,,,"HPA038915: AB_2676269, HPA040726: AB_2677101",,,,,,,unprognostic (9.12e-3),,,,,,,,,,
CEP162,"C6orf84, KIAA1009, QN1",ENSG00000135315,Centrosomal protein 162,Q5TB80,6,84124241-84227643,"Plasma proteins, Predicted intracellular proteins",Cilium biogenesis/degradation,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Early spermatids: 180.2;Late spermatids: 62.3;Oligodendrocytes: 59.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in all,,,Testis - Early spermatids,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA030170, HPA030171, HPA030172, HPA030173",Supported,,Approved,"Nucleoplasm,Centriolar satellite,Cytosol",,,,,,,Cluster 29: Non-specific - Unknown function,Cluster 16: Non-specific - Transcription,Cluster 46: Brainstem - Mixed function,Cluster 28: Non-specific - Nuclear processes,Cluster 18: Early spermatids - Unknown function,3.0,"Nucleoplasm, Cytosol",Centriolar satellite,"HPA030170: AB_10611113, HPA030171: AB_10601567, HPA030172: AB_10602414, HPA030173: AB_10602206",unprognostic (1.75e-1),unprognostic (1.46e-2),unprognostic (1.64e-1),unprognostic (1.26e-2),unprognostic (1.06e-1),unprognostic (1.63e-3),unprognostic (2.95e-4),unprognostic (1.03e-1),unprognostic (6.73e-2),unprognostic (1.21e-3),unprognostic (1.57e-3),unprognostic (3.98e-2),unprognostic (2.87e-3),unprognostic (3.27e-2),unprognostic (6.32e-2),unprognostic (3.58e-1),unprognostic (1.44e-3)
AGT,SERPINA8,ENSG00000135744,Angiotensinogen,P01019,1,230690776-230745576,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins",,"Vasoactive, Vasoconstrictor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,6.0,liver: 1563.6,Group enriched,Detected in many,4.0,Cholangiocytes: 984.4;Hepatocytes: 1899.1,Cancer enriched,Detected in all,4.0,liver cancer: 1163.4,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,6.0,liver cancer: 204.0,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Testis - Late spermatids",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB025798,Supported,,,,Secreted to blood,Other,,,5940000.0,65000000000.0,,Cluster 83: Liver - Metabolism,Cluster 44: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,8.0,,,CAB025798: ,unprognostic (7.77e-2),unprognostic (4.46e-1),unprognostic (2.15e-2),unprognostic (2.07e-2),unprognostic (2.67e-1),unprognostic (3.61e-2),unprognostic (5.75e-2),unprognostic (2.50e-1),unprognostic (2.20e-2),unprognostic (4.46e-2),unprognostic (4.32e-3),unprognostic (6.70e-2),unprognostic (9.28e-2),unprognostic (4.42e-3),unprognostic (2.17e-1),unprognostic (3.89e-1),unprognostic (1.38e-1)
TLN1,"ILWEQ, TLN",ENSG00000137076,Talin 1,Q9Y490,9,35696948-35732195,"Plasma proteins, Predicted intracellular proteins",Host-virus interaction,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,monocytes: 372.9,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Colon - Smooth muscle cells, Prostate - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002006, HPA004748",Supported,,Supported,"Plasma membrane,Focal adhesion sites,Centriolar satellite,Cytosol",,,,,,1300000000.0,Cluster 25: Non-specific - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 20: Macrophages & Microglia - Immune response,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 32: Smooth muscle cells - Muscle contraction,4.0,"Focal adhesion sites, Cytosol","Plasma membrane, Centriolar satellite","CAB002006: , HPA004748: AB_1857760",unprognostic (9.71e-2),unprognostic (2.02e-2),prognostic unfavorable (5.56e-4),unprognostic (1.96e-1),unprognostic (5.55e-2),unprognostic (2.52e-1),unprognostic (3.18e-2),unprognostic (5.07e-2),unprognostic (1.94e-1),unprognostic (6.46e-2),unprognostic (1.82e-1),unprognostic (1.27e-1),prognostic favorable (7.21e-4),unprognostic (1.36e-1),unprognostic (2.71e-2),unprognostic (7.83e-2),unprognostic (8.83e-3)
THBS1,"THBS, THBS-1, TSP, TSP-1, TSP1",ENSG00000137801,Thrombospondin 1,P07996,15,39581079-39599466,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Angiogenesis, Apoptosis, Cell adhesion, Inflammatory response, Unfolded protein response",Heparin-binding,Cancer-related genes,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in many,,,Cell type enhanced,Detected in many,,Macrophages: 678.5;monocytes: 1951.1;Mucus glandular cells: 699.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in some,,eosinophil: 15.8,Low lineage specificity,Detected in many,,,Low cancer specificity,Detected in all,,,Colon - Neutrophils,Low region specificity,Detected in many,,,Region enhanced,Detected in many,,spinal cord: 27.1,"CAB033678, HPA059756",Approved,,Approved,Plasma membrane,Secreted to extracellular matrix,Cell adhesion,,,16000000000.0,1400000000.0,Cluster 7: Non-specific - Innate immune response,Cluster 62: Connective tissue - ECM organization,Cluster 44: Non-specific - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 29: Monocytes - Innate immune response,2.0,Plasma membrane,,"CAB033678: AB_793044, HPA059756: AB_2684121",unprognostic (1.72e-2),unprognostic (9.55e-3),unprognostic (7.49e-2),unprognostic (3.31e-1),unprognostic (4.34e-2),unprognostic (1.03e-3),unprognostic (3.60e-1),unprognostic (1.53e-2),unprognostic (1.22e-1),unprognostic (2.07e-1),unprognostic (6.40e-2),unprognostic (9.16e-2),prognostic unfavorable (8.47e-5),prognostic unfavorable (8.50e-4),unprognostic (1.00e-1),unprognostic (9.25e-3),unprognostic (1.48e-3)
RBP4,,ENSG00000138207,Retinol binding protein 4,P02753,10,93591687-93601744,"Cancer-related genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Sensory transduction, Transport, Vision",,"Cancer-related genes, Disease variant, Microphthalmia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,19.0,liver: 10726.7,Cell type enriched,Detected in many,13.0,Hepatocytes: 12476.9,Cancer enriched,Detected in all,27.0,liver cancer: 3135.4,Region enriched,Detected in all,4.0,hypothalamus: 204.5,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,4.0,liver cancer: 195.7,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast), Liver - Hepatocytes, Lung - Macrophages, Pancreas - Beta cells, Skin - Adipocytes (Skin), Testis - Spermatogonia",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,"HPA001641, CAB004555",Supported,,,,Secreted to blood,Transport,,,46100000000.0,210000000000.0,,Cluster 83: Liver - Metabolism,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB004555: AB_670938, HPA001641: AB_1079795",unprognostic (9.42e-3),unprognostic (3.40e-2),unprognostic (1.90e-1),prognostic unfavorable (1.50e-4),unprognostic (2.60e-2),unprognostic (6.69e-4),prognostic favorable (1.74e-8),unprognostic (2.39e-1),unprognostic (5.76e-2),unprognostic (3.26e-2),unprognostic (3.26e-1),unprognostic (3.44e-1),unprognostic (7.14e-3),unprognostic (9.88e-3),unprognostic (2.31e-1),unprognostic (1.03e-1),unprognostic (8.60e-2)
MMRN1,"ECM, EMILIN4, GPIa*, MMRN",ENSG00000138722,Multimerin 1,Q13201,4,89879532-89954629,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in many,,,Cell type enriched,Detected in many,7.0,Lymphatic endothelial cells: 1678.6,Low cancer specificity,Detected in many,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,9.0,NK-cell: 6.3;plasmacytoid DC: 2.2,Group enriched,Detected in many,9.0,dendritic cells: 2.2;NK-cells: 6.3,Cancer enhanced,Detected in some,,Leukemia: 17.0;Rhabdoid: 13.3,"Liver - Vascular Endothelial cells, Prostate - Endothelial cells, Skin - Macrophages, Testis - Early spermatids",Not detected,Not detected,,,Not detected,Not detected,,,HPA035769,Enhanced,,Approved,Endoplasmic reticulum,Secreted to extracellular matrix,No annotated function,,,,200000000.0,Cluster 14: Non-specific - Unknown function,Cluster 62: Connective tissue - ECM organization,Cluster 44: Non-specific - Mixed function,Cluster 48: Adipocytes & Endothelial cells - Angiogenesis,Cluster 54: Lymphatic endothelial cells - Lymph vessel development,,Endoplasmic reticulum,,HPA035769: AB_10696511,unprognostic (1.15e-1),unprognostic (1.81e-2),unprognostic (1.23e-1),unprognostic (2.41e-1),unprognostic (2.11e-1),unprognostic (7.05e-3),unprognostic (1.62e-3),unprognostic (1.91e-1),unprognostic (1.88e-1),unprognostic (2.12e-1),unprognostic (9.71e-3),unprognostic (1.18e-1),prognostic unfavorable (1.77e-4),prognostic unfavorable (5.46e-4),unprognostic (2.14e-1),unprognostic (1.36e-1),unprognostic (2.23e-2)
SERPINA10,"PZI, ZPI",ENSG00000140093,Serpin family A member 10,Q9UK55,14,94280460-94293268,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins","Blood coagulation, Hemostasis","Heparin-binding, Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,113.0,liver: 338.3,Cell type enriched,Detected in some,17.0,Hepatocytes: 217.4,Cancer enriched,Detected in some,51.0,liver cancer: 40.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Breast - Breast glandular cells, Liver - Hepatocytes, Pancreas - Alpha cells, Stomach - Gastric enteroendocrine cells",Not detected,Not detected,,,,,,,HPA048739,,,Approved,"Nucleoplasm,Cytosol",Secreted to blood,Blood coagulation,,,3960000000.0,4700000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 9: Non-specific - Receptor signaling,Cluster 10: Ciliated cells - Ion channel activity,Cluster 62: Hepatocytes - Metabolism,2.0,Nucleoplasm,Cytosol,HPA048739: AB_2797237,unprognostic (7.14e-2),unprognostic (2.03e-1),unprognostic (2.69e-2),unprognostic (2.01e-1),unprognostic (1.21e-1),unprognostic (1.45e-1),prognostic favorable (9.00e-4),unprognostic (6.11e-2),,unprognostic (2.81e-4),unprognostic (2.31e-4),unprognostic (2.77e-2),unprognostic (2.91e-3),unprognostic (1.38e-1),unprognostic (1.58e-1),unprognostic (1.11e-1),unprognostic (7.93e-3)
AHSG,"A2HS, FETUA, HSGA",ENSG00000145192,Alpha 2-HS glycoprotein,P02765,3,186613060-186621318,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",Mineral balance,,"Cancer-related genes, Disease variant, Hypotrichosis, Intellectual disability",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,4328.0,liver: 5638.7,Cell type enriched,Detected in some,14.0,Hepatocytes: 1120.0,Cancer enriched,Detected in some,284.0,liver cancer: 1231.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,18.0,liver cancer: 479.5,"Liver - Hepatocytes, Testis - Late spermatids",Not detected,Not detected,,,Not detected,Not detected,,,"HPA001524, HPA001525, CAB026209",Enhanced,,Enhanced,Golgi apparatus,Secreted to blood,Other,,,864000000000.0,110000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,"CAB026209: , HPA001524: AB_1078851, HPA001525: AB_1078849",,unprognostic (6.40e-2),unprognostic (1.31e-1),unprognostic (2.03e-2),unprognostic (3.20e-2),unprognostic (1.07e-2),unprognostic (1.16e-2),unprognostic (7.47e-3),unprognostic (3.05e-1),unprognostic (5.27e-2),unprognostic (8.64e-2),,unprognostic (3.99e-7),unprognostic (5.21e-2),unprognostic (5.21e-2),unprognostic (1.04e-1),
GC,"DBP, hDBP, VDBP",ENSG00000145321,GC vitamin D binding protein,P02774,4,71741696-71804041,"Metabolic proteins, Plasma proteins, Predicted secreted proteins",Transport,Actin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,17.0,liver: 8007.3,Group enriched,Detected in some,9.0,Cholangiocytes: 1684.6;Hepatocytes: 2766.0,Cancer enriched,Detected in many,18.0,liver cancer: 1016.1,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,17.0,liver cancer: 29.9,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,"HPA001526, CAB008596, HPA019855",Supported,,,,Secreted to blood,Transport,,,143000000000.0,73000000000.0,,Cluster 83: Liver - Metabolism,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,"CAB008596: AB_1622398, HPA001526: AB_1078959, HPA019855: AB_1849545",,,,,,,prognostic favorable (8.08e-4),,,,unprognostic (1.06e-3),,prognostic unfavorable (5.81e-5),unprognostic (1.55e-1),unprognostic (2.15e-1),,
IGFBP3,"BP-53, IBP3",ENSG00000146674,Insulin like growth factor binding protein 3,P17936,7,45912245-45921874,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Apoptosis,Growth factor binding,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 693.4;placenta: 1799.7,Cell type enhanced,Detected in many,,Basal respiratory cells: 815.8;Club cells: 408.7;Extravillous trophoblasts: 2449.9;Ionocytes: 425.9,Cancer enhanced,Detected in all,,renal cancer: 377.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in many,5.0,plasmacytoid DC: 48.9,Lineage enriched,Detected in many,5.0,dendritic cells: 48.9,Cancer enriched,Detected in all,5.0,Kidney cancer: 3358.0,"Liver - Hepatic stellate cells, Testis - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,CAB010360,,,Uncertain,Vesicles,Secreted to blood,Other,,,3250000000.0,3600000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 58: Placenta - Pregnancy,Cluster 49: Hindbrain - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 50: Connective tissue cells - ECM organization,5.0,Vesicles,,CAB010360: AB_2233528,unprognostic (4.46e-3),unprognostic (4.84e-2),prognostic unfavorable (1.08e-4),unprognostic (2.30e-1),unprognostic (1.15e-1),unprognostic (6.54e-2),prognostic unfavorable (1.64e-4),unprognostic (8.14e-3),unprognostic (3.31e-2),unprognostic (2.03e-1),unprognostic (9.67e-3),unprognostic (2.80e-1),prognostic unfavorable (5.07e-7),unprognostic (2.36e-2),unprognostic (4.14e-2),unprognostic (2.37e-3),unprognostic (2.63e-1)
GSN,DKFZp313L0718,ENSG00000148180,Gelsolin,P06396,9,121207794-121332843,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Cilium biogenesis/degradation,"Actin capping, Actin-binding","Amyloidosis, Cancer-related genes, Corneal dystrophy, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,heart muscle: 2404.8,Cell type enhanced,Detected in all,,Adipocytes: 1460.5;Fibroblasts: 3746.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,eosinophil: 1140.0,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Breast - Adipocytes (Breast), Colon - Fibroblasts, Lung - Fibroblast_2, Skin - Fibroblast_2, Thyroid - Fibroblasts",Region enriched,Detected in all,4.0,white matter: 869.4,Low region specificity,Detected in all,,,"CAB010823, CAB016728, CAB036009, HPA054026",Supported,,Supported,Actin filaments,Secreted to blood,Other,,,112000000000.0,240000000000.0,Cluster 29: Non-specific - Unknown function,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 30: White matter - Myelination,Cluster 69: Skin cancer - ECM organization,Cluster 53: Fibroblasts - ECM organization,126.0,Actin filaments,,"CAB010823: , CAB016728: , CAB036009: , HPA054026: AB_2682347",unprognostic (3.25e-2),unprognostic (4.44e-3),unprognostic (1.22e-1),unprognostic (3.10e-3),unprognostic (4.23e-2),unprognostic (4.85e-2),unprognostic (1.21e-1),unprognostic (1.49e-1),unprognostic (1.22e-1),unprognostic (1.20e-1),unprognostic (6.54e-2),unprognostic (6.56e-2),unprognostic (3.06e-2),unprognostic (8.01e-3),unprognostic (4.98e-2),unprognostic (1.23e-2),prognostic unfavorable (1.79e-5)
HABP2,"FSAP, HABP, HGFAL, PHBP",ENSG00000148702,Hyaluronan binding protein 2,Q14520,10,113550837-113589602,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",,"Hydrolase, Protease, Serine protease",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,12.0,liver: 424.0,Cell type enhanced,Detected in some,,Cholangiocytes: 120.2;Ductal cells: 38.7;Hepatocytes: 185.7;Kupffer cells: 33.7;Oocytes: 85.3,Cancer enriched,Detected in many,5.0,liver cancer: 92.4,Region enhanced,Detected in some,,cerebral cortex: 2.3,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,5.0,Kidney cancer: 14.7;liver cancer: 19.4,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,HPA019518,Uncertain,,,,Secreted to blood,Enzyme,,,20200000000.0,4400000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 53: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,HPA019518: AB_1850467,unprognostic (3.89e-2),unprognostic (6.15e-2),unprognostic (1.33e-1),unprognostic (1.24e-1),unprognostic (1.45e-1),unprognostic (6.92e-2),unprognostic (1.01e-1),unprognostic (5.86e-3),unprognostic (1.67e-1),unprognostic (9.78e-2),unprognostic (5.10e-2),unprognostic (4.77e-2),unprognostic (9.18e-3),unprognostic (2.62e-3),unprognostic (2.11e-1),unprognostic (3.22e-1),unprognostic (9.05e-3)
SAA4,"C-SAA, CSAA",ENSG00000148965,"Serum amyloid A4, constitutive",P35542,11,18231355-18236802,"Plasma proteins, Predicted secreted proteins",Acute phase,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,125.0,liver: 1879.5,Cell type enriched,Detected in some,34.0,Hepatocytes: 1673.3,Cancer enriched,Detected in many,141.0,liver cancer: 118.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Bile duct cancer: 4.4;head and neck cancer: 6.3;liver cancer: 5.5,"Adipose visceral - Adipocytes (Visceral), Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,,,,,"CAB026061, HPA060139",Supported,,,,Secreted to blood,Acute phase,,,65000000000.0,33000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,,,"CAB026061: , HPA060139: AB_2684210",unprognostic (4.70e-4),unprognostic (1.17e-1),unprognostic (1.17e-1),unprognostic (4.83e-1),unprognostic (4.15e-2),unprognostic (6.05e-2),unprognostic (3.63e-3),unprognostic (5.94e-2),,unprognostic (2.40e-2),unprognostic (1.41e-1),unprognostic (7.35e-2),unprognostic (2.54e-8),unprognostic (2.49e-1),,,unprognostic (6.46e-2)
SERPING1,"C1-INH, C1IN, C1INH, C1NH, HAE1, HAE2",ENSG00000149131,Serpin family G member 1,P05155,11,57597387-57619171,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Complement pathway, Fibrinolysis, Hemostasis, Immunity, Innate immunity","Protease inhibitor, Serine protease inhibitor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 2545.7,Cell type enhanced,Detected in many,,Cholangiocytes: 662.0;Ductal cells: 686.0;Fibroblasts: 846.6;Hepatocytes: 2176.6;Leydig cells: 740.9;Mesothelial cells: 1959.4,Cancer enhanced,Detected in all,,liver cancer: 609.9,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 65.5;plasmacytoid DC: 60.7,Group enriched,Detected in many,231.0,dendritic cells: 60.7;granulocytes: 65.5;monocytes: 25.7,Cancer enhanced,Detected in many,,liver cancer: 37.5;testis cancer: 38.7,"Heart muscle - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_1, Prostate - Fibroblasts",Low region specificity,Detected in all,,,Region enhanced,Detected in all,,spinal cord: 255.7,"CAB026161, HPA048738",Supported,,,,Secreted to blood,Blood coagulation,,,,28000000000.0,Cluster 2: Dendritic cells - Unknown function,Cluster 83: Liver - Metabolism,Cluster 8: Immune cells - Immune response,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,,,"CAB026161: , HPA048738: AB_2680505",unprognostic (1.35e-2),unprognostic (2.24e-1),prognostic unfavorable (9.96e-4),unprognostic (4.26e-2),unprognostic (4.38e-2),unprognostic (2.32e-1),unprognostic (4.12e-3),unprognostic (2.13e-1),unprognostic (8.95e-2),prognostic favorable (8.03e-4),unprognostic (5.92e-3),unprognostic (3.76e-2),prognostic unfavorable (1.55e-4),unprognostic (2.60e-2),unprognostic (4.14e-2),unprognostic (2.56e-1),unprognostic (1.17e-1)
FERMT3,"KIND3, MGC10966, MIG2B, UNC112C, URP2",ENSG00000149781,FERM domain containing kindlin 3,Q86UX7,11,64205926-64223896,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",Cell adhesion,,Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,bone marrow: 100.1;lymphoid tissue: 127.0,Cell type enhanced,Detected in many,,dendritic cells: 141.5;Hofbauer cells: 200.8;Kupffer cells: 85.8;Langerhans cells: 108.4;Macrophages: 126.9;monocytes: 117.9;NK-cells: 77.3;T-cells: 73.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in many,,Leukemia: 126.8;lymphoma: 93.3;Myeloma: 55.6,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Skeletal muscle - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in many,,,HPA065231,,,Approved,Vesicles,,,,,,160000000.0,Cluster 10: Non-specific - Membrane trafficking,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 35: RS4;11 - Unknown function,Cluster 57: Platelets - Hemostasis,,Vesicles,,HPA065231: AB_2685439,unprognostic (1.96e-2),unprognostic (1.07e-2),unprognostic (3.38e-3),prognostic favorable (9.89e-4),unprognostic (8.77e-2),unprognostic (1.83e-2),unprognostic (3.56e-2),unprognostic (2.46e-1),unprognostic (4.20e-1),unprognostic (3.98e-1),unprognostic (2.70e-1),unprognostic (3.88e-1),prognostic unfavorable (2.12e-5),unprognostic (3.08e-3),unprognostic (5.25e-2),unprognostic (4.97e-2),unprognostic (1.75e-1)
ITIH2,H2P,ENSG00000151655,Inter-alpha-trypsin inhibitor heavy chain 2,P19823,10,7703316-7749520,"Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,566.0,liver: 2091.1,Cell type enriched,Detected in some,4.0,Hepatocytes: 406.0,Cancer enriched,Detected in many,279.0,liver cancer: 626.9,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,40.0,liver cancer: 147.1,Liver - Hepatocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA059150,Supported,,Approved,Golgi apparatus,Secreted to blood,Enzyme inhibitor,,,,32000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 16: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,HPA059150: AB_2683930,unprognostic (4.82e-2),unprognostic (6.10e-2),unprognostic (2.48e-2),unprognostic (1.21e-2),unprognostic (2.01e-2),unprognostic (2.55e-3),prognostic favorable (1.48e-4),unprognostic (1.37e-1),unprognostic (1.79e-1),unprognostic (1.47e-2),unprognostic (2.28e-1),unprognostic (2.02e-1),unprognostic (2.10e-8),unprognostic (9.91e-3),unprognostic (1.70e-1),unprognostic (2.35e-1),unprognostic (4.46e-4)
C8A,,ENSG00000157131,Complement C8 alpha chain,P07357,1,56854768-56918223,"Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,279.0,liver: 481.7,Cell type enriched,Detected in some,14.0,Hepatocytes: 257.7,Cancer enriched,Detected in single,279.0,liver cancer: 85.3,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,,,,,,Secreted to blood,Complement pathway,,,,6400000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,6.0,,,,,,,,,,unprognostic (3.73e-3),unprognostic (2.44e-1),,,unprognostic (1.28e-1),,,unprognostic (6.40e-2),,unprognostic (9.82e-2),
APOA2,,ENSG00000158874,Apolipoprotein A2,P02652,1,161222292-161223631,"Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters","Host-virus interaction, Lipid transport, Transport",,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,1343.0,liver: 34742.6,Cell type enriched,Detected in some,78.0,Hepatocytes: 51864.9,Cancer enriched,Detected in many,329.0,liver cancer: 11230.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,9.0,liver cancer: 2178.7,Liver - Hepatocytes,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB025885, HPA072575",Supported,,,,Secreted to blood,Apolipoprotein,,,115000000000.0,92000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 31: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,15.0,,,"CAB025885: , HPA072575: ",,unprognostic (2.05e-1),unprognostic (4.70e-2),unprognostic (1.12e-1),unprognostic (2.99e-1),,unprognostic (9.82e-2),unprognostic (1.92e-1),unprognostic (3.16e-1),unprognostic (2.79e-1),unprognostic (1.57e-2),,unprognostic (4.40e-3),unprognostic (3.16e-2),unprognostic (2.22e-1),unprognostic (1.60e-1),unprognostic (6.09e-2)
C1QC,C1QG,ENSG00000159189,Complement C1q C chain,P02747,1,22643014-22648110,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity",,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,lymphoid tissue: 923.4,Group enriched,Detected in many,5.0,Hofbauer cells: 1156.0;Kupffer cells: 1255.6;Macrophages: 969.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enriched,Detected in some,6.0,intermediate monocyte: 56.5,Lineage enriched,Detected in single,559.0,monocytes: 56.5,Not detected,Not detected,,,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Kidney - Macrophages, Liver - Kupffer cells, Lung - Macrophages, Pancreas - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Skin - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA001471, CAB009828",Supported,,,,Secreted to blood,Complement pathway,,,513000000.0,2100000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 70: Lymphoid tissue - Immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 58: Macrophages - Innate immune response,3.0,,,"CAB009828: AB_2067541, HPA001471: AB_1078553",unprognostic (2.97e-1),unprognostic (6.80e-2),unprognostic (2.40e-2),unprognostic (1.84e-1),unprognostic (7.40e-2),unprognostic (2.38e-1),unprognostic (1.98e-1),unprognostic (1.40e-1),unprognostic (1.66e-2),unprognostic (7.44e-2),unprognostic (2.75e-2),unprognostic (1.32e-1),prognostic unfavorable (1.17e-5),unprognostic (1.06e-1),unprognostic (1.63e-3),unprognostic (2.21e-2),unprognostic (3.73e-2)
AZGP1,"ZA2G, ZAG",ENSG00000160862,"Alpha-2-glycoprotein 1, zinc-binding",P25311,7,99966720-99976042,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,liver: 2718.3;salivary gland: 3732.5,Cell type enhanced,Detected in many,,Breast glandular cells: 1494.4;Hepatocytes: 4213.4;Mucus glandular cells: 2188.5;Prostatic glandular cells: 4198.4;Serous glandular cells: 4020.8,Group enriched,Detected in many,12.0,breast cancer: 412.6;liver cancer: 273.6;prostate cancer: 469.5,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,breast cancer: 226.3;prostate cancer: 78.4,"Adipose subcutaneous - Adipocytes (Subcutaneous), Adipose visceral - Adipocytes (Visceral), Breast - Breast glandular cells, Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Liver - Hepatocytes, Prostate - Prostate glandular cells, Stomach - Chief cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA012582, HPA012876, CAB016087, CAB032276",Enhanced,,Approved,"Nucleoplasm,Vesicles",Secreted to blood,No annotated function,,,55200000000.0,74000000000.0,,Cluster 68: Non-specific - Protein processing,Cluster 26: Oligodendrocytes - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 75: Serous glandular cells - Salivary secretion,2.0,Vesicles,Nucleoplasm,"CAB016087: AB_667849, CAB032276: AB_2062580, HPA012582: AB_1845226, HPA012876: ",unprognostic (8.14e-2),unprognostic (1.50e-1),unprognostic (3.41e-1),unprognostic (5.42e-3),unprognostic (4.98e-2),unprognostic (5.74e-3),prognostic favorable (2.90e-4),unprognostic (1.50e-1),unprognostic (1.85e-1),unprognostic (2.19e-1),unprognostic (2.35e-2),unprognostic (1.79e-1),prognostic favorable (1.53e-4),unprognostic (2.18e-1),unprognostic (2.08e-2),unprognostic (9.80e-2),unprognostic (3.51e-3)
PGLYRP2,"PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like",ENSG00000161031,Peptidoglycan recognition protein 2,Q96PD5,19,15468645-15498956,"Enzymes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Immunity,Hydrolase,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,45.0,liver: 250.7,Cell type enriched,Detected in some,8.0,Hepatocytes: 132.3,Cancer enriched,Detected in some,16.0,liver cancer: 42.9,Not detected,Not detected,,,Low immune cell specificity,Detected in many,,,Group enriched,Detected in many,7.0,granulocytes: 3.4;monocytes: 5.1;T-cells: 2.3,Group enriched,Detected in some,4.0,Bone cancer: 4.9;breast cancer: 5.8,"Breast - Breast glandular cells, Breast - Breast glandular cells, Liver - Hepatocytes, Testis - Sertoli cells",Not detected,Not detected,,,Not detected,Not detected,,,"CAB033468, HPA046311, HPA075237",Supported,,Approved,Cell Junctions,Secreted to blood,Immunity,,,,87000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 31: Liver - Plasma proteins,,Cluster 27: Breast cancer - Unknown function,Cluster 43: Hepatocytes - Metabolism,,Cell Junctions,,"CAB033468: AB_1127187, HPA046311: AB_2679621, HPA075237: AB_2686739",unprognostic (7.39e-3),unprognostic (1.52e-2),unprognostic (5.22e-2),unprognostic (8.79e-2),unprognostic (3.97e-1),unprognostic (4.88e-4),unprognostic (5.93e-3),unprognostic (6.48e-2),unprognostic (1.99e-1),unprognostic (1.18e-2),unprognostic (3.15e-2),unprognostic (2.40e-1),unprognostic (6.66e-16),unprognostic (6.35e-3),unprognostic (2.80e-1),unprognostic (2.45e-2),unprognostic (2.81e-4)
DCD,"AIDD, DCD-1, DSEP, HCAP, PIF",ENSG00000161634,Dermcidin,P81605,12,54644589-54648493,"Plasma proteins, Predicted secreted proteins, Transporters",,"Antibiotic, Antimicrobial, Fungicide, Hydrolase, Protease",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,7.0,skin 1: 2396.9,Cell type enriched,Detected in some,26.0,Melanocytes: 5710.1,Cancer enriched,Detected in some,9.0,breast cancer: 91.2,Low region specificity,Detected in many,,,Low immune cell specificity,Detected in some,,,Low lineage specificity,Detected in single,,,Group enriched,Detected in some,5.0,Bone cancer: 1.0;breast cancer: 3.9,Skin - Eccrine sweat gland cells,,,,,,,,,HPA063967,Enhanced,,,,Secreted in other tissues,Enzyme,,,,410000000.0,Cluster 15: NK-cells - Unknown function,Cluster 13: Skin - Cornification,Cluster 9: Non-specific - Receptor signaling,Cluster 27: Breast cancer - Unknown function,Cluster 26: Schwann cells & Melanocytes - Mixed function,2.0,,,HPA063967: AB_2685163,unprognostic (3.55e-2),,,,,,,,,,,,,unprognostic (1.61e-1),,,
ITIH3,H3P,ENSG00000162267,Inter-alpha-trypsin inhibitor heavy chain 3,Q06033,3,52794768-52808799,"Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,105.0,liver: 828.4,Group enriched,Detected in some,5.0,Hepatocytes: 920.9;Kupffer cells: 562.7,Cancer enriched,Detected in some,247.0,liver cancer: 273.1,Low region specificity,Detected in some,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,12.0,liver cancer: 5.1,"Adipose subcutaneous - Smooth muscle cells, Adipose visceral - Smooth muscle cells, Heart muscle - Smooth muscle cells, Lung - Smooth muscle cells, Skeletal muscle - Smooth muscle cells, Testis - Late spermatids, Thyroid - Smooth muscle cells",Low region specificity,Detected in all,,,Low region specificity,Detected in some,,,HPA017373,Approved,,,,Secreted to blood,Enzyme inhibitor,,,,9100000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 32: Cerebral cortex - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,,,HPA017373: AB_1851954,unprognostic (2.07e-2),unprognostic (5.79e-2),unprognostic (1.89e-1),unprognostic (3.30e-4),unprognostic (4.28e-2),unprognostic (3.26e-2),unprognostic (5.97e-2),unprognostic (6.07e-2),unprognostic (1.49e-1),unprognostic (7.05e-2),unprognostic (1.04e-1),unprognostic (3.19e-1),prognostic unfavorable (4.49e-8),unprognostic (2.09e-4),unprognostic (1.70e-1),unprognostic (2.55e-2),unprognostic (9.31e-2)
S100A9,"60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP-14, MRP14, NIF, P14, S100-A9",ENSG00000163220,S100 calcium binding protein A9,P06702,1,153357854-153361023,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Autophagy, Chemotaxis, Immunity, Inflammatory response, Innate immunity","Antimicrobial, Antioxidant",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,bone marrow: 31844.0;esophagus: 29726.6;vagina: 13605.6,Cell type enriched,Detected in many,4.0,Suprabasal keratinocytes: 51199.6,Cancer enhanced,Detected in all,,cervical cancer: 5468.0;head and neck cancer: 6692.8,Region enhanced,Detected in all,,cerebral cortex: 97.1,Group enriched,Detected in all,6.0,classical monocyte: 24645.2;neutrophil: 33874.3,Group enriched,Detected in all,6.0,granulocytes: 33874.3;monocytes: 24645.2,Cancer enhanced,Detected in many,,breast cancer: 536.0;head and neck cancer: 1157.4,"Breast - Macrophages, Colon - Neutrophils, Liver - Neutrophils, Lung - Neutrophil_2, Skeletal muscle - Neutrophils, Thyroid - Neutrophils",Low region specificity,Detected in many,,,Not detected,Not detected,,,"HPA004193, CAB009441, CAB080262",Enhanced,,Supported,"Plasma membrane,Intermediate filaments,Cytosol",Secreted to blood,Immunity,,,10600000.0,1200000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 77: Bone marrow - Cell proliferation,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 59: Suprabasal keratinocytes - Cornification,8.0,"Plasma membrane, Intermediate filaments, Cytosol",,"CAB009441: AB_2184420, CAB080262: , HPA004193: AB_1856537",unprognostic (1.72e-1),unprognostic (3.33e-2),unprognostic (2.40e-1),unprognostic (3.94e-3),unprognostic (1.36e-2),unprognostic (5.45e-3),prognostic unfavorable (1.13e-6),unprognostic (1.10e-2),unprognostic (4.31e-1),unprognostic (3.06e-1),unprognostic (1.35e-2),unprognostic (5.59e-2),prognostic unfavorable (8.10e-4),unprognostic (1.48e-1),unprognostic (7.52e-2),unprognostic (5.39e-2),unprognostic (1.75e-2)
ALB,,ENSG00000163631,Albumin,P02768,4,73397114-73421482,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,136.0,liver: 205952.1,Cell type enriched,Detected in many,4.0,Hepatocytes: 59612.0,Cancer enriched,Detected in many,384.0,liver cancer: 14213.7,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,24.0,liver cancer: 1846.4,"Kidney - Proximal tubular cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB006262, HPA031024, HPA031025",Enhanced,,Enhanced,"Endoplasmic reticulum,Golgi apparatus",Secreted to blood,Transport,,,40000000000000.0,,,Cluster 31: Liver - Plasma proteins,Cluster 33: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,Golgi apparatus,Endoplasmic reticulum,"CAB006262: AB_425297, HPA031024: AB_2673703, HPA031025: AB_2673704",unprognostic (1.38e-1),unprognostic (8.72e-2),unprognostic (1.73e-1),unprognostic (2.60e-1),unprognostic (4.44e-1),unprognostic (2.46e-1),unprognostic (9.53e-3),unprognostic (2.16e-2),unprognostic (2.40e-1),unprognostic (6.43e-2),unprognostic (3.84e-2),unprognostic (5.37e-2),unprognostic (1.25e-1),prognostic unfavorable (7.87e-4),unprognostic (7.23e-2),unprognostic (1.05e-3),unprognostic (1.02e-2)
PPBP,"b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1",ENSG00000163736,Pro-platelet basic protein,P02775,4,73986439-73988190,"Plasma proteins, Predicted secreted proteins",Chemotaxis,"Antibiotic, Antimicrobial, Cytokine, Growth factor, Mitogen",,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,bone marrow: 82.3;lymphoid tissue: 52.4,Cell type enhanced,Detected in some,,B-cells: 9.1;dendritic cells: 12.6;Kupffer cells: 10.5;Macrophages: 25.2;NK-cells: 39.3;T-cells: 7.3,Cancer enriched,Detected in many,7.0,colorectal cancer: 86.8,Low region specificity,Detected in some,,,Group enriched,Detected in many,15.0,basophil: 287.2;neutrophil: 86.7,Lineage enriched,Detected in all,23.0,granulocytes: 287.2,Group enriched,Detected in some,6.0,colorectal cancer: 8.4;lung cancer: 3.5,,Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA008354, CAB017624",Supported,,,,Secreted to blood,Cytokine,,,24500000.0,2900000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 12: Non-specific - Vasculature,Cluster 57: Stomach & Colon cancer - Digestion,Cluster 57: Platelets - Hemostasis,4.0,,,"CAB017624: AB_1127132, HPA008354: AB_1847353",unprognostic (2.13e-1),prognostic unfavorable (6.17e-4),unprognostic (7.69e-2),unprognostic (1.67e-1),unprognostic (4.37e-2),unprognostic (3.13e-1),unprognostic (2.79e-1),unprognostic (6.98e-3),unprognostic (2.58e-1),unprognostic (4.21e-2),unprognostic (1.81e-1),unprognostic (2.88e-1),unprognostic (2.38e-3),unprognostic (1.49e-1),unprognostic (2.90e-1),unprognostic (2.15e-3),unprognostic (2.59e-2)
PF4,"CXCL4, SCYB4",ENSG00000163737,Platelet factor 4,P02776,4,73980811-73982027,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Chemotaxis,"Cytokine, Heparin-binding",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in some,11.0,bone marrow: 29.2;lung: 10.2;lymphoid tissue: 30.8,Cell type enhanced,Detected in some,,B-cells: 6.3;Ductal cells: 5.9;Enteroendocrine cells: 9.3;Granulosa cells: 30.8;NK-cells: 24.9,Cancer enhanced,Detected in some,,colorectal cancer: 4.4,Region enhanced,Detected in single,,cerebral cortex: 1.9,Immune cell enriched,Detected in single,5.0,neutrophil: 2.0,Lineage enriched,Detected in single,9.0,granulocytes: 2.0,Not detected,Not detected,,,,,,,,,,,,"CAB026008, HPA052485",Enhanced,,,,Secreted to blood,Cytokine,,,7700000.0,,Cluster 4: Neutrophils - Degranulation,Cluster 81: Lymphoid tissue & Bone marrow - Innate immune response,Cluster 23: Choroid plexus - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 57: Platelets - Hemostasis,20.0,,,"CAB026008: , HPA052485: AB_2681847",,unprognostic (4.14e-4),unprognostic (1.00e-2),unprognostic (2.49e-1),unprognostic (1.96e-4),unprognostic (7.58e-2),unprognostic (1.42e-1),unprognostic (7.55e-2),unprognostic (2.04e-1),unprognostic (9.02e-3),unprognostic (1.84e-2),unprognostic (3.03e-2),unprognostic (9.54e-5),unprognostic (2.55e-1),unprognostic (8.77e-2),unprognostic (9.69e-2),unprognostic (4.81e-2)
CLEC3B,"TN, TNA",ENSG00000163815,C-type lectin domain family 3 member B,P05452,3,45001548-45036071,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adipose tissue: 406.8,Cell type enhanced,Detected in some,,Adipocytes: 37.5;Endothelial cells: 35.2;Fibroblasts: 79.6;Leydig cells: 17.6;Microglial cells: 66.2;Smooth muscle cells: 21.6,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Sarcoma: 16.1,"Liver - Sinusoid Endothelial cells, Liver - Vascular Endothelial cells, Skin - Fibroblast_1, Skin - Fibroblast_2, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB002582, HPA034794",Approved,,,,Secreted to blood,No annotated function,,,6540000000.0,25000000000.0,,Cluster 7: Adipose tissue - Mixed function,Cluster 19: Astrocytes - Mixed function,Cluster 64: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,,,,"CAB002582: AB_564027, HPA034794: AB_2674332",unprognostic (2.04e-1),unprognostic (1.80e-3),unprognostic (2.58e-1),unprognostic (4.57e-2),unprognostic (7.75e-2),prognostic favorable (1.53e-4),prognostic favorable (9.99e-9),unprognostic (1.75e-2),unprognostic (2.25e-1),unprognostic (4.02e-1),prognostic favorable (5.68e-4),unprognostic (9.33e-2),unprognostic (2.39e-2),unprognostic (7.46e-2),unprognostic (1.39e-1),unprognostic (5.54e-2),unprognostic (4.21e-2)
KLKB1,KLK3,ENSG00000164344,Kallikrein B1,P03952,4,186226438-186258471,"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis, Inflammatory response","Hydrolase, Protease, Serine protease","Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,28.0,liver: 318.1,Cell type enriched,Detected in many,4.0,Hepatocytes: 223.6,Cancer enriched,Detected in some,17.0,liver cancer: 27.6,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in many,,,,,,,,Secreted to blood,Blood coagulation,,,28900000000.0,5300000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 23: Choroid plexus - Mixed function,Cluster 12: Bone cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,8.0,,,,unprognostic (4.80e-2),unprognostic (4.53e-3),unprognostic (4.36e-2),unprognostic (4.17e-2),unprognostic (5.93e-2),unprognostic (1.90e-2),unprognostic (1.15e-2),unprognostic (2.83e-1),unprognostic (8.14e-2),unprognostic (1.35e-1),unprognostic (1.38e-2),unprognostic (1.15e-1),unprognostic (1.45e-2),unprognostic (6.01e-2),unprognostic (7.30e-2),unprognostic (1.20e-1),unprognostic (1.59e-2)
YWHAZ,"14-3-3-zeta, KCIP-1, YWHAD",ENSG00000164924,Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta,P63104,8,100916523-100953388,"Plasma proteins, Predicted intracellular proteins, Transporters",,,Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Cell type enhanced,Detected in all,,Late spermatids: 2282.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,"Skin - Keratinocyte (other), Thyroid - Thyroid glandular cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB005065,Approved,,,,,,,,,320000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 29: Squamous epithelium - Innate immune response,Cluster 14: Neurons - Synaptic function,Cluster 40: Non-specific - Unknown function,Cluster 45: Non-specific - Mixed function,128.0,,,CAB005065: AB_2218378,unprognostic (4.70e-3),unprognostic (7.38e-3),unprognostic (8.09e-2),prognostic unfavorable (3.91e-4),unprognostic (1.83e-3),unprognostic (2.00e-2),prognostic unfavorable (2.28e-5),prognostic unfavorable (3.93e-4),unprognostic (1.65e-1),unprognostic (3.72e-1),prognostic unfavorable (1.20e-5),unprognostic (1.09e-1),prognostic unfavorable (2.03e-6),unprognostic (1.02e-1),unprognostic (1.69e-1),unprognostic (1.20e-1),unprognostic (1.49e-1)
MBL2,"COLEC1, MBL, MBP, MBP-C, MBP1",ENSG00000165471,Mannose binding lectin 2,P11226,10,52765380-52772784,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement activation lectin pathway, Complement pathway, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,2727.0,liver: 272.6,Cell type enriched,Detected in some,98.0,Hepatocytes: 230.9,Cancer enriched,Detected in single,275.0,liver cancer: 22.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in single,5.0,liver cancer: 1.0,Liver - Hepatocytes,Not detected,Not detected,,,Region enriched,Detected in single,13.0,basal ganglia: 1.3,"HPA002027, CAB016782",Enhanced,,,,Secreted to blood,Complement pathway,,,1220000000.0,1900000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,9.0,,,"CAB016782: , HPA002027: AB_1079324",,,,,,,unprognostic (1.72e-2),,unprognostic (3.03e-1),,,,,,,,
TPM4,,ENSG00000167460,Tropomyosin 4,P67936,19,16067021-16103002,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",,"Actin-binding, Muscle protein",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in many,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Breast - Smooth muscle cells,Low region specificity,Detected in all,,,,,,,"CAB004685, HPA047089, HPA053624",Approved,,Approved,"Actin filaments,Cytosol",,,,,,370000000.0,Cluster 33: Non-specific - ATP binding,Cluster 62: Connective tissue - ECM organization,Cluster 25: Non-specific - Transcription,Cluster 64: Connective tissue cells - ECM organization,Cluster 45: Non-specific - Mixed function,3.0,Actin filaments,Cytosol,"CAB004685: AB_425723, HPA047089: AB_2679928, HPA053624: AB_2682210",unprognostic (1.27e-1),unprognostic (1.53e-2),unprognostic (3.62e-3),unprognostic (7.38e-3),unprognostic (3.80e-1),unprognostic (2.40e-2),unprognostic (3.11e-2),unprognostic (2.75e-3),unprognostic (1.38e-2),unprognostic (3.61e-1),prognostic unfavorable (3.07e-4),unprognostic (1.03e-1),prognostic unfavorable (1.26e-10),unprognostic (3.85e-2),unprognostic (2.25e-1),unprognostic (1.48e-1),unprognostic (1.78e-1)
SERPINF2,"A2AP, AAP, ALPHA-2-PI, alpha2AP, API, PLI",ENSG00000167711,Serpin family F member 2,P08697,17,1742836-1755265,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor",Disease variant,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,16.0,liver: 1539.8,Cell type enriched,Detected in many,4.0,Hepatocytes: 814.9,Cancer enriched,Detected in all,6.0,liver cancer: 450.6,Region enriched,Detected in all,7.0,choroid plexus: 21.0,Immune cell enriched,Detected in some,4.0,plasmacytoid DC: 44.8,Lineage enriched,Detected in many,23.0,dendritic cells: 44.8,Group enriched,Detected in many,14.0,Gastric cancer: 46.8;liver cancer: 36.6,"Kidney - Proximal tubular cells, Liver - Hepatocytes, Skin - Macrophages",Not detected,Not detected,,,Low region specificity,Detected in many,,,"HPA001885, HPA005943, CAB024863",Approved,,Approved,Golgi apparatus,Secreted to blood,Acute phase,,,11900.0,61000000000.0,Cluster 8: Plasmacytoid DCs - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,"CAB024863: , HPA001885: AB_1079922, HPA005943: ",unprognostic (2.17e-3),unprognostic (2.56e-3),unprognostic (2.48e-1),unprognostic (7.57e-3),unprognostic (3.69e-2),unprognostic (1.45e-2),prognostic favorable (2.26e-5),unprognostic (1.44e-1),unprognostic (2.32e-2),unprognostic (1.38e-1),unprognostic (1.88e-3),unprognostic (2.18e-1),unprognostic (1.09e-3),unprognostic (7.05e-2),unprognostic (2.81e-1),unprognostic (7.68e-3),unprognostic (2.93e-1)
KRT1,"EHK1, KRT1A",ENSG00000167768,Keratin 1,P04264,12,52674736-52680407,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, Ichthyosis, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,10.0,skin 1: 12670.5,Cell type enriched,Detected in some,11.0,Suprabasal keratinocytes: 6357.5,Group enriched,Detected in many,5.0,head and neck cancer: 313.8;melanoma: 478.9,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,memory CD4 T-cell: 2.3,Lineage enriched,Detected in single,23.0,T-cells: 2.3,Group enriched,Detected in some,5.0,Bladder cancer: 10.9;Esophageal cancer: 23.0;head and neck cancer: 17.4,Skin - Keratinocyte (other),Low region specificity,Detected in all,,,Not detected,Not detected,,,"CAB002153, HPA017917, HPA062908",Enhanced,,,,,,,,,35000000000.0,Cluster 11: T-cells - Unknown function,Cluster 13: Skin - Cornification,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 12: Squamous epithelial cells - Keratinization,32.0,,,"CAB002153: AB_563790, HPA017917: AB_1852192, HPA062908: AB_2684901",unprognostic (8.05e-2),unprognostic (8.49e-3),unprognostic (5.06e-3),unprognostic (6.44e-2),unprognostic (1.25e-2),unprognostic (1.53e-1),unprognostic (2.07e-1),unprognostic (3.24e-1),unprognostic (1.30e-1),unprognostic (2.16e-1),unprognostic (9.24e-2),unprognostic (6.63e-2),unprognostic (3.23e-4),unprognostic (1.58e-1),unprognostic (3.40e-2),unprognostic (1.36e-1),unprognostic (1.09e-2)
KRT9,"CK-9, EPPK, K9",ENSG00000171403,Keratin 9,P35527,17,41565836-41572059,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,5.0,lymphoid tissue: 11.8,Cell type enhanced,Detected in some,,Basal keratinocytes: 2.7;Basal squamous epithelial cells: 1.1;Breast myoepithelial cells: 3.8;Extravillous trophoblasts: 2.9,Cancer enriched,Detected in some,6.0,melanoma: 21.2,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,cervical cancer: 4.2;head and neck cancer: 3.0,"Breast - Breast myoepithelial cells, Testis - Spermatogonia",Region enhanced,Detected in many,,basal ganglia: 25.1,,,,,"HPA007261, CAB037322",Supported,,,,,,,,,24000000000.0,,Cluster 71: Thymus - Adaptive immune response,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 4: Extravillous trophoblasts - Unknown function,,,,"CAB037322: , HPA007261: AB_1079182",unprognostic (2.13e-2),unprognostic (5.08e-2),,unprognostic (4.97e-2),,unprognostic (3.65e-2),,unprognostic (2.89e-3),unprognostic (1.36e-1),unprognostic (1.19e-1),unprognostic (5.92e-7),unprognostic (1.28e-1),,unprognostic (3.02e-2),unprognostic (1.40e-1),,unprognostic (4.15e-2)
FGG,,ENSG00000171557,Fibrinogen gamma chain,P02679,4,154604134-154612967,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,330.0,liver: 16058.1,Cell type enriched,Detected in some,10.0,Hepatocytes: 9849.5,Cancer enriched,Detected in many,19.0,liver cancer: 1503.5,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,6.0,liver cancer: 229.6,Liver - Hepatocytes,Not detected,Not detected,,,Not detected,Not detected,,,"HPA027529, CAB033120, HPA074638",Supported,,Approved,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,267000000000.0,73000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,3.0,Endoplasmic reticulum,,"CAB033120: AB_2103818, HPA027529: AB_10601322, HPA074638: ",unprognostic (1.26e-2),,,,unprognostic (4.77e-3),unprognostic (6.33e-3),unprognostic (3.69e-3),unprognostic (2.18e-3),,unprognostic (9.63e-2),unprognostic (7.57e-3),,prognostic unfavorable (1.00e-6),unprognostic (1.75e-3),unprognostic (3.21e-1),,unprognostic (1.14e-1)
FGA,,ENSG00000171560,Fibrinogen alpha chain,P02671,4,154583126-154590742,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity",,"Amyloidosis, Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,386.0,liver: 17848.7,Cell type enriched,Detected in many,30.0,Hepatocytes: 13631.3,Cancer enriched,Detected in many,43.0,liver cancer: 2431.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,6.0,liver cancer: 180.5,"Liver - Hepatocytes, Stomach - Parietal cells, Testis - Early spermatids, Testis - Late spermatids",,,,,,,,,"CAB016776, HPA051370, HPA064755",Supported,,Enhanced,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,407000000.0,140000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,3.0,Endoplasmic reticulum,,"CAB016776: , HPA051370: AB_2681458, HPA064755: AB_2685345",,unprognostic (5.95e-2),unprognostic (6.25e-2),unprognostic (2.02e-1),,unprognostic (5.68e-2),prognostic favorable (7.33e-4),unprognostic (1.29e-3),,,unprognostic (1.84e-1),,prognostic unfavorable (4.23e-6),unprognostic (4.20e-1),unprognostic (1.41e-1),,
FGB,,ENSG00000171564,Fibrinogen beta chain,P02675,4,154563011-154572807,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity",,"Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,372.0,liver: 17393.5,Cell type enriched,Detected in some,8.0,Hepatocytes: 15989.7,Cancer enriched,Detected in many,42.0,liver cancer: 2262.6,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,8.0,liver cancer: 219.4,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001900, HPA001901, CAB008624",Enhanced,,Enhanced,Endoplasmic reticulum,Secreted to blood,Blood coagulation,,,,110000000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,Endoplasmic reticulum,,"CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864",unprognostic (1.16e-1),unprognostic (3.89e-2),unprognostic (4.65e-2),unprognostic (3.44e-1),,,unprognostic (2.20e-3),unprognostic (1.42e-2),,,unprognostic (1.79e-1),,prognostic unfavorable (5.72e-5),unprognostic (2.48e-2),unprognostic (7.91e-2),,
CFL1,CFL,ENSG00000172757,Cofilin 1,P23528,11,65823022-65862026,"Plasma proteins, Predicted intracellular proteins",Host-virus interaction,Actin-binding,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,Low region specificity,Detected in all,,,,,,,"CAB033687, CAB037077, HPA053761, HPA077782",Approved,,Supported,Plasma membrane,,,,,,290000000.0,Cluster 29: Non-specific - Unknown function,Cluster 25: Small intestine - Absorption,Cluster 14: Neurons - Synaptic function,Cluster 24: Non-specific - Unknown function,Cluster 45: Non-specific - Mixed function,12.0,Plasma membrane,,"CAB033687: AB_1121774, CAB037077: AB_1078547, HPA053761: AB_2682251, HPA077782: ",unprognostic (1.14e-1),unprognostic (2.37e-2),unprognostic (7.69e-3),unprognostic (4.32e-3),unprognostic (3.14e-2),unprognostic (2.09e-2),prognostic unfavorable (1.73e-5),unprognostic (1.59e-3),unprognostic (2.52e-1),unprognostic (5.88e-3),unprognostic (6.57e-3),unprognostic (2.09e-1),unprognostic (6.19e-3),unprognostic (1.72e-2),unprognostic (1.82e-1),unprognostic (1.49e-1),unprognostic (2.06e-1)
KRT2,"KRT2A, KRTE",ENSG00000172867,Keratin 2,P35908,12,52644558-52652211,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Disease variant, FDA approved drug targets, Ichthyosis",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,57.0,skin 1: 4511.5,Cell type enriched,Detected in some,30.0,Suprabasal keratinocytes: 130.9,Cancer enriched,Detected in some,5.0,melanoma: 23.4,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,naive CD4 T-cell: 1.4,Lineage enriched,Detected in single,14.0,T-cells: 1.4,Not detected,Not detected,,,Skin - Keratinocyte (other),Group enriched,Detected in some,6.0,amygdala: 1.7;hippocampal formation: 2.7,Not detected,Not detected,,,CAB037321,Enhanced,,,,,,,,,9700000000.0,Cluster 43: Non-specific - Transcription & Translation,Cluster 82: Skin - Keratinization,,Cluster 24: Non-specific - Unknown function,Cluster 12: Squamous epithelial cells - Keratinization,11.0,,,CAB037321: ,unprognostic (1.22e-1),unprognostic (1.60e-1),unprognostic (1.34e-1),unprognostic (2.56e-1),unprognostic (8.47e-3),unprognostic (1.69e-2),,unprognostic (1.84e-1),unprognostic (3.59e-1),,unprognostic (2.12e-1),unprognostic (4.76e-2),unprognostic (3.56e-7),unprognostic (6.43e-2),unprognostic (5.98e-3),unprognostic (6.69e-2),unprognostic (3.46e-1)
C1QA,,ENSG00000173372,Complement C1q A chain,P02745,1,22635077-22639678,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Host-virus interaction, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,choroid plexus: 621.7;lymphoid tissue: 1066.3,Group enriched,Detected in many,5.0,Hofbauer cells: 1545.9;Kupffer cells: 3931.0;Macrophages: 1776.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in some,38.0,intermediate monocyte: 227.9;non-classical monocyte: 184.6,Lineage enriched,Detected in many,59.0,monocytes: 227.9,Not detected,Not detected,,,"Adipose subcutaneous - Macrophages, Adipose visceral - Macrophages, Breast - Macrophages, Colon - Macrophages, Heart muscle - Macrophages, Kidney - Macrophages, Liver - Kupffer cells, Lung - Macrophages, Pancreas - Macrophages, Prostate - Macrophages, Skeletal muscle - Macrophages, Skin - Macrophages, Stomach - Macrophages, Testis - Macrophages, Thyroid - Macrophages",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002350, CAB009823",Supported,,,,Secreted to blood,Complement pathway,,,,2700000000.0,Cluster 40: Monocytes - Innate immune response,Cluster 70: Lymphoid tissue - Immune response,Cluster 20: Macrophages & Microglia - Immune response,Cluster 1: Neuronal - Visual perception,Cluster 58: Macrophages - Innate immune response,3.0,,,"CAB009823: AB_2228238, HPA002350: AB_1078552",unprognostic (1.97e-1),unprognostic (1.14e-2),unprognostic (1.98e-3),unprognostic (3.07e-2),unprognostic (6.10e-2),unprognostic (2.60e-1),unprognostic (1.16e-1),unprognostic (2.13e-1),unprognostic (1.67e-2),unprognostic (1.99e-1),unprognostic (4.42e-2),unprognostic (1.86e-1),prognostic unfavorable (1.58e-6),unprognostic (1.54e-1),unprognostic (2.11e-3),unprognostic (2.75e-2),unprognostic (7.30e-2)
SAA1,"PIG4, SAA, TP53I4",ENSG00000173432,Serum amyloid A1,P0DJI8,11,18266260-18269977,"Disease related genes, Predicted secreted proteins",Acute phase,Heparin-binding,Amyloidosis,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,20.0,liver: 46934.0,Cell type enriched,Detected in many,9.0,Hepatocytes: 88360.6,Cancer enriched,Detected in many,16.0,liver cancer: 1249.6,Group enriched,Detected in many,5.0,choroid plexus: 3.7;pons: 8.3;thalamus: 14.1,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,head and neck cancer: 445.5,"Adipose visceral - Adipocytes (Visceral), Breast - Adipocytes (Breast)",,,,,,,,,,,,,,Secreted to blood,Acute phase,,,300000000.0,11000000000.0,,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 62: Hepatocytes - Metabolism,,,,,unprognostic (2.86e-3),unprognostic (1.41e-1),unprognostic (2.82e-1),unprognostic (1.50e-1),unprognostic (4.54e-3),unprognostic (1.79e-2),unprognostic (1.63e-2),unprognostic (7.04e-2),unprognostic (1.54e-1),unprognostic (1.08e-2),unprognostic (8.95e-2),unprognostic (1.90e-2),prognostic unfavorable (4.57e-12),unprognostic (5.15e-2),unprognostic (9.78e-2),unprognostic (9.23e-3),unprognostic (1.64e-1)
APOF,,ENSG00000175336,Apolipoprotein F,Q13790,12,56360568-56362857,"Plasma proteins, Predicted secreted proteins","Cholesterol metabolism, Lipid metabolism, Lipid transport, Steroid metabolism, Sterol metabolism, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,346.0,liver: 404.0,Cell type enriched,Detected in some,5.0,Hepatocytes: 299.3,Cancer enriched,Detected in some,6.0,liver cancer: 34.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in single,,prostate cancer: 1.0,"Liver - Hepatocytes, Prostate - Prostate glandular cells, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,,,,,,,,,,Secreted to blood,Apolipoprotein,,,18000000000.0,2200000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 48: Non-specific - Mixed function,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,,,,,unprognostic (3.55e-2),unprognostic (1.13e-1),unprognostic (1.48e-2),unprognostic (8.99e-3),unprognostic (9.84e-2),unprognostic (3.29e-2),unprognostic (2.08e-3),unprognostic (7.84e-2),unprognostic (4.22e-1),unprognostic (5.69e-2),unprognostic (2.68e-3),unprognostic (8.55e-2),unprognostic (2.42e-2),unprognostic (2.77e-1),unprognostic (5.57e-2),unprognostic (2.87e-1),unprognostic (4.43e-2)
A2M,"CPAMD5, FWP007, S863-7",ENSG00000175899,Alpha-2-macroglobulin,P01023,12,9067664-9116229,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",,"Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,liver: 1212.9;lung: 1626.5,Cell type enhanced,Detected in many,,Adipocytes: 1247.2;Cardiomyocytes: 393.1;Endothelial cells: 861.7;Hepatocytes: 654.0;Microglial cells: 339.1;Smooth muscle cells: 471.0,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in single,,gdT-cell: 1.5,Lineage enhanced,Detected in single,,T-cells: 1.5,Cancer enhanced,Detected in many,,Brain cancer: 48.1;liver cancer: 106.6;skin cancer: 72.1,"Adipose subcutaneous - Endothelial cells, Adipose visceral - Endothelial cells, Breast - Endothelial cells, Colon - Endothelial cells, Heart muscle - Macrophages, Kidney - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_1, Prostate - Fibroblasts, Skeletal muscle - Endothelial cells, Thyroid - Endothelial cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA002265, CAB017621",Supported,,,,Secreted to blood,Enzyme inhibitor,,,1630000000000.0,170000000000.0,Cluster 1: T-cells - Unknown function,Cluster 11: Liver - Plasma proteins,Cluster 47: Endothelial cells - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 41: Adipocytes & Endothelial cells - Mixed function,51.0,,,"CAB017621: AB_1118894, HPA002265: AB_1078142",unprognostic (1.73e-2),unprognostic (1.05e-3),unprognostic (1.72e-1),unprognostic (2.29e-2),unprognostic (7.36e-2),unprognostic (3.91e-2),unprognostic (7.95e-2),unprognostic (3.65e-2),unprognostic (2.38e-1),unprognostic (7.19e-2),unprognostic (4.71e-2),unprognostic (2.06e-2),unprognostic (1.28e-2),unprognostic (8.04e-3),unprognostic (2.32e-2),unprognostic (8.58e-2),unprognostic (9.03e-3)
C8G,,ENSG00000176919,Complement C8 gamma chain,P07360,9,136945185-136946975,"Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Innate immunity",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,18.0,liver: 550.5,Cell type enriched,Detected in some,9.0,Hepatocytes: 1036.6,Cancer enriched,Detected in all,58.0,liver cancer: 260.0,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,Gastric cancer: 6.2;liver cancer: 2.1,,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA046269,Approved,,,,Secreted to blood,Complement pathway,,,,2800000000.0,,Cluster 31: Liver - Plasma proteins,,Cluster 57: Stomach & Colon cancer - Digestion,Cluster 62: Hepatocytes - Metabolism,2.0,,,HPA046269: AB_2679606,unprognostic (5.00e-2),unprognostic (4.05e-3),prognostic unfavorable (2.99e-4),unprognostic (3.94e-1),unprognostic (4.53e-1),unprognostic (2.75e-2),unprognostic (1.71e-3),unprognostic (2.79e-1),unprognostic (1.88e-1),unprognostic (3.67e-1),unprognostic (2.96e-2),unprognostic (3.00e-1),unprognostic (5.02e-3),unprognostic (2.16e-1),unprognostic (7.67e-2),unprognostic (1.65e-1),unprognostic (1.05e-2)
F2,,ENSG00000180210,"Coagulation factor II, thrombin",P00734,11,46719196-46739506,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Blood coagulation, Hemostasis","Hydrolase, Protease, Serine protease","Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in single,1310.0,liver: 1180.6,Cell type enriched,Detected in some,7.0,Hepatocytes: 841.1,Cancer enriched,Detected in some,110.0,liver cancer: 508.2,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in some,10.0,liver cancer: 64.3,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB016780, HPA051476, HPA054698",Enhanced,,,,Secreted to blood,Blood coagulation,,,108000000000.0,41000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 15: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB016780: , HPA051476: AB_2681498, HPA054698: AB_2682578",unprognostic (1.98e-1),unprognostic (2.52e-1),unprognostic (2.64e-2),unprognostic (1.85e-1),unprognostic (2.29e-1),unprognostic (2.81e-1),unprognostic (2.23e-2),unprognostic (3.94e-2),,unprognostic (5.79e-2),unprognostic (8.29e-2),unprognostic (4.46e-2),prognostic unfavorable (6.75e-12),unprognostic (5.65e-3),unprognostic (5.80e-2),,unprognostic (1.54e-3)
C1S,,ENSG00000182326,Complement C1s,P09871,12,6988259-7071032,"Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Disease variant, Ehlers-Danlos syndrome, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,liver: 2762.6,Cell type enhanced,Detected in many,,Fibroblasts: 717.8;Hepatocytes: 2248.0;Leydig cells: 1204.3;Mesothelial cells: 578.3;Ovarian stromal cells: 401.7;Peritubular cells: 631.2,Cancer enhanced,Detected in all,,liver cancer: 276.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Adipose progenitor cells, Breast - Fibroblasts, Liver - Hepatocytes, Lung - Fibroblast_2, Skin - Fibroblast_2",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,"CAB016722, HPA018852",Supported,,Approved,"Nucleoplasm,Cytosol",Secreted to blood,Complement pathway,,,93000000000.0,14000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 39: Astrocytes - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,2.0,Nucleoplasm,Cytosol,"CAB016722: , HPA018852: AB_1847112",unprognostic (2.72e-3),unprognostic (7.31e-2),unprognostic (9.37e-2),unprognostic (1.39e-2),unprognostic (1.05e-2),unprognostic (9.63e-2),prognostic favorable (7.73e-4),unprognostic (6.38e-2),unprognostic (1.16e-1),unprognostic (6.14e-2),unprognostic (1.57e-1),unprognostic (1.85e-2),prognostic unfavorable (7.44e-15),unprognostic (2.02e-2),unprognostic (5.68e-3),unprognostic (1.19e-2),unprognostic (5.39e-2)
PROS1,PROS,ENSG00000184500,Protein S,P07225,3,93873051-93980003,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Blood coagulation, Fibrinolysis, Hemostasis",,"Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,choroid plexus: 137.3;liver: 274.9,Cell type enhanced,Detected in many,,Hepatocytes: 261.3;Mesothelial cells: 85.9,Cancer enhanced,Detected in all,,thyroid cancer: 64.8,Region enriched,Detected in all,34.0,choroid plexus: 214.4,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,skin cancer: 46.7,"Breast - Fibroblasts, Liver - Hepatocytes",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"HPA007724, HPA023974, CAB032610",Approved,,,,Secreted to blood,Blood coagulation,,,22500000000.0,5000000000.0,,Cluster 83: Liver - Metabolism,Cluster 36: Choroid plexus - Mixed function,Cluster 15: Kidney cancer - Membrane components,Cluster 53: Fibroblasts - ECM organization,4.0,,,"CAB032610: AB_2237647, HPA007724: AB_1079688, HPA023974: AB_1855738",unprognostic (2.00e-2),unprognostic (2.81e-2),unprognostic (9.21e-2),unprognostic (8.03e-3),unprognostic (3.35e-2),unprognostic (2.41e-1),unprognostic (6.48e-2),unprognostic (3.07e-1),unprognostic (5.18e-2),unprognostic (3.12e-1),unprognostic (1.10e-1),unprognostic (1.91e-1),unprognostic (1.10e-1),prognostic unfavorable (8.35e-4),unprognostic (4.90e-2),unprognostic (1.05e-2),prognostic unfavorable (4.42e-5)
KRT10,"CK10, K10, KPP",ENSG00000186395,Keratin 10,P13645,17,40818117-40822614,"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,,"Disease variant, Ichthyosis",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,14.0,skin 1: 15346.8,Cell type enriched,Detected in all,8.0,Suprabasal keratinocytes: 6950.7,Group enriched,Detected in all,4.0,head and neck cancer: 310.0;melanoma: 562.4,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in many,,,Low lineage specificity,Detected in all,,,Cancer enhanced,Detected in all,,Rhabdoid: 214.5,Skin - Keratinocyte (other),Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,"CAB000132, HPA012014",Enhanced,,,,Secreted in other tissues,No annotated function,,,,18000000000.0,Cluster 45: Eosinophils - Unknown function,Cluster 13: Skin - Cornification,Cluster 55: Non-specific - Transcription,Cluster 5: Rhabdoid - Unknown function,Cluster 12: Squamous epithelial cells - Keratinization,1.0,,,"CAB000132: , HPA012014: AB_1852195",unprognostic (3.07e-1),unprognostic (5.19e-2),unprognostic (1.71e-1),unprognostic (1.37e-2),unprognostic (2.00e-2),unprognostic (2.60e-1),unprognostic (3.02e-2),unprognostic (1.29e-2),unprognostic (1.09e-1),unprognostic (1.56e-1),unprognostic (1.00e-2),unprognostic (2.14e-1),prognostic unfavorable (9.32e-5),unprognostic (1.64e-1),unprognostic (1.85e-1),unprognostic (1.66e-2),unprognostic (8.10e-2)
KRT14,"EBS3, EBS4",ENSG00000186847,Keratin 14,P02533,17,41582279-41586895,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins",,,"Cancer-related genes, Disease variant, Ectodermal dysplasia, Epidermolysis bullosa, Palmoplantar keratoderma",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,skin 1: 6776.5,Group enriched,Detected in many,6.0,Basal keratinocytes: 28244.3;Suprabasal keratinocytes: 10636.2,Cancer enriched,Detected in many,5.0,head and neck cancer: 5910.5,Not detected,Not detected,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,4.0,head and neck cancer: 2098.9,"Breast - Breast myoepithelial cells, Skin - Keratinocyte (other)",Not detected,Not detected,,,Region enhanced,Detected in single,,cerebral cortex: 1.5,"CAB000134, HPA000452, HPA000539, HPA023040",Enhanced,,Enhanced,Intermediate filaments,,,,,,1600000000.0,,Cluster 13: Skin - Cornification,,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 12: Squamous epithelial cells - Keratinization,21.0,Intermediate filaments,,"CAB000134: , HPA000452: AB_1079177, HPA000539: , HPA023040: AB_1852201",prognostic favorable (2.66e-4),unprognostic (1.64e-1),unprognostic (1.01e-2),unprognostic (1.42e-2),unprognostic (1.66e-1),unprognostic (1.02e-2),,unprognostic (2.03e-2),unprognostic (2.74e-1),unprognostic (1.35e-1),unprognostic (1.00e-2),unprognostic (5.74e-3),unprognostic (1.49e-8),unprognostic (8.91e-2),unprognostic (2.00e-1),unprognostic (8.80e-3),unprognostic (1.22e-2)
SERPINA5,"PAI3, PCI, PLANH3, PROCI",ENSG00000188488,Serpin family A member 5,P05154,14,94561442-94593118,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins","Fertilization, Lipid transport, Transport","Heparin-binding, Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 469.3;liver: 761.5;testis: 419.6,Cell type enhanced,Detected in many,,Basal prostatic cells: 239.3;Cholangiocytes: 360.6;Glandular and luminal cells: 330.8;Hepatocytes: 174.8;Late spermatids: 271.4;Peritubular cells: 139.8;Sertoli cells: 356.3,Cancer enhanced,Detected in many,,liver cancer: 121.1,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,Gastric cancer: 27.3;liver cancer: 67.0,"Liver - Hepatocytes, Pancreas - Macrophages, Skin - Fibroblast_2, Testis - Sertoli cells",Not detected,Not detected,,,Not detected,Not detected,,,HPA078846,Enhanced,,,,Secreted to blood,Transport,,,,2100000000.0,,Cluster 78: Testis - Transcription,Cluster 44: Non-specific - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 37: Glandular & Luminal cells - Unknown function,1.0,,,HPA078846: ,unprognostic (5.94e-3),unprognostic (2.64e-4),unprognostic (1.13e-1),prognostic favorable (7.72e-4),unprognostic (3.34e-3),unprognostic (6.10e-3),unprognostic (3.94e-2),unprognostic (1.39e-3),unprognostic (5.36e-1),unprognostic (1.50e-1),unprognostic (6.16e-2),unprognostic (1.87e-2),unprognostic (8.39e-3),unprognostic (3.38e-3),unprognostic (9.92e-2),unprognostic (8.08e-2),unprognostic (3.23e-1)
HBA2,HBA-T2,ENSG00000188536,Hemoglobin subunit alpha 2,P69905,16,172876-173710,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport",,"Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,5.0,bone marrow: 37617.4,Cell type enriched,Detected in many,96.0,Erythroid cells: 55683.9,Cancer enhanced,Detected in all,,glioma: 59.7,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,eosinophil: 316.7;neutrophil: 961.9;plasmacytoid DC: 488.2,Group enriched,Detected in all,7.0,dendritic cells: 488.2;granulocytes: 961.9,Cancer enriched,Detected in many,34.0,Leukemia: 1053.9,Liver - Erythroid cells,,,,,,,,,"CAB038417, HPA043780",Enhanced,,,,,,,,,14000000000.0,Cluster 22: Eosinophils - Transcription,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,13.0,,,"CAB038417: , HPA043780: AB_2678667",unprognostic (1.57e-1),unprognostic (7.02e-2),unprognostic (2.59e-2),unprognostic (2.13e-1),unprognostic (3.59e-1),unprognostic (3.18e-1),unprognostic (3.39e-2),unprognostic (2.12e-1),unprognostic (4.99e-2),unprognostic (4.43e-1),unprognostic (1.09e-2),unprognostic (1.19e-2),unprognostic (1.72e-3),unprognostic (1.36e-1),unprognostic (2.11e-1),unprognostic (4.73e-2),unprognostic (8.92e-2)
APOD,Apo-D,ENSG00000189058,Apolipoprotein D,P05090,3,195568705-195584033,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Transport,,Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,breast: 4898.1;choroid plexus: 4317.9,Cell type enhanced,Detected in many,,Fibroblasts: 4290.5;Leydig cells: 1994.7;Melanocytes: 1348.5;Peritubular cells: 1105.2;Serous glandular cells: 920.5,Cancer enriched,Detected in all,4.0,melanoma: 925.2,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,14.0,memory B-cell: 5.0,Lineage enriched,Detected in single,14.0,B-cells: 5.0,Group enriched,Detected in many,4.0,breast cancer: 117.8;prostate cancer: 92.2;skin cancer: 170.8,Pancreas - Fibroblasts,Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,HPA040520,Enhanced,,Approved,Plasma membrane,Secreted to blood,Apolipoprotein,,,98900000000.0,90000000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 60: Choroid plexus - Transmembrane transport,Cluster 30: White matter - Myelination,Cluster 44: Connective tissue cells - ECM organization,Cluster 53: Fibroblasts - ECM organization,38.0,Plasma membrane,,HPA040520: AB_2677020,prognostic favorable (5.51e-4),unprognostic (7.62e-3),unprognostic (7.85e-3),unprognostic (3.34e-3),unprognostic (2.20e-1),unprognostic (1.02e-2),unprognostic (3.09e-2),unprognostic (2.06e-3),unprognostic (1.26e-1),unprognostic (3.45e-1),unprognostic (3.38e-1),unprognostic (3.19e-1),unprognostic (6.90e-3),prognostic unfavorable (6.02e-4),unprognostic (1.38e-1),prognostic unfavorable (4.12e-4),unprognostic (1.71e-3)
SERPINA3,"AACT, ACT",ENSG00000196136,Serpin family A member 3,P01011,14,94612384-94624055,"Cancer-related genes, Candidate cardiovascular disease genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Acute phase,"Protease inhibitor, Serine protease inhibitor","Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,5.0,liver: 8942.3;pancreas: 4764.3,Cell type enhanced,Detected in some,,Ductal cells: 21.1;Exocrine glandular cells: 41.9;Fibroblasts: 14.7;Hepatocytes: 11.4;Mucus glandular cells: 36.7;Serous glandular cells: 13.8,Cancer enhanced,Detected in many,,liver cancer: 4.0,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,Bile duct cancer: 142.2;skin cancer: 409.0,"Breast - Breast glandular cells, Prostate - Macrophages, Thyroid - Macrophages",Not detected,Not detected,,,Not detected,Not detected,,,"HPA000893, HPA002560, CAB016647",Enhanced,,,,Secreted to blood,Acute phase,,,697000000000.0,94000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 69: Skin cancer - ECM organization,Cluster 49: Non-specific - Transcription,6.0,,,"CAB016647: AB_1611882, HPA000893: AB_10794315, HPA002560: AB_1856717",prognostic favorable (8.92e-4),unprognostic (3.33e-3),unprognostic (9.21e-2),unprognostic (1.53e-2),unprognostic (1.05e-1),unprognostic (1.72e-1),unprognostic (2.00e-2),unprognostic (1.00e-2),unprognostic (2.23e-1),unprognostic (9.60e-2),unprognostic (1.20e-2),unprognostic (9.92e-2),unprognostic (3.74e-12),unprognostic (6.47e-2),unprognostic (1.33e-2),,unprognostic (2.02e-2)
PPIA,CYPA,ENSG00000196262,Peptidylprolyl isomerase A,P62937,7,44796680-44824564,"Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Apoptosis, Host-virus interaction","Isomerase, Rotamase",FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Low tissue specificity,Detected in all,,,Low cell type specificity,Detected in all,,,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Low immune cell specificity,Detected in all,,,Low lineage specificity,Detected in all,,,Low cancer specificity,Detected in all,,,,,,,,,,,,"CAB004655, HPA058345",Uncertain,,,,Secreted to blood,Enzyme,,,,230000000.0,Cluster 13: Non-specific - Mitochondria,Cluster 33: Brain - Neuronal signaling,Cluster 14: Neurons - Synaptic function,Cluster 67: Non-specific - Unknown function,Cluster 49: Non-specific - Transcription,10.0,,,"CAB004655: AB_425607, HPA058345: AB_2683685",unprognostic (3.10e-1),unprognostic (2.28e-1),unprognostic (1.27e-1),unprognostic (7.86e-2),unprognostic (9.27e-2),unprognostic (2.19e-2),prognostic unfavorable (2.27e-6),unprognostic (1.12e-3),unprognostic (3.30e-2),unprognostic (3.92e-2),unprognostic (8.68e-3),unprognostic (2.52e-1),unprognostic (6.35e-3),unprognostic (2.77e-1),unprognostic (1.24e-1),unprognostic (7.84e-2),unprognostic (1.16e-1)
SERPINA1,"A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1",ENSG00000197249,Serpin family A member 1,P01009,14,94376747-94390693,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Acute phase, Blood coagulation, Hemostasis","Protease inhibitor, Serine protease inhibitor",Cancer-related genes,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,45.0,liver: 33156.1,Cell type enriched,Detected in many,7.0,Hepatocytes: 38353.1,Cancer enriched,Detected in all,10.0,liver cancer: 3850.6,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,classical monocyte: 2484.3;intermediate monocyte: 3414.0;neutrophil: 2835.2;non-classical monocyte: 4540.7,Group enriched,Detected in all,5.0,granulocytes: 2835.2;monocytes: 4540.7,Cancer enhanced,Detected in many,,Gastric cancer: 303.1;liver cancer: 783.6;lymphoma: 293.1,"Adipose visceral - Neutrophils, Liver - Hepatocytes, Skeletal muscle - Neutrophils",Not detected,Not detected,,,,,,,"HPA000927, HPA001292, CAB013211, CAB016648, CAB073396",Enhanced,,Enhanced,Vesicles,Secreted to blood,Blood coagulation,,,2070000000000.0,140000000000.0,Cluster 37: Monocytes & Neutrophils - Innate immune response,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 62: Hepatocytes - Metabolism,4.0,Vesicles,,"CAB013211: , CAB016648: AB_1611888, CAB073396: , HPA000927: AB_1844761, HPA001292: AB_1844762",prognostic favorable (1.61e-5),unprognostic (3.37e-1),prognostic favorable (5.86e-4),unprognostic (1.38e-2),unprognostic (1.98e-2),unprognostic (5.50e-3),unprognostic (3.81e-2),unprognostic (6.78e-2),unprognostic (2.54e-2),unprognostic (7.96e-2),unprognostic (1.08e-1),unprognostic (4.54e-1),unprognostic (1.23e-2),unprognostic (1.89e-1),unprognostic (1.30e-2),unprognostic (1.17e-2),unprognostic (1.96e-1)
CFD,"ADN, DF, PFD",ENSG00000197766,Complement factor D,P00746,19,859453-867884,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease",Disease variant,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,adipose tissue: 1448.6,Group enriched,Detected in many,9.0,Fibroblasts: 7755.6;Leydig cells: 5061.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in all,,basophil: 1712.8,Lineage enriched,Detected in all,6.0,granulocytes: 1712.8,Cancer enhanced,Detected in all,,Leukemia: 84.8,"Liver - Kupffer cells, Pancreas - Fibroblasts, Prostate - Fibroblasts, Skeletal muscle - Fibroblasts, Skin - Fibroblast_2",Not detected,Not detected,,,Low region specificity,Detected in all,,,,,,,,Secreted to blood,Immunity,,,732000000.0,4400000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 41: Smooth muscle tissue - ECM organization,Cluster 48: Non-specific - Mixed function,Cluster 14: Myeloid leukemia - Innate immune response,Cluster 53: Fibroblasts - ECM organization,,,,,unprognostic (3.00e-2),unprognostic (6.09e-2),unprognostic (2.44e-1),unprognostic (1.22e-3),unprognostic (6.92e-2),unprognostic (5.28e-2),unprognostic (8.11e-3),unprognostic (2.48e-1),unprognostic (1.46e-2),unprognostic (8.10e-2),prognostic favorable (1.77e-4),unprognostic (9.53e-2),prognostic unfavorable (7.09e-4),unprognostic (1.23e-1),unprognostic (4.55e-2),unprognostic (1.92e-2),unprognostic (9.75e-2)
LPA,"LP, Lp(a)",ENSG00000198670,Lipoprotein(a),P08519,6,160531482-160664275,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Lipid transport, Transport","Hydrolase, Protease, Serine protease",Atherosclerosis,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,65.0,liver: 74.5,Cell type enriched,Detected in some,6.0,Hepatocytes: 34.5,Cancer enriched,Detected in single,38.0,liver cancer: 3.6,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,"Kidney - Proximal tubular cells, Liver - Hepatocytes",,,,,,,,,"CAB016072, HPA060604",Supported,,,,Secreted to blood,Transport,,,78800000000.0,1800000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 56: Hypothalamus - Neuropeptide signaling,Cluster 59: Leukemia - T-cell receptor,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB016072: AB_2135240, HPA060604: AB_2684330",,unprognostic (2.16e-1),unprognostic (5.10e-1),unprognostic (7.75e-3),unprognostic (6.70e-2),unprognostic (1.60e-1),unprognostic (4.17e-3),unprognostic (1.59e-1),,unprognostic (6.38e-3),unprognostic (3.63e-2),unprognostic (3.18e-1),unprognostic (7.45e-3),unprognostic (2.56e-1),unprognostic (1.80e-1),unprognostic (1.34e-1),unprognostic (3.72e-2)
F5,,ENSG00000198734,Coagulation factor V,P12259,1,169511951-169586588,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Blood coagulation, Hemostasis",,"Disease variant, FDA approved drug targets, Thrombophilia",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,6.0,choroid plexus: 79.3;liver: 171.0;placenta: 45.4,Group enriched,Detected in many,7.0,Cholangiocytes: 95.4;Cytotrophoblasts: 83.4;Hepatocytes: 220.7;Syncytiotrophoblasts: 60.4,Cancer enriched,Detected in many,7.0,liver cancer: 69.6,Region enriched,Detected in all,22.0,choroid plexus: 306.3,Group enriched,Detected in some,4.0,classical monocyte: 4.1;eosinophil: 8.1;neutrophil: 7.0;T-reg: 6.2,Group enriched,Detected in many,13.0,granulocytes: 8.1;monocytes: 4.1;T-cells: 6.2,Cancer enhanced,Detected in many,,liver cancer: 17.9,"Breast - Adipocytes (Breast), Kidney - Podocytes, Liver - Hepatocytes, Lung - Neutrophil_2, Prostate - Urothelial cells, Skin - Eccrine sweat gland cells",Group enriched,Detected in many,5.0,basal ganglia: 2.7;hippocampal formation: 6.6;pons and medulla: 4.4;thalamus: 5.5,Group enriched,Detected in all,7.0,amygdala: 53.1;basal ganglia: 46.2;cerebral cortex: 89.3;hippocampal formation: 80.9;olfactory bulb: 37.0,HPA002036,,,Approved,Golgi apparatus,Secreted to blood,Blood coagulation,,,7670000000.0,13000000000.0,Cluster 7: Non-specific - Innate immune response,Cluster 11: Liver - Plasma proteins,Cluster 36: Choroid plexus - Mixed function,Cluster 2: Mucus-secreting cells - Unknown function,Cluster 62: Hepatocytes - Metabolism,,Golgi apparatus,,HPA002036: AB_1078787,unprognostic (3.67e-2),unprognostic (2.77e-4),unprognostic (5.42e-2),unprognostic (2.56e-4),unprognostic (2.03e-1),unprognostic (2.39e-4),unprognostic (3.46e-3),unprognostic (9.25e-3),unprognostic (2.02e-1),unprognostic (8.99e-3),unprognostic (6.55e-3),unprognostic (1.32e-1),unprognostic (2.01e-2),prognostic unfavorable (3.39e-4),unprognostic (7.15e-2),unprognostic (3.41e-1),unprognostic (4.31e-1)
APOM,"Apo-M, G3a, NG20",ENSG00000204444,Apolipoprotein M,O95445,6,31652416-31658210,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,4.0,liver: 381.2,Group enriched,Detected in many,7.0,Hepatocytes: 703.0;Proximal tubular cells: 402.9,Cancer enriched,Detected in all,13.0,liver cancer: 185.9,Low region specificity,Detected in single,,,Immune cell enhanced,Detected in some,,basophil: 3.0,Low lineage specificity,Detected in many,,,Cancer enhanced,Detected in some,,liver cancer: 6.4,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Testis - Early spermatids, Testis - Late spermatids",Not detected,Not detected,,,Low region specificity,Detected in all,,,"CAB034086, HPA051006",Approved,,Approved,Golgi apparatus,Secreted to blood,Apolipoprotein,,,7400000000.0,8200000000.0,Cluster 32: Basophils - Transcription,Cluster 1: Liver & Kidney - Metabolism,Cluster 25: Non-specific - Transcription,Cluster 18: Liver cancer - Metabolism,Cluster 56: Proximal tubular cells - Amino acid metabolism,,Golgi apparatus,,"CAB034086: AB_1119033, HPA051006: AB_2681307",unprognostic (2.76e-3),unprognostic (1.69e-2),unprognostic (8.66e-2),unprognostic (2.61e-2),unprognostic (1.12e-1),unprognostic (5.28e-2),unprognostic (3.78e-1),unprognostic (1.97e-2),unprognostic (1.80e-1),unprognostic (6.04e-3),unprognostic (2.27e-2),unprognostic (1.48e-1),unprognostic (7.28e-2),unprognostic (5.71e-2),unprognostic (1.96e-1),unprognostic (1.30e-1),unprognostic (3.20e-2)
CFI,"C3b-INA, FI, IF, KAF",ENSG00000205403,Complement factor I,P05156,4,109731008-109802150,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Complement pathway, Host-virus interaction, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,5.0,liver: 952.1,Cell type enhanced,Detected in many,,Cholangiocytes: 108.7;Hepatocytes: 454.5;Muller glia cells: 114.1;Proximal tubular cells: 195.1,Cancer enhanced,Detected in all,,liver cancer: 90.2,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Low cancer specificity,Detected in many,,,"Adipose subcutaneous - Endothelial cells, Colon - Endothelial cells, Kidney - Proximal tubular cells, Liver - Hepatocytes, Skeletal muscle - Endothelial cells, Skin - Endothelial cells",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA001143, CAB016777, HPA024061",Supported,,,,Secreted to blood,Complement pathway,,,,12000000000.0,,Cluster 1: Liver & Kidney - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 71: Lymphoma - Inflammatory response,Cluster 62: Hepatocytes - Metabolism,1.0,,,"CAB016777: , HPA001143: AB_1078555, HPA024061: AB_1847129",unprognostic (1.04e-1),unprognostic (5.79e-2),unprognostic (1.68e-1),unprognostic (6.32e-2),unprognostic (1.55e-2),unprognostic (8.58e-2),unprognostic (2.95e-2),unprognostic (3.00e-1),unprognostic (2.00e-2),unprognostic (5.42e-3),unprognostic (1.41e-1),unprognostic (3.61e-1),unprognostic (8.63e-2),unprognostic (1.29e-1),unprognostic (3.42e-2),unprognostic (1.74e-1),prognostic unfavorable (6.06e-4)
HBA1,HBA-T3,ENSG00000206172,Hemoglobin subunit alpha 1,P69905,16,176680-177522,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport",,"Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,4.0,bone marrow: 23966.1,Cell type enriched,Detected in many,105.0,Erythroid cells: 56964.9,Group enriched,Detected in many,4.0,endometrial cancer: 2.6;glioma: 6.3;ovarian cancer: 2.6;stomach cancer: 2.6,Low region specificity,Detected in all,,,Immune cell enhanced,Detected in many,,neutrophil: 143.5;plasmacytoid DC: 101.4,Group enriched,Detected in all,5.0,dendritic cells: 101.4;granulocytes: 143.5,Cancer enriched,Detected in many,55.0,Leukemia: 983.6,Liver - Erythroid cells,,,,,,,,,"CAB032534, HPA043780",Enhanced,,,,,,,,,14000000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,13.0,,,"CAB032534: AB_2294993, HPA043780: AB_2678667",unprognostic (1.16e-1),unprognostic (1.45e-2),unprognostic (8.87e-2),unprognostic (9.78e-3),unprognostic (3.02e-1),unprognostic (1.44e-1),unprognostic (1.67e-1),unprognostic (1.35e-1),unprognostic (6.21e-3),unprognostic (1.92e-2),unprognostic (1.64e-1),unprognostic (1.02e-2),unprognostic (3.59e-2),unprognostic (3.79e-1),unprognostic (6.61e-2),unprognostic (2.67e-2),unprognostic (9.56e-2)
GPX3,,ENSG00000211445,Glutathione peroxidase 3,P22352,5,151020591-151028988,"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",,"Oxidoreductase, Peroxidase",,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,kidney: 10840.5,Group enriched,Detected in many,5.0,Muller glia cells: 4288.3;Proximal tubular cells: 16878.3,Cancer enhanced,Detected in all,,renal cancer: 605.6;thyroid cancer: 856.0,Group enriched,Detected in all,4.0,choroid plexus: 1127.5;medulla oblongata: 588.7,Immune cell enriched,Detected in some,5.0,neutrophil: 20.8,Lineage enriched,Detected in many,5.0,granulocytes: 20.8,Cancer enhanced,Detected in all,,ovarian cancer: 198.7;thyroid cancer: 178.6,"Adipose subcutaneous - Adipocytes (Subcutaneous), Breast - Adipocytes (Breast), Kidney - Proximal tubular cells, Kidney - Proximal tubular cells",Region enhanced,Detected in all,,hypothalamus: 239.6,Low region specificity,Detected in all,,,CAB069456,Approved,,,,Secreted to blood,Enzyme,,,5090000000.0,6200000000.0,Cluster 21: Neutrophils - Unknown function,Cluster 52: Kidney - Transmembrane transport,Cluster 44: Non-specific - Mixed function,Cluster 44: Connective tissue cells - ECM organization,Cluster 38: Proximal tubular cells - Transmembrane transport,,,,CAB069456: AB_1616682,unprognostic (4.03e-1),unprognostic (7.35e-2),unprognostic (5.05e-3),unprognostic (9.01e-2),unprognostic (1.41e-2),unprognostic (8.13e-2),unprognostic (1.39e-2),unprognostic (1.62e-1),unprognostic (5.75e-3),unprognostic (2.70e-3),unprognostic (8.17e-3),unprognostic (1.14e-2),unprognostic (2.95e-1),prognostic unfavorable (1.65e-4),unprognostic (2.14e-1),unprognostic (5.11e-2),unprognostic (1.26e-1)
IGKV4-1,"B3, IGKV41",ENSG00000211598,Immunoglobulin kappa variable 4-1,P06312,2,88885397-88886153,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 1742.2;lymphoid tissue: 3074.1,Cell type enriched,Detected in some,33.0,Plasma cells: 27833.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in many,590.0,memory B-cell: 3048.7;naive B-cell: 3092.7,Lineage enriched,Detected in all,595.0,B-cells: 3092.7,Cancer enriched,Detected in some,11.0,lymphoma: 582.0,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Not detected,Not detected,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,8500000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (6.41e-5),unprognostic (9.19e-2),unprognostic (4.29e-3),unprognostic (5.42e-3),unprognostic (2.08e-2),prognostic favorable (8.25e-4),unprognostic (1.79e-2),unprognostic (1.12e-1),unprognostic (3.32e-1),unprognostic (3.71e-3),unprognostic (1.56e-1),unprognostic (3.29e-1),prognostic unfavorable (2.52e-6),unprognostic (1.99e-1),unprognostic (1.01e-1),unprognostic (6.29e-2),unprognostic (1.19e-1)
IGLV1-51,,ENSG00000211644,Immunoglobulin lambda variable 1-51,P01701,22,22322472-22322969,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in all,,intestine: 1270.8;lymphoid tissue: 2930.7;urinary bladder: 1531.4,Cell type enriched,Detected in some,262.0,Plasma cells: 14574.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in all,,,Group enriched,Detected in some,9.0,memory B-cell: 277.1;naive B-cell: 179.3,Lineage enriched,Detected in many,11.0,B-cells: 277.1,Group enriched,Detected in many,52.0,lymphoma: 181.2;Myeloma: 189.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,1700000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 37: Neurons - Mixed function,Cluster 55: Lymphoma - Immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (1.85e-4),unprognostic (1.71e-2),unprognostic (3.12e-3),unprognostic (1.76e-3),unprognostic (1.61e-1),prognostic favorable (1.95e-5),unprognostic (3.55e-3),unprognostic (3.78e-2),unprognostic (1.84e-1),unprognostic (1.61e-2),unprognostic (1.41e-1),unprognostic (4.86e-1),prognostic unfavorable (1.40e-5),unprognostic (1.21e-1),unprognostic (5.70e-2),unprognostic (1.89e-1),unprognostic (1.07e-1)
IGLV1-47,,ENSG00000211648,Immunoglobulin lambda variable 1-47,P01700,22,22357739-22358260,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 683.5;lymphoid tissue: 1747.6,Cell type enriched,Detected in some,10.0,Plasma cells: 8877.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,639.0,memory B-cell: 1525.2;naive B-cell: 824.7,Lineage enriched,Detected in many,830.0,B-cells: 1525.2,Cancer enriched,Detected in some,235.0,Myeloma: 3497.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,3000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 61: Plasma cells - Immunoglobulins & histones,,,,,unprognostic (5.19e-3),unprognostic (2.69e-2),unprognostic (1.11e-2),unprognostic (1.33e-2),unprognostic (1.26e-1),prognostic favorable (2.66e-4),unprognostic (4.44e-2),unprognostic (1.09e-1),unprognostic (5.69e-2),unprognostic (3.14e-2),unprognostic (2.28e-1),unprognostic (2.64e-1),prognostic unfavorable (5.12e-8),unprognostic (5.00e-3),unprognostic (1.62e-1),unprognostic (7.08e-2),unprognostic (1.15e-2)
IGLV3-21,,ENSG00000211662,Immunoglobulin lambda variable 3-21,P80748,22,22711689-22713203,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,lymphoid tissue: 1760.6;urinary bladder: 747.9,Cell type enriched,Detected in some,118.0,Plasma cells: 5888.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in some,,,Group enriched,Detected in some,337.0,memory B-cell: 433.3;naive B-cell: 225.5,Lineage enriched,Detected in single,444.0,B-cells: 433.3,Cancer enriched,Detected in some,15.0,Myeloma: 691.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Testis - Early spermatids, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,4700000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,,,,unprognostic (1.75e-3),unprognostic (6.04e-3),unprognostic (4.21e-2),unprognostic (2.59e-3),unprognostic (4.06e-3),prognostic favorable (3.26e-7),unprognostic (1.63e-1),unprognostic (1.78e-1),unprognostic (1.53e-1),unprognostic (5.30e-2),unprognostic (3.86e-1),unprognostic (2.35e-1),prognostic unfavorable (9.54e-8),unprognostic (7.83e-2),unprognostic (1.88e-1),unprognostic (2.67e-1),unprognostic (7.52e-2)
IGLC2,IGLC,ENSG00000211677,Immunoglobulin lambda constant 2,P0DOY2,22,22900976-22901437,"Immunoglobulin genes, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Immunity",Bence-Jones protein,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 9437.0;lymphoid tissue: 19382.3;stomach 1: 10530.9,Cell type enriched,Detected in many,8.0,Plasma cells: 107273.2,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,36.0,memory B-cell: 11410.9;naive B-cell: 10729.1,Lineage enriched,Detected in all,37.0,B-cells: 11410.9,Cancer enriched,Detected in many,10.0,Myeloma: 14457.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 20: Myeloma - Immune response,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (5.76e-5),unprognostic (2.29e-2),unprognostic (4.54e-3),unprognostic (1.46e-2),unprognostic (4.02e-2),prognostic favorable (1.14e-4),unprognostic (1.96e-2),unprognostic (7.52e-2),unprognostic (7.15e-2),unprognostic (7.69e-3),unprognostic (2.83e-1),unprognostic (4.41e-2),prognostic unfavorable (4.47e-9),unprognostic (2.00e-1),unprognostic (3.43e-1),unprognostic (1.19e-1),unprognostic (1.45e-1)
IGLC3,IGLC,ENSG00000211679,Immunoglobulin lambda constant 3 (Kern-Oz+ marker),P0DOY3,22,22906342-22906803,"Immunoglobulin genes, Predicted intracellular proteins, Predicted secreted proteins","Adaptive immunity, Immunity",Bence-Jones protein,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 3970.7;lymphoid tissue: 7928.0;stomach 1: 4009.5;urinary bladder: 3601.8,Cell type enriched,Detected in many,11.0,Plasma cells: 37474.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,34.0,memory B-cell: 7287.2;naive B-cell: 6162.3,Lineage enriched,Detected in all,37.0,B-cells: 7287.2,Cancer enriched,Detected in many,19.0,Myeloma: 12802.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"CAB000050, CAB016533",Supported,,,,Immunoglobulin genes,Immunity,,,,,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"CAB000050: , CAB016533: AB_629719",prognostic favorable (2.32e-4),unprognostic (1.18e-2),unprognostic (4.35e-3),unprognostic (4.54e-2),unprognostic (8.41e-2),prognostic favorable (3.33e-4),unprognostic (5.45e-2),unprognostic (4.59e-2),unprognostic (8.77e-2),prognostic favorable (4.58e-4),unprognostic (9.71e-2),unprognostic (2.31e-1),prognostic unfavorable (1.04e-9),unprognostic (1.21e-1),unprognostic (2.52e-1),unprognostic (1.37e-1),unprognostic (5.97e-2)
IGHA2,,ENSG00000211890,Immunoglobulin heavy constant alpha 2 (A2m marker),P01877,14,105583731-105588395,"Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,23.0,intestine: 562.7,Cell type enriched,Detected in many,30.0,Plasma cells: 9424.7,Low cancer specificity,Detected in all,,,Not detected,Not detected,,,Group enriched,Detected in some,878.0,memory B-cell: 280.4;naive B-cell: 124.8,Lineage enriched,Detected in single,1215.0,B-cells: 280.4,Cancer enriched,Detected in some,5.0,Myeloma: 47.8,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001217, HPA006013",Approved,,,,Immunoglobulin genes,Immunity,,,,67000000000.0,Cluster 17: B-cells - Immunoglobulins,,,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"HPA001217: AB_1079120, HPA006013: AB_1079119",prognostic favorable (1.98e-9),unprognostic (3.20e-2),unprognostic (2.23e-2),unprognostic (1.53e-2),unprognostic (1.93e-2),prognostic favorable (8.40e-5),unprognostic (4.56e-2),unprognostic (2.59e-1),unprognostic (3.17e-1),unprognostic (3.69e-2),unprognostic (1.20e-1),unprognostic (1.18e-1),prognostic unfavorable (7.50e-6),unprognostic (2.12e-1),unprognostic (3.28e-2),unprognostic (9.70e-2),unprognostic (4.47e-1)
IGHG4,,ENSG00000211892,Immunoglobulin heavy constant gamma 4 (G4m marker),P01861,14,105620506-105626066,"FDA approved drug targets, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,4.0,lymphoid tissue: 2402.4,Group enriched,Detected in some,4.0,B-cells: 423.0;Plasma cells: 595.5,Low cancer specificity,Detected in all,,,Low region specificity,Detected in some,,,Group enriched,Detected in some,457.0,memory B-cell: 123.0;naive B-cell: 74.3,Lineage enriched,Detected in single,569.0,B-cells: 123.0,Group enriched,Detected in some,43.0,lymphoma: 133.6;Myeloma: 34.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Mesothelial cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Lung - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells",,,,,,,,,HPA001245,Approved,,,,Immunoglobulin genes,Immunity,,,,170000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 43: Hindbrain - Mixed function,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,HPA001245: AB_1079121,unprognostic (7.29e-3),unprognostic (5.20e-2),unprognostic (1.32e-2),unprognostic (3.16e-2),unprognostic (1.16e-2),prognostic favorable (1.16e-4),unprognostic (4.58e-1),unprognostic (1.92e-2),unprognostic (3.49e-1),unprognostic (8.63e-2),unprognostic (4.74e-2),unprognostic (6.71e-2),prognostic unfavorable (9.09e-8),unprognostic (2.84e-2),unprognostic (4.23e-1),unprognostic (9.24e-2),unprognostic (7.72e-2)
IGHG2,,ENSG00000211893,Immunoglobulin heavy constant gamma 2 (G2m marker),P01859,14,105639559-105644790,"FDA approved drug targets, Immunoglobulin genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,lymphoid tissue: 189.5;urinary bladder: 108.3,Cell type enriched,Detected in some,11.0,Plasma cells: 4935.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,460.0,memory B-cell: 344.6;naive B-cell: 128.5,Lineage enriched,Detected in single,670.0,B-cells: 344.6,Group enriched,Detected in some,9.0,lymphoma: 19.2;Myeloma: 54.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA001245,Approved,,,,Immunoglobulin genes,Immunity,,,,250000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,HPA001245: AB_1079121,prognostic favorable (3.53e-4),unprognostic (6.88e-3),unprognostic (2.40e-2),unprognostic (1.55e-2),unprognostic (2.40e-2),prognostic favorable (3.30e-6),unprognostic (1.06e-1),unprognostic (6.67e-2),unprognostic (1.74e-1),unprognostic (7.59e-2),unprognostic (1.80e-1),unprognostic (1.41e-1),prognostic unfavorable (4.30e-8),unprognostic (4.72e-2),unprognostic (3.32e-2),unprognostic (1.05e-1),unprognostic (7.40e-2)
IGHA1,AL928768.3,ENSG00000211895,Immunoglobulin heavy constant alpha 1,P01876,14,105703995-105708665,"Disease related genes, Immunoglobulin genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 7198.9;salivary gland: 4545.3;stomach 1: 6480.0,Cell type enriched,Detected in many,16.0,Plasma cells: 107776.7,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in many,203.0,memory B-cell: 2579.2;naive B-cell: 1123.4,Lineage enriched,Detected in many,282.0,B-cells: 2579.2,Cancer enriched,Detected in some,20.0,Myeloma: 1517.6,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001217, HPA006013",Approved,,,,Immunoglobulin genes,Immunity,,,,130000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,"HPA001217: AB_1079120, HPA006013: AB_1079119",prognostic favorable (8.87e-5),unprognostic (5.36e-3),unprognostic (2.10e-2),unprognostic (1.59e-2),unprognostic (3.75e-2),prognostic favorable (3.81e-5),unprognostic (1.17e-1),unprognostic (3.86e-1),unprognostic (2.62e-1),unprognostic (3.26e-2),unprognostic (1.66e-1),unprognostic (1.34e-1),prognostic unfavorable (1.83e-7),unprognostic (8.10e-2),unprognostic (5.08e-2),unprognostic (1.16e-1),unprognostic (2.99e-2)
IGHG1,,ENSG00000211896,Immunoglobulin heavy constant gamma 1 (G1m marker),P01857,14,105736343-105743071,"Disease related genes, FDA approved drug targets, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,FDA approved drug targets,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,7.0,lymphoid tissue: 5665.1;urinary bladder: 3867.4,Cell type enriched,Detected in many,5.0,Plasma cells: 12047.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Immune cell enriched,Detected in some,6.0,memory B-cell: 768.6,Lineage enriched,Detected in many,122.0,B-cells: 768.6,Cancer enriched,Detected in some,8.0,Myeloma: 1184.5,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,"HPA001245, CAB008642",Supported,,,,Immunoglobulin genes,Immunity,,,,230000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,1.0,,,"CAB008642: AB_1617595, HPA001245: AB_1079121",unprognostic (6.47e-3),unprognostic (4.39e-3),unprognostic (2.91e-2),unprognostic (2.32e-3),unprognostic (1.55e-2),prognostic favorable (2.67e-4),unprognostic (3.90e-2),unprognostic (3.25e-1),unprognostic (7.52e-2),unprognostic (5.36e-3),unprognostic (8.06e-2),unprognostic (1.09e-1),prognostic unfavorable (2.49e-9),unprognostic (3.12e-1),unprognostic (3.52e-1),unprognostic (8.96e-2),unprognostic (7.61e-2)
IGHM,,ENSG00000211899,Immunoglobulin heavy constant mu,P01871,14,105851705-105856218,"Disease related genes, Immunoglobulin genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,intestine: 1279.4;lymphoid tissue: 3116.6,Group enriched,Detected in some,8.0,B-cells: 2732.6;Plasma cells: 9466.1,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in all,16.0,memory B-cell: 4293.6;naive B-cell: 6750.1,Lineage enriched,Detected in all,19.0,B-cells: 6750.1,Cancer enriched,Detected in some,4.0,lymphoma: 1665.3,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",Low region specificity,Detected in all,,,Low region specificity,Detected in all,,,CAB008643,Uncertain,,,,Immunoglobulin genes,Immunity,,,,110000000000.0,Cluster 18: Non-specific - Translation,,Cluster 8: Immune cells - Immune response,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,CAB008643: AB_1617732,unprognostic (2.91e-3),prognostic favorable (6.49e-4),unprognostic (9.30e-3),unprognostic (9.90e-3),unprognostic (2.05e-1),prognostic favorable (3.70e-6),unprognostic (9.61e-3),unprognostic (1.01e-1),unprognostic (1.52e-2),unprognostic (3.23e-3),unprognostic (2.46e-2),unprognostic (7.13e-2),prognostic unfavorable (5.20e-5),unprognostic (3.01e-1),unprognostic (1.76e-1),unprognostic (3.24e-2),unprognostic (6.28e-3)
IGHV3-13,,ENSG00000211942,Immunoglobulin heavy variable 3-13,P01766,14,106129540-106130072,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 65.0;lymphoid tissue: 133.1;urinary bladder: 87.5,Cell type enriched,Detected in some,19.0,Plasma cells: 84.5,Low cancer specificity,Detected in many,,,Not detected,Not detected,,,Group enriched,Detected in some,194.0,memory B-cell: 18.9;naive B-cell: 19.7,Lineage enriched,Detected in single,197.0,B-cells: 19.7,Not detected,Not detected,,,"Adipose visceral - Plasma cells, Breast - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,33000000000.0,Cluster 14: Non-specific - Unknown function,,,Cluster 59: Leukemia - T-cell receptor,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (3.24e-4),unprognostic (7.42e-2),unprognostic (1.96e-2),unprognostic (5.03e-2),,prognostic favorable (6.67e-6),unprognostic (5.44e-2),unprognostic (1.23e-2),unprognostic (1.53e-1),unprognostic (5.31e-2),unprognostic (8.27e-2),unprognostic (2.45e-1),prognostic unfavorable (7.21e-5),unprognostic (6.79e-2),unprognostic (3.21e-1),unprognostic (4.45e-1),unprognostic (7.87e-2)
IGHV3-23,,ENSG00000211949,Immunoglobulin heavy variable 3-23,P01764,14,106268606-106269140,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 1624.0;lymphoid tissue: 2897.8,Cell type enriched,Detected in some,117.0,Plasma cells: 10240.3,Low cancer specificity,Detected in all,,,Low region specificity,Detected in many,,,Group enriched,Detected in some,404.0,memory B-cell: 550.6;naive B-cell: 338.3,Lineage enriched,Detected in many,501.0,B-cells: 550.6,Cancer enriched,Detected in some,18.0,Myeloma: 724.1,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,42000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,,unprognostic (1.17e-3),unprognostic (5.43e-2),unprognostic (9.68e-3),unprognostic (3.31e-3),unprognostic (1.34e-2),prognostic favorable (3.85e-4),unprognostic (3.26e-1),unprognostic (4.79e-1),unprognostic (7.26e-2),unprognostic (6.52e-3),unprognostic (1.72e-1),unprognostic (2.45e-1),prognostic unfavorable (1.79e-7),unprognostic (6.22e-2),unprognostic (1.84e-1),unprognostic (1.36e-1),unprognostic (6.42e-2)
C4B,"C4B1, C4B3, C4F, CH, CO4, CPAMD3",ENSG00000224389,Complement C4B (Chido blood group),P0C0L5,6,32014795-32035418,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins","Complement pathway, Immunity, Inflammatory response, Innate immunity",Blood group antigen,"FDA approved drug targets, Systemic lupus erythematosus",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,5.0,adrenal gland: 214.6;liver: 375.4,Group enriched,Detected in some,5.0,Hepatocytes: 7.1;Mesothelial cells: 13.6,Cancer enhanced,Detected in many,,liver cancer: 33.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 6.7;Myeloma: 3.9,Liver - Hepatocytes,,,,,,,,,"HPA046356, HPA048287, HPA050103",Approved,,,,Secreted to blood,Complement pathway,,,,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,1.0,,,"HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016",unprognostic (1.29e-1),unprognostic (2.99e-2),unprognostic (5.50e-3),unprognostic (1.30e-1),unprognostic (8.09e-2),unprognostic (6.24e-2),unprognostic (6.09e-2),unprognostic (1.05e-1),unprognostic (4.81e-2),unprognostic (1.12e-1),unprognostic (6.24e-2),unprognostic (6.86e-2),unprognostic (1.04e-1),unprognostic (3.12e-2),unprognostic (1.30e-1),unprognostic (3.99e-3),unprognostic (1.11e-2)
ORM2,"AGP-B, AGP-B', AGP2",ENSG00000228278,Orosomucoid 2,P19652,9,114329869-114333251,"FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Acute phase, Transport",,FDA approved drug targets,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,297.0,liver: 8652.9,Cell type enriched,Detected in some,44.0,Hepatocytes: 9678.3,Cancer enriched,Detected in many,34.0,liver cancer: 873.1,Low region specificity,Detected in some,,,Immune cell enriched,Detected in single,39.0,neutrophil: 13.2,Lineage enriched,Detected in single,39.0,granulocytes: 13.2,Cancer enriched,Detected in some,27.0,liver cancer: 95.6,"Liver - Hepatocytes, Testis - Late spermatids",,,,,,,,,"HPA046438, HPA047725, HPA057726",Approved,,Approved,"Golgi apparatus,Vesicles",Secreted to blood,Acute phase,,,422000000.0,41000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 33: Neurons - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,,Vesicles,Golgi apparatus,"HPA046438: AB_2679666, HPA047725: AB_2680133, HPA057726: AB_2683512",unprognostic (6.77e-2),unprognostic (8.00e-2),unprognostic (1.19e-1),unprognostic (4.44e-3),unprognostic (1.18e-1),unprognostic (5.61e-2),unprognostic (5.66e-2),unprognostic (9.70e-2),unprognostic (3.05e-1),unprognostic (1.48e-1),unprognostic (1.99e-2),unprognostic (5.76e-2),prognostic unfavorable (1.23e-9),unprognostic (3.23e-1),unprognostic (6.80e-2),unprognostic (7.62e-2),unprognostic (9.15e-4)
ORM1,,ENSG00000229314,Orosomucoid 1,P02763,9,114323098-114326479,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins","Acute phase, Transport",,"Cancer-related genes, FDA approved drug targets",Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,177.0,liver: 41892.9,Cell type enriched,Detected in some,53.0,Hepatocytes: 54806.5,Cancer enriched,Detected in many,16.0,liver cancer: 2506.9,Low region specificity,Detected in single,,,Immune cell enriched,Detected in some,47.0,neutrophil: 201.8,Lineage enriched,Detected in many,47.0,granulocytes: 201.8,Cancer enriched,Detected in many,4.0,liver cancer: 243.4,"Liver - Hepatocytes, Lung - Neutrophil_2",,,,,,,,,"CAB006265, HPA046438, HPA047725, HPA057726",Approved,,Approved,"Golgi apparatus,Vesicles",Secreted to blood,Acute phase,,,945000000000.0,61000000000.0,Cluster 4: Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 54: Immune cells - T cell receptor,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,1.0,Vesicles,Golgi apparatus,"CAB006265: AB_425575, HPA046438: AB_2679666, HPA047725: AB_2680133, HPA057726: AB_2683512",unprognostic (3.85e-1),unprognostic (2.12e-1),unprognostic (1.09e-2),unprognostic (2.16e-2),unprognostic (3.22e-2),unprognostic (1.47e-1),unprognostic (2.29e-1),unprognostic (2.26e-1),,unprognostic (1.16e-1),unprognostic (4.85e-2),unprognostic (1.74e-1),prognostic unfavorable (2.35e-4),unprognostic (2.10e-1),unprognostic (4.38e-2),unprognostic (9.32e-3),unprognostic (4.51e-2)
APOC2,,ENSG00000234906,Apolipoprotein C2,P02655,19,44946035-44949565,"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins","Lipid degradation, Lipid metabolism, Lipid transport, Transport",,"Disease variant, Hyperlipidemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,130.0,liver: 9320.5,Cell type enriched,Detected in some,23.0,Hepatocytes: 820.6,Cancer enriched,Detected in some,17.0,liver cancer: 49.7,Low region specificity,Detected in all,,,Immune cell enriched,Detected in single,29.0,NK-cell: 3.2,Lineage enriched,Detected in single,29.0,NK-cells: 3.2,Cancer enhanced,Detected in many,,Brain cancer: 55.3;Leukemia: 80.3;liver cancer: 81.2,"Kidney - Proximal tubular cells, Kidney - Proximal tubular cells, Pancreas - Macrophages",Not detected,Not detected,,,Not detected,Not detected,,,HPA055877,Supported,,,,Secreted to blood,Apolipoprotein,,,43000000000.0,49000000000.0,Cluster 14: Non-specific - Unknown function,Cluster 31: Liver - Plasma proteins,Cluster 20: Macrophages & Microglia - Immune response,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,1.0,,,HPA055877: AB_2682953,unprognostic (4.28e-2),unprognostic (7.73e-3),unprognostic (1.33e-1),unprognostic (3.66e-2),unprognostic (8.91e-2),unprognostic (1.90e-1),unprognostic (2.07e-1),unprognostic (5.41e-2),unprognostic (2.56e-1),unprognostic (1.96e-2),unprognostic (2.86e-1),unprognostic (1.15e-2),unprognostic (5.14e-8),unprognostic (1.32e-1),unprognostic (1.45e-1),unprognostic (1.77e-2),unprognostic (9.80e-3)
IGKV3-20,,ENSG00000239951,Immunoglobulin kappa variable 3-20,P01619,2,89142574-89143160,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 2965.7;lymphoid tissue: 5079.6,Cell type enriched,Detected in some,120.0,Plasma cells: 38821.5,Low cancer specificity,Detected in all,,,Region enhanced,Detected in many,,spinal cord: 17.6,Group enriched,Detected in many,327.0,memory B-cell: 1609.9;naive B-cell: 1229.8,Lineage enriched,Detected in many,370.0,B-cells: 1609.9,Group enriched,Detected in many,367.0,lymphoma: 353.5;Myeloma: 1322.2,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA047702,Approved,,Approved,Plasma membrane,Immunoglobulin genes,Immunity,,,,20000000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 20: Myeloma - Immune response,Cluster 77: Plasma cells - Protein processing,,Plasma membrane,,HPA047702: ,prognostic favorable (1.86e-4),unprognostic (4.16e-2),unprognostic (1.64e-2),unprognostic (1.97e-2),unprognostic (1.13e-1),prognostic favorable (9.01e-4),unprognostic (1.43e-1),unprognostic (3.43e-1),unprognostic (1.37e-1),unprognostic (3.93e-3),unprognostic (8.44e-2),unprognostic (1.97e-1),prognostic unfavorable (1.07e-6),unprognostic (7.35e-2),unprognostic (5.08e-1),unprognostic (6.64e-2),unprognostic (2.70e-2)
IGKV1D-33,,ENSG00000239975,Immunoglobulin kappa variable 1D-33,P01593,2,89913982-89914545,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in some,,gallbladder: 1.9;lymphoid tissue: 2.1;stomach 1: 2.2;urinary bladder: 1.8,Cell type enriched,Detected in some,501.0,Plasma cells: 2537.1,Cancer enhanced,Detected in many,,stomach cancer: 5.0,Not detected,Not detected,,,Immune cell enhanced,Detected in single,,memory B-cell: 2.7,Lineage enriched,Detected in single,27.0,B-cells: 2.7,Cancer enhanced,Detected in single,,lymphoma: 2.4,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA048721,Approved,,,,Immunoglobulin genes,Immunity,,,,4900000000.0,Cluster 23: B-cells - Immunoglobulins,,,Cluster 55: Lymphoma - Immune response,Cluster 23: Plasma cells - Humoral immune response,,,,HPA048721: ,unprognostic (5.10e-3),unprognostic (2.03e-1),unprognostic (2.11e-2),,,unprognostic (2.03e-4),,unprognostic (7.90e-2),,unprognostic (6.50e-2),unprognostic (6.82e-2),,,unprognostic (4.54e-2),unprognostic (4.23e-2),,
IGKV1-17,"A30, IGKV117",ENSG00000240382,Immunoglobulin kappa variable 1-17,P01599,2,89117342-89117844,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 361.0;lymphoid tissue: 439.5,Cell type enriched,Detected in some,119.0,Plasma cells: 3624.8,Low cancer specificity,Detected in all,,,Low region specificity,Detected in single,,,Group enriched,Detected in some,426.0,memory B-cell: 106.2;naive B-cell: 82.7,Lineage enriched,Detected in single,479.0,B-cells: 106.2,Not detected,Not detected,,,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA048721,Approved,,,,Immunoglobulin genes,Immunity,,,,8400000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,,,HPA048721: ,unprognostic (7.72e-3),unprognostic (1.60e-1),unprognostic (7.37e-3),unprognostic (1.78e-2),unprognostic (5.08e-3),prognostic favorable (4.11e-4),unprognostic (8.04e-2),unprognostic (1.00e-1),unprognostic (9.59e-2),unprognostic (1.76e-2),unprognostic (5.06e-2),unprognostic (2.54e-1),prognostic unfavorable (3.44e-7),unprognostic (3.12e-3),unprognostic (8.83e-2),unprognostic (3.80e-1),unprognostic (7.28e-2)
IGKV3-11,,ENSG00000241351,Immunoglobulin kappa variable 3-11,P04433,2,89027171-89027731,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in many,4.0,intestine: 1323.4;lymphoid tissue: 2723.2;stomach 1: 765.4;urinary bladder: 1760.7,Cell type enriched,Detected in some,94.0,Plasma cells: 16738.2,Low cancer specificity,Detected in all,,,Region enriched,Detected in many,15.0,spinal cord: 34.2,Group enriched,Detected in many,290.0,memory B-cell: 1738.3;naive B-cell: 1408.8,Lineage enriched,Detected in many,321.0,B-cells: 1738.3,Cancer enriched,Detected in some,17.0,Myeloma: 5519.7,"Adipose subcutaneous - Plasma cells, Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Heart muscle - Plasma cells, Kidney - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Skeletal muscle - Plasma cells, Skin - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,HPA047702,Approved,,Approved,Plasma membrane,Immunoglobulin genes,Immunity,,,,18000000000.0,Cluster 23: B-cells - Immunoglobulins,,Cluster 7: Non-specific - Ribosome,Cluster 51: Myeloma - Immunoglobulins,Cluster 23: Plasma cells - Humoral immune response,,Plasma membrane,,HPA047702: ,unprognostic (3.97e-3),unprognostic (1.17e-2),unprognostic (3.51e-2),unprognostic (1.91e-2),unprognostic (2.70e-2),prognostic favorable (1.36e-5),unprognostic (2.02e-1),unprognostic (3.20e-1),unprognostic (5.73e-2),unprognostic (2.86e-2),unprognostic (1.70e-1),unprognostic (2.34e-1),prognostic unfavorable (2.26e-8),unprognostic (5.93e-2),unprognostic (2.48e-1),unprognostic (1.22e-1),unprognostic (1.07e-1)
IGKV2D-28,,ENSG00000242534,Immunoglobulin kappa variable 2D-28,P01615,2,89959979-89960748,"Immunoglobulin genes, Predicted secreted proteins","Adaptive immunity, Immunity",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,esophagus: 87.3;intestine: 106.0;lymphoid tissue: 93.9;salivary gland: 116.8;stomach 1: 98.6,Cell type enriched,Detected in some,177.0,Plasma cells: 2633.1,Low cancer specificity,Detected in many,,,Region enhanced,Detected in single,,medulla oblongata: 1.3,Group enriched,Detected in many,221.0,memory B-cell: 2988.8;naive B-cell: 2094.9,Lineage enriched,Detected in all,260.0,B-cells: 2988.8,Cancer enriched,Detected in single,43.0,lymphoma: 42.9,"Adipose visceral - Plasma cells, Breast - Plasma cells, Colon - Plasma cells, Liver - Plasma cells, Lung - Plasma cells, Pancreas - Plasma cells, Prostate - Plasma cells, Stomach - Plasma cells, Thyroid - Plasma cells",,,,,,,,,,,,,,Immunoglobulin genes,Immunity,,,,3500000000.0,Cluster 17: B-cells - Immunoglobulins,,Cluster 29: Forebrain - Mixed function,Cluster 46: Lymphoma - Humoral immune response,Cluster 77: Plasma cells - Protein processing,,,,,unprognostic (3.88e-3),unprognostic (2.68e-2),,,,unprognostic (2.51e-3),,unprognostic (1.22e-1),,unprognostic (1.13e-1),unprognostic (4.17e-1),,,unprognostic (1.13e-1),unprognostic (2.66e-1),,
CFB,"BF, BFD, H2-Bf",ENSG00000243649,Complement factor B,P00751,6,31945650-31952086,"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Complement alternate pathway, Immunity, Innate immunity","Hydrolase, Protease, Serine protease","Age-related macular degeneration, Disease variant, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,20.0,liver: 2453.1,Cell type enhanced,Detected in many,,Ductal cells: 913.7;Exocrine glandular cells: 569.1;Hepatocytes: 199.3;Mesothelial cells: 453.1;Pancreatic endocrine cells: 368.5,Cancer enhanced,Detected in all,,liver cancer: 78.3,Low region specificity,Detected in single,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enriched,Detected in many,5.0,head and neck cancer: 34.6,"Adipose subcutaneous - Adipose progenitor cells, Adipose visceral - Mesothelial cells, Liver - Hepatocytes",Not detected,Not detected,,,Low region specificity,Detected in all,,,"HPA000951, HPA001817, HPA001832, CAB016381",Supported,,Approved,"Endoplasmic reticulum,Vesicles,Cell Junctions",Secreted to blood,Immunity,,,879000000.0,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 12: Non-specific - Vasculature,Cluster 53: Squamous epithelial cells - Keratinization,Cluster 45: Non-specific - Mixed function,,"Endoplasmic reticulum, Vesicles",Cell Junctions,"CAB016381: AB_627562, HPA000951: AB_2797216, HPA001817: AB_1078779, HPA001832: AB_1078778",prognostic favorable (2.76e-5),unprognostic (1.02e-1),unprognostic (1.44e-1),unprognostic (7.94e-2),unprognostic (1.82e-2),unprognostic (8.56e-2),unprognostic (8.08e-3),unprognostic (8.81e-2),unprognostic (3.51e-1),unprognostic (2.26e-2),unprognostic (1.32e-2),unprognostic (6.57e-2),prognostic unfavorable (1.53e-5),unprognostic (1.36e-1),unprognostic (5.13e-2),unprognostic (1.05e-2),unprognostic (3.68e-2)
CFHR1,"CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2",ENSG00000244414,Complement factor H related 1,Q03591,1,196819731-196837159,"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins",,,"Cancer-related genes, Hemolytic uremic syndrome",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,224.0,liver: 2010.5,Cell type enhanced,Detected in some,,Granulosa cells: 65.7;Hepatocytes: 223.4;Kupffer cells: 55.4,Cancer enriched,Detected in single,798.0,liver cancer: 182.4,Region enhanced,Detected in single,,midbrain: 1.7,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,Sarcoma: 3.3;thyroid cancer: 7.0,Liver - Hepatocytes,Not detected,Not detected,,,,,,,"HPA038915, HPA038922, HPA040726",Supported,,Approved,Vesicles,Secreted to blood,Complement pathway,,,,13000000000.0,,Cluster 31: Liver - Plasma proteins,Cluster 41: Monoamines - Neurotransmitter signalling,Cluster 16: Thyroid cancer - Neuronal signaling,Cluster 62: Hepatocytes - Metabolism,6.0,Vesicles,,"HPA038915: AB_2676269, HPA038922: AB_2676271, HPA040726: AB_2677101",unprognostic (2.28e-1),unprognostic (3.18e-1),,,unprognostic (3.50e-2),unprognostic (1.88e-2),prognostic favorable (8.71e-6),unprognostic (3.02e-1),unprognostic (3.70e-1),unprognostic (2.50e-1),unprognostic (8.48e-2),,unprognostic (7.21e-4),unprognostic (7.01e-4),unprognostic (1.13e-1),,unprognostic (6.41e-2)
C4A,"C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG",ENSG00000244731,Complement C4A (Rodgers blood group),P0C0L4,6,31982057-32002681,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins","Complement pathway, Immunity, Inflammatory response, Innate immunity",Blood group antigen,"Disease variant, FDA approved drug targets, Systemic lupus erythematosus",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,adrenal gland: 112.2;liver: 328.2,Group enriched,Detected in some,4.0,Hepatocytes: 6.8;Mesothelial cells: 8.5,Cancer enhanced,Detected in many,,liver cancer: 27.8,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in some,,liver cancer: 8.8;Myeloma: 6.7,"Breast - Breast glandular cells, Kidney - Proximal tubular cells, Liver - Hepatocytes",,,,,,,,,"CAB009811, CAB032603, HPA046356, HPA048287, HPA050103",Supported,,,,Secreted to blood,Complement pathway,,,342000000.0,120000000000.0,,Cluster 83: Liver - Metabolism,Cluster 39: Astrocytes - Mixed function,Cluster 70: DU4475 - Unknown function,Cluster 62: Hepatocytes - Metabolism,2.0,,,"CAB009811: AB_2066891, CAB032603: AB_2290613, HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016",unprognostic (2.13e-1),unprognostic (3.02e-2),unprognostic (3.74e-2),unprognostic (3.10e-1),unprognostic (5.29e-2),unprognostic (3.09e-2),unprognostic (2.48e-2),unprognostic (1.02e-1),unprognostic (2.00e-1),unprognostic (1.44e-1),unprognostic (3.70e-1),unprognostic (3.15e-1),unprognostic (4.47e-2),unprognostic (3.20e-2),unprognostic (5.20e-2),unprognostic (3.97e-2),unprognostic (8.63e-2)
HBB,"beta-globin, CD113t-C",ENSG00000244734,Hemoglobin subunit beta,P68871,11,5225464-5229395,"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters","Oxygen transport, Transport","Hypotensive agent, Vasoactive","Congenital dyserythropoietic anemia, Disease variant, FDA approved drug targets, Hereditary hemolytic anemia",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in all,11.0,bone marrow: 131241.6,Cell type enriched,Detected in many,216.0,Erythroid cells: 265225.8,Group enriched,Detected in all,4.0,cervical cancer: 66.4;glioma: 244.6;renal cancer: 65.1,Low region specificity,Detected in all,,,Group enriched,Detected in all,5.0,neutrophil: 662.1;plasmacytoid DC: 380.8,Group enriched,Detected in all,11.0,dendritic cells: 380.8;granulocytes: 662.1,Cancer enriched,Detected in many,5.0,Leukemia: 132.1,Liver - Erythroid cells,,,,,,,,,"CAB009526, HPA043234",Enhanced,,,,,,,,,10000000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 77: Bone marrow - Cell proliferation,Cluster 42: Choroid plexus - Mitochondria,Cluster 47: Leukemia - Hemostasis,Cluster 1: Erythroid cells - Oxygen transport,5.0,,,"CAB009526: AB_2143058, HPA043234: AB_2678378",unprognostic (2.41e-1),unprognostic (8.55e-2),unprognostic (2.40e-1),unprognostic (4.40e-2),unprognostic (1.14e-1),unprognostic (3.22e-1),unprognostic (4.88e-2),unprognostic (7.46e-2),unprognostic (2.91e-2),unprognostic (1.76e-1),unprognostic (1.91e-1),unprognostic (8.11e-3),unprognostic (2.40e-2),unprognostic (5.81e-2),unprognostic (1.42e-1),unprognostic (8.87e-3),unprognostic (6.41e-2)
SELENOP,"SELP, SeP, SEPP, SEPP1",ENSG00000250722,Selenoprotein P,P49908,5,42799880-42887392,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Group enriched,Detected in all,4.0,intestine: 2030.1;liver: 6077.3,Cell type enhanced,Detected in many,,Hepatocytes: 3136.6;Proximal enterocytes: 5404.0,Cancer enriched,Detected in all,4.0,liver cancer: 116.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Cancer enhanced,Detected in many,,liver cancer: 182.2,"Liver - Hepatocytes, Liver - Hepatocytes, Thyroid - Fibroblasts",Low region specificity,Detected in all,,,,,,,HPA036287,Approved,,Uncertain,"Nucleoplasm,Golgi apparatus",Secreted to blood,No annotated function,,,2220000000.0,1800000000.0,Cluster 12: Non-specific - Mitochondrial translation,Cluster 83: Liver - Metabolism,Cluster 30: White matter - Myelination,Cluster 18: Liver cancer - Metabolism,Cluster 22: Proximal enterocytes - Digestion,1.0,"Nucleoplasm, Golgi apparatus",,HPA036287: AB_10794618,unprognostic (7.96e-2),unprognostic (2.10e-1),unprognostic (4.28e-3),unprognostic (1.19e-3),unprognostic (6.67e-2),unprognostic (6.37e-2),unprognostic (9.22e-2),unprognostic (2.19e-2),unprognostic (1.44e-2),unprognostic (2.88e-1),unprognostic (2.07e-2),unprognostic (1.05e-1),prognostic favorable (6.97e-6),unprognostic (1.35e-2),unprognostic (4.19e-2),unprognostic (2.89e-1),unprognostic (1.42e-1)
IGLL5,,ENSG00000254709,Immunoglobulin lambda like polypeptide 5,B9A064,22,22887780-22896111,"Predicted intracellular proteins, Predicted secreted proteins",,,,Evidence at protein level,Evidence at transcript level,Evidence at transcript level,Evidence at protein level,Tissue enhanced,Detected in many,,intestine: 397.1;lymphoid tissue: 656.5;stomach 1: 300.1,Cell type enriched,Detected in some,9.0,Plasma cells: 1531.4,Low cancer specificity,Detected in all,,,Low region specificity,Detected in single,,,Group enriched,Detected in some,227.0,memory B-cell: 517.6;naive B-cell: 619.6,Lineage enriched,Detected in many,247.0,B-cells: 619.6,Cancer enriched,Detected in some,4.0,Myeloma: 1179.4,,,,,,,,,,,,,,,Secreted to blood,No annotated function,,,,53000000000.0,Cluster 23: B-cells - Immunoglobulins,Cluster 70: Lymphoid tissue - Immune response,Cluster 8: Immune cells - Immune response,Cluster 51: Myeloma - Immunoglobulins,Cluster 77: Plasma cells - Protein processing,,,,,prognostic favorable (6.10e-4),unprognostic (7.64e-3),unprognostic (4.33e-2),unprognostic (1.51e-3),unprognostic (2.82e-2),prognostic favorable (3.41e-5),unprognostic (1.76e-2),unprognostic (2.18e-1),unprognostic (7.28e-2),unprognostic (1.87e-2),unprognostic (1.01e-1),unprognostic (3.73e-1),prognostic unfavorable (5.94e-8),unprognostic (1.85e-1),unprognostic (4.63e-1),unprognostic (8.52e-2),unprognostic (6.50e-2)
HP,,ENSG00000257017,Haptoglobin,P00738,16,72054505-72061055,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins","Acute phase, Immunity","Antibiotic, Antimicrobial, Antioxidant, Serine protease homolog","Cancer-related genes, Disease variant",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in many,85.0,liver: 54575.6,Group enriched,Detected in many,45.0,Hepatocytes: 52816.7;Mesothelial cells: 16337.1,Cancer enriched,Detected in many,81.0,liver cancer: 1297.4,Region enhanced,Detected in all,,medulla oblongata: 56.4,Group enriched,Detected in many,5.0,classical monocyte: 49.5;eosinophil: 80.5,Group enriched,Detected in many,7.0,granulocytes: 80.5;monocytes: 49.5,Group enriched,Detected in some,12.0,Gastric cancer: 6.6;Leukemia: 4.1;liver cancer: 15.7,Liver - Hepatocytes,,,,,,,,,"CAB003787, HPA047750, HPA066795",Enhanced,,Approved,Vesicles,Secreted to blood,Acute phase,,,998000000000.0,100000000000.0,Cluster 36: Eosinophils - Protein ubiquitination,Cluster 31: Liver - Plasma proteins,Cluster 12: Non-specific - Vasculature,Cluster 18: Liver cancer - Metabolism,Cluster 43: Hepatocytes - Metabolism,3.0,Vesicles,,"CAB003787: , HPA047750: AB_2680146, HPA066795: ",unprognostic (6.38e-3),unprognostic (7.73e-3),unprognostic (1.23e-1),unprognostic (2.41e-2),unprognostic (2.34e-3),unprognostic (2.07e-1),unprognostic (7.79e-3),unprognostic (1.37e-1),unprognostic (2.31e-1),unprognostic (1.84e-1),unprognostic (6.30e-2),unprognostic (8.18e-2),prognostic unfavorable (6.94e-13),unprognostic (4.34e-4),unprognostic (1.80e-1),unprognostic (6.61e-2),unprognostic (2.49e-2)
ITGB3,"CD61, GP3A, GPIIIa",ENSG00000259207,Integrin subunit beta 3,P05106,17,47253827-47313743,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins","Cell adhesion, Host-virus interaction","Host cell receptor for virus entry, Integrin, Receptor","Cancer-related genes, Disease variant, FDA approved drug targets",Evidence at protein level,Evidence at protein level,Evidence at protein level,Evidence at protein level,Tissue enhanced,Detected in many,,thyroid gland: 54.6,Cell type enhanced,Detected in many,,Collecting duct cells: 9.7;Pancreatic endocrine cells: 10.2;Proximal tubular cells: 19.4;Salivary duct cells: 14.8;Sertoli cells: 13.6,Group enriched,Detected in many,6.0,melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5,Low region specificity,Detected in all,,,Group enriched,Detected in some,17.0,basophil: 5.6;neutrophil: 3.0,Lineage enriched,Detected in single,22.0,granulocytes: 5.6,Cancer enhanced,Detected in many,,Kidney cancer: 99.0;skin cancer: 125.1,"Liver - Vascular Endothelial cells, Prostate - Smooth muscle cells, Testis - Spermatogonia",Low region specificity,Detected in many,,,Low region specificity,Detected in all,,,HPA027852,Approved,,Supported,"Nucleoplasm,Plasma membrane",Intracellular and membrane,Receptor,,,,38000000.0,Cluster 35: Neutrophils - Protein binding,Cluster 51: Thyroid gland - Unknown function,Cluster 12: Non-specific - Vasculature,Cluster 69: Skin cancer - ECM organization,Cluster 57: Platelets - Hemostasis,9.0,Plasma membrane,Nucleoplasm,HPA027852: AB_10601760,unprognostic (1.13e-2),unprognostic (1.97e-3),unprognostic (2.47e-1),unprognostic (3.00e-2),unprognostic (1.91e-2),unprognostic (6.04e-3),unprognostic (3.70e-1),unprognostic (3.00e-1),unprognostic (1.44e-1),unprognostic (3.85e-1),unprognostic (6.35e-2),unprognostic (7.22e-2),unprognostic (1.36e-1),unprognostic (1.03e-2),unprognostic (2.72e-2),unprognostic (1.48e-1),unprognostic (1.17e-3)
HPR,,ENSG00000261701,Haptoglobin-related protein,P00739,16,72063148-72077246,"Enzymes, Plasma proteins, Predicted secreted proteins",,Serine protease homolog,,Evidence at protein level,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Tissue enriched,Detected in many,6.0,liver: 786.9,Cell type enriched,Detected in some,7.0,Hepatocytes: 205.7,Cancer enriched,Detected in some,53.0,liver cancer: 185.1,Low region specificity,Detected in many,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Group enriched,Detected in some,4.0,liver cancer: 2.3;prostate cancer: 3.5,Liver - Hepatocytes,,,,,,,,,HPA047750,Supported,,Approved,Vesicles,Secreted to blood,Other,,,49000000000.0,55000000000.0,,Cluster 83: Liver - Metabolism,Cluster 19: Astrocytes - Mixed function,Cluster 18: Liver cancer - Metabolism,Cluster 15: Non-specific - Mixed function,,Vesicles,,HPA047750: AB_2680146,unprognostic (2.43e-1),,unprognostic (4.69e-2),unprognostic (5.97e-3),unprognostic (2.42e-1),,unprognostic (2.32e-3),unprognostic (2.36e-1),,unprognostic (1.66e-1),unprognostic (8.21e-2),unprognostic (2.30e-1),unprognostic (3.44e-6),unprognostic (2.09e-2),unprognostic (1.45e-1),unprognostic (1.29e-1),
APOC4,,ENSG00000267467,Apolipoprotein C4,P55056,19,44942237-44945496,"Plasma proteins, Predicted secreted proteins","Lipid transport, Transport",,,Evidence at protein level,Evidence at transcript level,Evidence at protein level,Evidence at protein level,Tissue enriched,Detected in some,505.0,liver: 607.5,Cell type enriched,Detected in single,40.0,Hepatocytes: 15.2,Cancer enriched,Detected in single,15.0,liver cancer: 0.7,Low region specificity,Detected in all,,,Not detected in immune cells,Not detected,,,Not detected,Not detected,,,Not detected,Not detected,,,Liver - Hepatocytes,Not detected,Not detected,,,Low region specificity,Detected in all,,,HPA062671,Approved,,,,Secreted to blood,Apolipoprotein,,,1000000000.0,980000000.0,Cluster 38: Monocytes & Neutrophils - Degranulation,Cluster 31: Liver - Plasma proteins,Cluster 34: Non-specific - Mixed function,Cluster 47: Leukemia - Hemostasis,Cluster 43: Hepatocytes - Metabolism,22.0,,,HPA062671: AB_2684828,,,,,,,unprognostic (1.82e-3),,,,,,,,,,
